Getting a grip on myotonic dystrophy type 1 by Hermans, M.C.E.
  
 
Getting a grip on myotonic dystrophy type 1
Citation for published version (APA):
Hermans, M. C. E. (2013). Getting a grip on myotonic dystrophy type 1. Maastricht: Universitaire Pers
Maastricht.
Document status and date:
Published: 01/01/2013
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 04 Dec. 2019
Getting a grip on 
myotonic dystrophy type 1
© M.C.E. Hermans, 2013
Lay-out: Jos Hendrix
Cover photo: Wat Rong Khun, Chiang Rai, Thailand
Production: Universitaire Pers Maastricht
ISBN 978 94 6159 231 6
This research project was financially supported 
by a grant from the Prinses Beatrix Spierfonds.
Getting a grip on 
myotonic dystrophy type 1
PROEFSCHRIFT
ter verkrijging van de graad van doctor aan de Universiteit Maastricht,
op gezag van de Rector Magnificus, Prof. dr. L.L.G. Soete
volgens het besluit van het College van Decanen,
in het openbaar te verdedigen 
op vrijdag 21 juni 2013 om 10.00 uur
door
Mieke Catharina Elisabeth Hermans
UNIVERSITAIRE
PERS MAASTRICHT
P
M
Promotor 
 Prof. dr. Y.M. Pinto (Academisch Medisch Centrum, Amsterdam)
Co-promotores 
 Dr. C.G. Faber
 Dr. I.S.J. Merkies
Beoordelingscommissie 
 Prof. dr. R.J. van Oostenbrugge, voorzitter
 Dr. L.R.C. Dekker (Catharina Ziekenhuis, Eindhoven)
 Prof. dr. B.G.M. van Engelen (UMC St. Radboud, Nijmegen)
 Dr. A.J. van der Kooi (Academisch Medisch Centrum, Amsterdam)
Table of contents
PART I INTRODUCTION
 Chapter 1.1 General introduction  9
 Chapter 1.2 Outline of the thesis  23
PART II CARDIAC DISEASE IN 
 MYOTONIC DYSTROPHY TYPE 1 
 Chapter 2 Hereditary muscular dystrophies and the heart 27
 Chapter 3 Sudden death in myotonic dystrophy type 1  65
 Chapter 4 Structural and functional cardiac changes in  77
  myotonic dystrophy type 1: a cardiac magnetic  
  resonance imaging study
 Chapter 5 Changes in global gene expression in hearts of  93
  myotonic dystrophy type 1 patients
PART III OUTCOME MEASURES IN 
 MYOTONIC DYSTROPHY TYPE 1
 Chapter 6 Outcome measures in adults with myotonic  123
  dystrophy type 1
 Chapter 7 An introduction to the Rasch Measurement  149
  Model
 Chapter 8 Rasch-built myotonic dystrophy type 1 activity  163
  and participation scale (DM1Activ)
 Chapter 9 Reconstructing the Rasch-built myotonic  183
  dystrophy type 1 activity and participation 
  Scale (DM1Activc)
 Chapter 10 Fatigue and daytime sleepiness scale  195
  in myotonic dystrophy type 1
PART IV SUMMARY 
 Chapter 11 Summary, general discussion and  211
  future perspectives
 Chapter 12 Nederlandse samenvatting 223
Dankwoord 231
Curriculum vitae  234
List of publications 235
Appendices 236

PART I
Introduction 

Chapter 1.1
General introduction
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Myotonic dystrophy type 1
Myotonic dystrophy type 1 (DM1; OMIM #160900) is the most common type 
of muscular dystrophy in adults with a prevalence of about 5-20 per 100 000 in 
Western-Europe but higher prevalences have been found in certain populations 
due to founder effect and genetic isolation.1 It was identified as a distinct 
disorder in 1909 by Steinert in Germany and by Batten and Gibb in the UK, 
but it took almost a century to delineate its main clinical features.2 The most 
noticeable symptoms are myotonia, i.e. inability to relax the voluntary muscles 
after activity, and progressive weakness of facial and distal muscles. Along with 
these neuromuscular features, multiple systemic manifestations are seen (table 
1.1). 
Table 1.1. Systemic involvement in myotonic dystrophy type 1
System Principal involvement
Cardiovascular Conduction disorders
Cardiomyopathy
Low arterial blood pressure
Vasomotor symptoms
Lungs Aspiration
Pneumonia
Alveolar hypoventilation
Smooth muscle Gastro-intestinal tract (pharynx, oesophagus, 
stomach, colon, anal sphincter)
Urinary bladder
Uterus
Gall bladder
Eye Cataract
Retinal degeneration
Ptosis
Brain Variable mental retardation (congenital and childhood-onset type)
Hypersomnia
Apathy
Increased ventricular size (congenital type)
Increased focal hyperintense lesions on T2-MRI brain imaging
Endocrine Testicular atrophy
Insuline resistance
Skin Early balding
Pilomatrixomata
Skeletal Cranial hyperostosis
Jaw and palate abnormalities
Talipes (congenital and childhood-onset type)
Other Anesthetic complications
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Genetics
A single mutation in the 3’untranslated region of the dystrophia myotonica 
protein kinase (DMPK) gene on chromosome 19q13.3 was identified in 1992.3-5 
A repetitive trinucleotide segment (CTG) is abnormally expanded, forming an 
unstable region. Unaffected individuals have between 5 and 37 copies of the 
trinucleotide sequence. Repeat lengths of 38-50 are considered premutation 
alleles, whereas DM1 patients have at least 50 repeats. Apparent new mutations 
result from healthy individuals with an increased repeat number that is 
insufficient to cause symptoms, but are unstable during germline transmission 
and can result in disease in the offspring. A larger repeat expansion leads to an 
earlier onset and more severe phenotype (figure 1.1).6 This causes anticipation, 
i.e. an earlier age of onset and increased severity in subsequent generations.7 
However, analysis of CTG repeats from lymphocytes may be of limited value in 
individual patients because of the large overlap between expansion sizes seen 
in different phenotypes. Other genotype-phenotype correlations are unclear, 
probably because of differing levels of instability of mutant alleles in various 
somatic tissues.8
Figure 1.1. DMPK pre-mRNA with relationship between CUG repeat size and phenotype
The clinical picture
Patients with DM1 can present with 4 different phenotypes: congenital type; 
childhood-onset type; adult-onset (classical) type, and late-onset (mild) type.6 
Late-onset type has its onset after 50 years marked by cataract, mild muscle 
weakness and myotonia. Disease course is generally benign, and life 
expectancy is probably within the normal range. 
Adult-onset type is the most prevalent form and manifests between 10 and 
60 years. It is characterized by myotonia and muscle weakness. Myotonia 
is experienced predominantly in the hands and the tongue. Repeated 
contractions may diminish myotonia (warm-up phenomenon). The pattern 
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n
DMPK coding sequence 3’UTR
5’ 3’
50 -80 mild
N=5-37 normal
80-1000 adult
500-2000 childhood
1000-5000 congenital
MBNL1
CUGBP1
miRNA metabolism
alternative splicing
miRNA metabolism
alternative splicing
DNA transcription
RNA
sequestration
p
p
p
p
p
p
p
p
p
MBNL1 (loss of function) CUGBP1 (gain of function)
U
G C
C G
G C
C G
G C
C G
G C
C G
G C
C G
U
U U
U U
U U
U U
U U
disruption of disruption of
12
of muscle involvement includes facial weakness, involvement of anterior 
neck muscles, and distal weakness of the limbs. Weakness and wasting of 
facial, levator palpebrae and masticatory muscles lead to ptosis and a typical 
myopathic appearance (figure 1.2). As the disease progresses more general 
muscle weakness occurs. Axonal neuropathy is usually subclinical, but may 
contribute to muscle weakness in DM1.9 Patients at an advanced state of 
muscle weakness are mostly able to maintain a limited mobility within the 
house, but half of them become partly or completely wheelchair bound.10 
Multi-organ symptoms, such as cataracts, cardiac involvement, sleep related 
breathing disorders, daytime sleepiness, apathy and avoidant personality 
features, early frontal balding in men and gastro-intestinal complaints develop 
at some time in their illness and may be of considerably greater importance to 
patients than the muscular aspects. Median survival is 59-60 years for adult-
onset type patients.10 Progressive respiratory failure is the leading cause of 
mortality, followed by death from cardiac causes in 20-30%.10-12 
Childhood-onset type presents between 1 and 12 years of age and is characterized 
by dysarthria, learning difficulties, psychosocial problems and sometimes de-
layed motor development.13 Swallowing difficulties may be present and articu-
lation is often poor, due to weakness of the bulbar musculature. Intelligence 
is commonly in the lower normal range (IQ> 70-100) or mild mental retar-
dation (IQ 50-70).14, 15 Attention deficit problems seem to be a frequent pro-
blem in the population of children with DM1. Muscular weakness gradually 
progresses with age and patients finally exhibit the multi-system features of 
adult-onset type disease. Survival is lower in childhood-onset phenotype than 
in the adult-onset type of the disease, with a mean age at death of 44.7 years.11
Congenital type is characterized by hypotonia, bilateral facial weakness, respi-
ratory deficiency, feeding and swallowing difficulties, talipes and other con-
tractures in the neonatal period. Mortality during the neonatal period has 
been estimated at 25% of patients.16 Patients who survive infancy are mentally 
retarded with total IQ ranging from 40-69 (median 54) and require special 
needs schooling.17 Children with congenital type DM1 are able to walk. Pro-
gressive muscle weakness and myotonia become present over the age of 10 
years. Median survival is 35 years for the congenital type. A child with conge-
nital DM1 inherits the mutation from the mother, with very few exceptions.
Cardiac involvement
Involvement of the heart is one of the main systemic features of DM1 affecting a 
majority of patients. It was first recognized by Griffith in 1911, who noted extreme 
bradycardia in a DM1 patient. However, few patients had cardiac symptoms and 
it was not until the routine implementation of electrocardiography (ECG) that 
cardiac involvement was found to be frequent.1 
13
Chapter
1.1
Figure 1.2. Variation of facial appearance in DM1
Legend to figure 1.2. Left: mother with adult-onset type and daughter with childhood-onset type 
DM1. Both show weakness and atrophy of the facial muscles. Reprinted from Ned Tijdschr 
Geneeskd. 2005 Oct 8;149(41):2316. Right: typical inverted V-shaped upper lip in congenital type 
DM1.
Cardiac tissue is affected by interstitial fibrosis and fatty infiltration.18 This 
degenerative process results in progressive failure of the conduction system. 
Cardiac involvement initially manifests as asymptomatic ECG abnormalities, 
commonly prolongation of the PR interval and QRS duration. Intracardiac 
electrophysiological studies revealed abnormalities in all areas of the 
conduction system, most commonly in the His-Purkinje system.19 Arrhythmias 
can occur, including progressive heart block, atrial tachycardia, flutter, or 
fibrillation, and ventricular tachycardia or fibrillation.20 Less commonly, 
myocardial involvement leads to left ventricular systolic dysfunction and 
clinically overt heart failure. Involvement of the heart is a major prognostic 
factor, since it is responsible for one third of deaths in patients with DM1.10, 11
In those with cardiac death, the rate of sudden death (84.6%) seems 
disproportionately greater than the rate of progressive heart failure (15.4%) when 
compared to other more standard heart failure populations.21 Progression to 
complete atrioventricular block or development of ventricular tachyarrhythmia is 
believed to be the cause of sudden death in these patients. However, it remains 
a challenge to identify patients who may benefit from primary prevention with 
implantable pacemakers or cardioverter-defibrillators.
Pathogenic mechanisms
Unlike most dominant inherited disorders, the expanded mutation in the DMPK 
gene does not produce dysfunctional proteins since the CTG triplet repeat 
lies outside the gene’s open reading frame, but results in non-coding RNA 
transcripts. The underlying molecular mechanisms have not been completely 
14
unravelled, but several hypotheses have been proposed and tested.
Expansion of the CTG repeat reduces the expression of DMPK itself.22 Mutant 
transcripts accumulate in the nucleus,23, 24 and presumably result in a depletion 
of mRNA in the cytoplasm and reduction of DMPK protein levels. Deficiency 
of the protein kinase may play a role in cardiac features since knockout mice 
show atrioventricular conduction delay and progression of conduction block 
with age, similar to the human phenotype.25-27 However, histopathologic cardiac 
evaluation showed no degeneration of conduction fibres or myocardium in 
these mice.28 Furthermore, myopathy is mild and other multisystem clinical 
features are absent in knockout mice.29, 30 In conclusion, mouse DMPK knock-
out models failed to reproduce the major features of DM1.
Another proposed mechanism is a decrease in expression of neighbouring ge-
nes through a change in chromatin structure caused by the repeat expansion. 
SIX homeobox 5 (SIX5) is located immediately downstream31 and is expressed 
in various tissues, including muscle, heart and eye lens.32 SIX5-/- and SIX5+/- 
mice developed cataracts, but no myopathy or myotonia.33-35 Heterozygous mice 
showed subtle intraventricular conduction delay and some enlargement of the 
left ventricle.35 Another neighbouring gene located upstream is dystrophia myo-
tonica-containing WD repeat (DMWD). It is highly expressed in testis and brain 
and proposed to play a part in mental retardation and male infertility in DM1, but 
there is no model to prove this hypothesis.36 
There is strong evidence that the mutant RNA transcribed from the expanded 
allele plays a major role in myotonic dystrophy. In 1998, a second type of myoto-
nic dystrophy (DM2) was identified resulting from a CCTG expansion within in-
tron 1 of the zinc finger 9 (ZNF9) gene on chromosome 3.37 DM2 patients have 
features resembling those in adult-onset DM1. The fact that repeat sequences 
localized on two different genomic loci with no apparent functional relationship 
cause similar clinical symptoms, suggests a common pathogenic mechanism 
involving RNA gain-of-function. RNA transcripts of the mutant allele accumula-
te in nuclear foci and interfere with trans-acting RNA-binding proteins CUG-bin-
ding protein 1 (CUGBP1) and muscleblind-like 1 (MBNL1) activity (figure 1.3). 
In DM1, MBNL1 is sequestered in ribonuclear foci in the nucleus resulting in 
decreased activity levels, while nuclear and cytoplasmic CUGBP1 levels are up-
regulated by hyperphosphorylation via different signalling pathways.38 CUGBP1 
and MBNL1 function as splice factors and altered activities of these regulatory 
proteins deregulate alternative splicing of a subset of developmentally regula-
ted genes in multiple tissues, leading to inappropriate expression of embryonic 
splicing isoforms in adult tissues.39 For example, CLCN1 chloride channel mis-
splicing in skeletal muscles leads to a non-functional channel, which results in 
myotonia,40 whereas abnormal splicing of the insulin receptor (INSR) might 
contribute to insulin resistance41.
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Loss of function of MBNL1 (and other members of the MBNL protein family) 
and CUGBP-1 up-regulation deregulates not only alternative splicing, but also 
transcription, miRNA metabolism and translation efficiency (figure 1.3).42 
Sequestration of transcription factors and other nuclear factors may contribute 
to deregulation of gene expression.
Figure 1.3. Molecular pathogenesis of DM1
Legend to figure 1.3. The pathogenic consequences of an expanded number of CUG repeats in the 
DMPK RNA include the sequestration of muscleblind-like protein 1 (MBNL1) into RNA foci and 
hyperphosphorylation and up-regulation of CUG triplet repeat RNA-binding protein 1 (CUGBP1), 
which leads to deregulation of global splicing events and other pathways in nuclei and cytoplasm 
of cells. 
Transgenic mouse models have recreated many molecular and phenotypic 
disease features, pointing to an RNA-mediated disease mechanism. 
Overexpression of untranslated CUG repeats in the skeletal muscle of HSALR 
(long repeat length) transgenic mice showed myotonia, histologically defined 
myopathy, MBNL1 sequestration in nuclear foci and spliceopathy, but no muscle 
weakness or wasting.43 MBNL1-/- knockout mice develop myopathy, cataracts 
and RNA splicing abnormalities.44 Neither mouse model was sufficient to 
recreate all muscle abnormalities. Induced CUGBP1 overexpression in adult 
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skeletal muscle reproduces molecular, histopathologic and functional changes 
typical of DM1, suggesting that CUGBP1 has a major role in DM1 skeletal 
muscle pathogenesis.45-47 A heart-specific mouse model expressing expanded 
CUG RNA exhibited systolic and diastolic dysfunction, PR prolongation, QRS 
widening and arrhythmias,48 which could be reproduced by overexpression of 
CUGBP1 in hearts of adult animals.49 
The underlying molecular mechanisms of myotonic dystrophy are likely to be 
exceedingly complex as the mutation can affect gene expression in multiple 
ways. Misregulation of alternative splicing plays a central role in the development 
of important DM1 symptoms, but major disease symptoms, such as muscle 
wasting and cardiac arrhythmias, cannot be readily explained by any of the 
splicing changes identified to date. Several mechanisms may have independent 
as well as overlapping downstream effects, leading to multiple symptoms of 
DM1.
Therapeutic strategies 
At present, treatment consists of symptomatic therapy and supportive care 
by a multidisciplinary team. Many professionals may be involved, including a 
neurologist and cardiologist, physical therapist, occupational therapist, speech 
therapist, specialist in rehabilitation medicine, pulmonologist, ophthalmologist, 
social worker and psychologist. Moderate intensity strength training or exercise 
programs can be recommended in all patients without an increased risk of 
damage to the muscles but there is insufficient evidence to conclude that it offers 
benefit.50 Pharmacological interventions aimed at improving muscle strength 
and function (creatine, recombinant human insulin-like growth factor I and 
dehydroepiandrosterone) have been used with little success.51-53 Mexiletine is 
used occasionally for treat ment of myotonia.54 Psychostimulants (e.g. modafinil, 
dexamphetamine or methylphenidate) are routinely applied in clinical practice 
to address excessive daytime sleepiness.55 Although management of symptoms 
can help diminish complaints, improve daily life, and prolong survival, it fails to 
slow or halt disease progression. 
Advances in understanding of the pathogenesis have led to experimental 
approaches with therapeutic potential aimed at reversing symptoms. 
Approaches targeting the mutant RNA transcript with the use of antisense 
oligonucleotides (AON) hold great prospect for therapeutic intervention in 
DM1. These AONs have been shown to reduce transcripts from the mutant 
DMPK allele in animal models, leading to a decrease in mutant RNA, as well 
as diminished ribonuclear foci and a reversal of selected splicing deficits.56, 57 
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Alternative approaches targeting downstream changes include up-regulation of 
MBNL activity,58 reduction of CUGBP1 protein levels,59 and reversal of specific 
aberrant splicing events.60 
Recommendations for DM1 management are based more on expert consensus 
and clinical experience than on evidence from randomized controlled trials. 
Future trials evaluating the efficacy of interventions in a clinical setting 
require appropriate outcome measures in order to accurately detect clinically 
meaningful changes. 
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Chapter 1.2
Outline of the thesis
This thesis focuses on cardiac involvement and clinical measurement in 
patients with myotonic dystrophy type 1 (DM1). 
In the first part of this thesis, we address the risk of sudden cardiac death, 
the presence of cardiomyopathy and its pathogenic mechanism. Objectives 
were to:
-	 provide a pragmatic approach for cardiac evaluation in hereditary 
muscular dystrophies based on literature review and consensus 
guidelines (chapter 2) 
-	 determine the occurrence rate of sudden death in DM1 and identify 
patients at risk (chapter 3)
-	 determine the presence and nature of cardiomyopathy in DM1 using 
cardiovascular magnetic resonance imaging (chapter 4) 
-	 identify differential gene expression patterns in DM1 hearts (chapter 5)
In the second part of the thesis, we show the importance of modern 
clinimetric methods and construct outcome measures for future DM1 
studies. Objectives were to:
-	 perform a systematic literature review on the outcome measures used in 
DM1 clinical trials (chapter 6)
-	 introduce Rasch analysis to develop disease-specific interval scales 
(chapter 7)
-	 develop an activity and participation scale using the Rasch Model 
(chapter 8 and 9) 
-	 develop a fatigue and daytime sleepiness scale using the Rasch Model 
(chapter 10)
The findings and conclusions described in this thesis and directions for 
future research are discussed in chapter 11.
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Summary
Cardiac disease is a common clinical manifestation of neuromuscular 
disorders, particularly of muscular dystrophies. Heart muscle cells as well as 
specialized conducting myocardial fibres may be affected by the dystrophic 
process. The incidence and nature of cardiac involvement vary with different 
types of muscular dystrophies. Some mainly lead to myocardial disease, 
resulting in cardiomyopathy and heart failure, while others particularly affect 
the conduction system, leading to arrhythmias and sudden death. As prognosis 
of muscular dystrophy patients may be directly related to cardiac status, 
surveillance and timely management of cardiac complications are important. 
However, recognition of cardiac involvement requires active investigation and 
remains challenging since typical signs and symptoms of cardiac dysfunction 
may not be present and progression is unpredictable. In this review, we present 
a comprehensive overview of hereditary muscular dystrophies associated with 
cardiac disease to provide an efficient strategy for expertise management of 
these diseases.
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Introduction
Muscular dystrophies form a heterogeneous group of inherited disorders 
that are clinically characterized by progressive skeletal muscle wasting and 
weakness. Clinical diagnosis is based on distribution and severity of muscular 
involvement, mode of inheritance and concomitant symptoms. Genetic testing 
can confirm the diagnosis if the gene defect is known (table 2.1).
Cardiac disease is a common clinical manifestation of neuromuscular disorders, 
particularly of muscular dystrophies. Cardiac involvement is not necessarily 
related to the degree of skeletal myopathy and may even be the presenting or 
predominant symptom. Cardiac death can result from progressive heart failure, 
due to ventricular dysfunction, or from sudden death, presumably caused 
by heart block or malignant arrhythmias. As quality of life and survival of 
muscular dystrophy patients have improved as a result of advances in medical 
management, heart failure and arrhythmias contribute to a larger extent to 
mortality.
This review serves as a comprehensive overview of the extensive literature on 
hereditary muscular dystrophies associated with cardiac disease. Molecular 
pathology, clinical aspects, cardiac findings and the mechanism and risk of 
cardiac death of these disorders are summarized to provide insight into the 
appropriate clinical approach and therapeutic options.
Search strategy and selection criteria
A literature search was performed to find individual studies and reviews 
published on cardiac involvement in muscular dystrophies. Muscular dystrophies 
and myopathies of interest were identified using PubMed and OMIM database. 
Subsequently, a more extensive PubMed search was performed using the specific 
type of muscular dystrophy in combination with any of the following keywords: 
aetiology, diagnosis, heart disease, cardiomyopathy, arrhythmias, (sudden) 
death, prognosis, treatment. Furthermore, the bibliographies of all review 
articles published in the past 10 years regarding the cardiac involvement in 
muscular dystrophies were checked. 
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Table 2.1. Classification of muscular dystrophies1
Gene/protein; chromosome
Dystrophinopathy
Duchene muscular dystrophy Dystrophin; Xp21.2
Becker muscular dystrophy Dystrophin; Xp21.2
X-linked dilated cardiomyopathy Dystrophin; Xp21.2
Emery Dreifuss muscular dystrophy (EDMD)
X-linked EDMD (EDMD1) Emerin; Xq28
     Autosomal dominant EDMD (EDMD2) Lamin A/C; 1q21.2
Limb girdle muscular dystrophy (LGMD)
     Autosomal dominant LGMD (type 1)
-- LGMD 1A Myotilin; 5q31
-- LGMD 1B Lamin A/C; 1q21.2
-- LGMD 1C Caveolin-3; 3p25
-- LGMD 1D 7q
-- LGMD 1E 6q23
-- LGMD 1F 7q32
-- LGMD 1G 4q21
     Autosomal recessive LGMD (type 2)
-- LGMD 2A Calpain-3 ;15q15
-- LGMD 2B Dysferlin; 2p13.2
-- LGMD 2C γ-Sarcoglycan; 13q12
-- LGMD 2D α-Sarcoglycan; 17q21
-- LGMD 2E β-Sarcoglycan; 4q12
-- LGMD 2F δ-Sarcoglycan; 5q33
-- LGMD 2G Telethonin; 17q12
-- LGMD 2H TRIM32; 9q31-q33
-- LGMD 2I Fukutin-related protein; 19q13.3
-- LGMD 2J Titin; 2q31
-- LGMD 2K POMT1; 9q34.1
-- LGMD 2L Anoctamin 5; 11p14
-- LGMD 2M Fukutin; 9q31
Myotonic dystrophy (DM)
DM type 1 (Steinert’s disease) DMPK; 19q13.2-q13.3
DM type 2 (proximal myotonic myopathy: PROMM) ZNF9; 3q13.3-q24
Congenital muscular dystrophy (MDC)
Non-syndromic MDC
-- MDC 1A (merosin deficient) Laminin α2; 6q22-23
-- MDC 1B 1q42
-- MDC 1C Fukutin-related protein; 19q13.3
-- Ullrich MDC Collagen type 6A1-A3; 21q22.3 
and 2q37.3
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Syndromic MDC
-- Fukuyama MDC Fukitin; 9q31
-- Muscle-eye-brain disease (Santavuori) POMGnT1; 1p32-p34
-- Walker Warburg syndromes POMT1; 9q34.1 - POMT2; 
14q24.3
-- MDC 1D LARGE; 22q12.3-13.1
Facioscapulohumeral muscular dystrophy (FSHD) 4q35
Myofibrillar myopathies (MFM)
Desmin-related MFM Desmin; 2q35
αB-crystallinopathy αB-crystallin; 11q22.3-q23.1
Filamin C-related MFM Filamin C; 7q32
Myotilin-related MFM Myotilin; 5q31
Rigid spine syndrome SEPN1; 1p36-p35
ZASP-related MFM ZASP; 10q22.2-q23.3
BAG3-related MFM BAG3: 10q25.2-q26.2
Other 
Other muscular dystrophies
Distal myopathies
-- Welander 2p13
-- Myioshi Dysferlin; 2p13.1
-- Finnish type Titin; 2q31
-- Nonaka (hereditary inclusion body myositis 2) GNE; 9p12-p11
-- Gowers Laing MYH7; 14q11
-- Distal dystrophy with rimmed vacuoles 19p13.3
X-linked vacuolar cardiomyopathy and myopathy  
(Danon disease)
LAMP-2; Xq24
Barth syndrome TAZ (Tafazzin); Xp28
McLeod syndrome XK membrane transport  
protein; Xp21.1
Reducing body myopathy (RBM) FHL1; Xq26-q27.2
X-linked scapuloperoneal myopathy FHL1; Xq26-q27.2
X-linked myopathy with postural muscle  
atrophy (XMPMA)
FHL1; Xq26-q27.2
Early-onset myopathy with fatal cardiomyopathy Titin; 2q31
Various phenotypes MYH7; 14q12
Gene/protein; chromosome
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Dystrophinopathies
Dystrophinopathies refer to the disorders Duchenne muscular dystrophy 
(DMD), Becker muscular dystrophy (BMD) and X-linked dilated cardiomyopathy 
(XLCM). The incidence of DMD is estimated at 1 in 3500 male new-borns with 
a prevalence of 6 in 100 000 males.2 DMD is characterized by weakness of leg, 
pelvic and shoulder girdle muscles starting in early childhood. The introduction 
of home nocturnal ventilation has raised the mean age of death from 19 to at 
least 25 years.3
BMD is a milder variant of DMD with a better prognosis. Incidence of BMD 
is approximately 1 in 18 450 males and prevalence is 2.4 per 100 000 in the 
general population.2, 4 First symptoms usually appear between the age of 3 and 
21 years with a mean age of onset at 11 years. Age at death is 21-89 years with an 
average age of about 45 years.5-8
XLCM is a rare disorder with rapidly progressive cardiomyopathy but almost no 
skeletal muscle impairment. The distinction between XLCM and a BMD patient 
with mild skeletal muscle weakness can be unclear. Therefore, it is argued to 
consider these entities of dystrophinopathy as part of a continuum of disease 
expression.9
The dystrophin gene codes for a large protein (dystrophin) that is part of a 
multimeric protein complex called the dystrophin-glycoprotein complex. In DMD 
patients, mutations disrupt the reading frame, while in BMD the reading frame 
is maintained.10 Absence of the dystrophin protein (DMD) and reduced levels 
or abnormal configuration of dystrophin (BMD) leads to membrane fragility 
making muscle cells susceptible to damage from contraction.11 Secondary 
increase in free radicals and activation of calcium-dependent proteases are 
thought to further contribute to muscle degeneration. As muscle disease 
advances, muscle repair and regeneration cannot adequately compensate 
for damage, leading to degeneration and necrosis of skeletal myofibers and 
cardiomyocytes and gradual replacement by fibrofatty tissue.12 
Cardiac involvement in Duchenne muscular dystrophy
In a large series of DMD patients, the evolution of cardiac involvement has been 
investigated.13-15 Conduction defects, dilated and hypertrophic cardiomyopathy 
are first evident on ECG and echocardiography after 10 years of age. The 
incidence increases with age, being present in all patients over 18 years of 
age. Most patients develop dilated cardiomyopathy, sometimes preceded by 
localized hypertrophy and isolated conduction defects.16 Characteristic ECG 
abnormalities are summarized in table 2.2. Rhythm abnormalities include 
sinus arrhythmia, atrial flutter, frequent premature atrial and ventricular beats. 
Ventricular arrhythmias occur frequently in DMD patients with impaired 
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ventricular function and may be an additional marker of deteriorating myocardial 
function.17, 18
Progressive heart disease due to congestive heart failure or sudden death is the 
cause of death in 10-20% of DMD patients, but the percentage of primary cardiac 
death is expected to rise now that more successful management of respiratory 
complications reduces mortality due to pulmonary causes.19 Indeed, ventricular 
dysfunction appears to be a powerful predictor of mortality.20 Clinical studies 
demonstrated a beneficial effect of ACE inhibitors on onset and progression of 
ventricular dysfunction and survival.21, 22 ACE inhibition also improved skeletal 
muscle regeneration in the mdx mouse model for DMD.23, 24
Cardiac involvement in Becker muscular dystrophy
In BMD, the heart becomes invariably affected and cardiac disease can even be 
more pronounced than skeletal muscle weakness. ECG and echocardiographic 
abnormalities can be found in 17-74% of patients (table 2.2).25-28 In a longitudinal 
study of 68 BMD patients, the occurrence of clinically apparent cardiomyopathy 
increased significantly with age, from 44% in patients under 20 years of age to 
82% in patients older than 40 years during a mean follow-up period of 8 years.26 
In a series on 27 BMD patients, the incidence of ECG abnormalities progressed 
from 44% to 71% and dilated cardiomyopathy from 15% to 33% of patients over 
a 13-year period.8
As the level of physical activity is higher and respiratory function is better 
than in DMD, patients with BMD survive long enough to develop cardiac 
complications. Death from congestive heart failure and arrhythmias is estimated 
to occur in up to 50% of cases.29 BMD has a high heart transplantation rate in 
the first year after diagnosis of cardiomyopathy.30 The potential cardiac benefit 
of early treatment with afterload-reducing therapy has hardly been investigated 
in BMD patients. A retrospective observational study of 31 males with DMD 
or BMD reported normalized left ventricular size and function in 3 out of 4 
treated BMD patients, indicating ventricular remodelling.31 Although the timing 
of cardiomyopathy development remains unpredictable, mutations in specific 
regions of the dystrophin gene predispose BMD patients to early onset DCM.32 
These patients may benefit from early medical therapy or heart transplantation.
Cardiac involvement in female carriers
The prevalence of cardiac abnormalities in DMD and BMD carriers differs 
between studies, possibly because definitions vary widely. A 10-year follow-
up study of 152 DMD and 45 BMD carriers reported clinical features of heart 
disease, such as hypertrophy, arrhythmias or dilated cardiomyopathy, in 
40%.33 The percentage of clinical cardiac involvement increased significantly 
with age, from 15% in carriers aged under 16 years to 45% in carriers 16 years 
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and older. By contrast, a retrospective study suggested that clinically relevant 
cardiac abnormalities are unlikely in female carriers under 16 years.34 In a 
cross-sectional study of 85 DMD and 44 BMD carriers aged 18-58 years, left 
ventricular dilatation (18%) and dilated cardiomyopathy (8%) were found on 
echocardiography.35 Dilated cardiomyopathy was found only in DMD carriers, 
whereas left ventricular dilatation was present in a proportion of both DMD 
and BMD carriers. ECG abnormalities were found in 47% of this population.36 
Another series of 56 adult carriers revealed no such ECG abnormalities, but 
found ventricular dilatation or hypertrophy in 14% and dilated cardiomyopathy 
in 7% of females.37 Nevertheless, severe heart failure may develop in some 
women and require heart transplantation or result in premature (sudden) 
death.33, 38, 39 Cardiac examination is recommended every 5 years in order to start 
timely therapy.29 However, the benefit of early treatment awaits confirmation 
since a recent limited population-based study argues that it is unclear whether 
carriers of DMD and BMD have a reduced life expectancy or higher risk of 
cardiac death.40
X-linked dilated cardiomyopathy (XLCM)
XLCM is a primary myocardial dystrophinopathy, presenting as congestive heart 
failure in teenage males. The disease course is rapidly progressive resulting 
in cardiac death within 1-2 years. Manifesting female carriers have later onset, 
usually during the fifth decade, and slow progression of heart failure.9, 41 Most 
reported XLCM families have mutations in the 5’ end of the dystrophin gene, 
resulting in absence of the M-isoform in heart and skeletal muscle.42 Skeletal 
muscle, however, escapes the dystrophic changes by maintaining dystrophin 
synthesis by exon skipping or alternative splicing that the heart is not able to 
put in place.42 
The reported cardiac abnormalities and mortality data of patients with 
dystrophin mutations are summarized in table 2.2.
Emery-Dreifuss muscular dystrophy
Emery-Dreifuss muscular dystrophy (EDMD) is characterized by early 
contractures of elbows, Achilles tendons (toe walking) and posterior cervical 
muscles (rigid spine), and muscle weakness in a humero-peroneal distribution. 
Joint contractures occur in early childhood, often before there is any significant 
weakness. 
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Table 2.2. Cardiac abnormalities and prognosis in dystrophinopathies
Disease ECG Echo Cardiac death Age at death
DMD - tall R waves or R/S ratio >1  
in lead V1 or V2
- Q waves in lateral leads
- complete or incomplete LBBB  
or complete RBBB 
- tachyarrhythmias
- myocardial 
hypertrophy
- dilated 
cardiomyopathy
10-20%29 mean 19 years in 
non- ventilated 
patients, mean 25 
years in ventilated 
patients3
BMD - tall R waves or R/S ratio >1  
in lead V1
- Q waves in lateral leads 
- complete or incomplete LBBB  
or complete RBBB
- tachyarrhythmias
- myocardial 
hypertrophy
- dilated 
cardiomyopathy
50%29 mean 45 years, 
range
21-89 years5-8
Carriers - tall R waves or R/S ratio >1  
in lead V1 or V2
- Q waves in lateral leads
- incomplete LBBB and  
complete RBBB
- myocardial 
hypertrophy 
- left ventricular 
dilatation
- dilated 
cardiomyopathy
no major 
cause of 
death40
unknown
XLCM - dilated 
cardiomyopathy
~100% mean 22 years, 
range 15-52 years9, 
41, 42
X-linked recessive EDMD (EDMD1) has a prevalence of 1 in 100 000 males. 
It can result from various mutations in the STA gene.43 The protein product 
(emerin) is a component of the inner nuclear membrane. It is a member of a 
protein complex that links filamentous actin in the cytoskeleton to the nuclear 
lamina and/or chromatin.44, 45 Heterogeneous mutations have been reported 
and almost always result in complete absence of emerin in muscle.46 
Autosomal dominant EDMD (EDMD2) and a rare autosomal recessive form 
of EDMD are caused by a mutation in the lamin A/C gene.47, 48 Prevalences 
are unknown. Lamin A/C codes for alternatively spliced lamins A and C. 
Interestingly, lamin A/C mutations can cause several other phenotypes, 
including limb-girdle muscular dystrophy type 1B (LGMD1B), autosomal 
dominant dilated cardiomyopathy with conduction defects (CMD1A), autosomal 
recessive EDMD, autosomal recessive axonal neuropathy, familial partial 
lipodystrophy, mandibuloacral dysplasia and progeria syndromes, all referred 
to as laminopathies. Hundreds of mutations are found along the lamin A/C 
gene, without phenotype-specific hotspots.49 De novo mutations are frequent 
in the LMNA gene.50
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The EDMD phenotypes caused by emerin or lamin A/C mutations are 
clinically indistinguishable, suggesting a close functional relationship between 
the two proteins.51 In the absence of an informative family history, emerin 
immunodetection studies help to distinguish between EDMD1 and EDMD2.52 
Recently, it has been shown that mutations in genes encoding nesprins 1 and 2 
(proteins binding both emerin and lamins A/C) can also cause EDMD.53 Some 
have suggested that muscle cells lacking emerin or lamin A/C may be particularly 
sensitive to mechanic stress during contraction due to loss of structural 
integrity of the nuclear membrane.54 An alternative hypothesis suggests that 
these nuclear envelope proteins may have a role in chromatin organization and 
regulation of gene expression. As a result, lamin A/C and emerin mutations 
may cause defective cellular signaling in response to mechanical stimulation, 
impaired activation of anti-apoptotic genes and abnormal apoptosis defective 
muscle differentiation and regeneration.55, 56
Cardiac involvement in EDMD1
In EDMD1, cardiac disease often presents as conduction disturbances (table 
2.3).57 Ventricular myocardium may become involved leading to mild ventricular 
dilatation and low-normal systolic function.58, 59 Eventually atrial paralysis 
will occur, with loss of electrical and mechanical activity of the atria. Under 
microscopy, marked loss of atrial myocardium and its replacement by fibrous 
and fat tissue have been observed, as well as various degrees of interstitial 
fibrosis in the ventricular myocardium. However, no specific degeneration of 
the conduction system was found.60
Sudden death is by far the most common cause of death and can be highly 
unpredictable.61 Therefore, routine ECG and yearly Holter monitoring are 
indicated and pacemaker implantation should be considered if sinus node or 
AV node disease develops.29 Pacemakers are often needed by 30 years of age 
(range 14-44).62-64 Once patients are successfully paced, the incidence of sudden 
death appears low.64 However, atrial arrhythmias and atrial standstill can cause 
disabling embolic stroke.63 Heart failure and ventricular arrhythmias seem to 
occur only in a minority of patient, but the risk may increase as patients with a 
pacemaker may survive longer.59, 63
Cardiac involvement in carriers
Female carriers of an emerin mutation have no muscular symptoms, though 
some may be at risk of cardiac arrhythmias,46, 59, 64 and sudden death.60 Reports 
may have been biased by cases of autosomal dominant disease. Systemic 
studies on the natural history of cardiac involvement in EDMD1 carriers are not 
available, but it seems appropriate to offer ECG surveillance.
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Cardiac involvement in EDMD2 and other laminopathies
The laminopathies EDMD2 and LGMD1B have an overlapping cardiac phenotype. 
LGMD1B differs from the EDMD2 phenotype by later onset of muscular 
weakness, the absence of significant early contractures and the predominance 
of pelvic girdle weakness with late involvement of humeral muscles and sparing 
of the peroneal and tibial muscles.65 CMD1A is characterized by progressive 
conduction-system disease and dilated cardiomyopathy without muscular 
symptoms.66 It is interesting to note that the same mutation within a family 
can lead to either EDMD2, CMD1A or LGMD1B phenotypes.67, 68
A review from the literature of 299 patients with lamin A/C mutation causing 
LGMD1B, EDMD2 or CMD1A, reported conduction disease as well as cardiac 
failure.69 Dysrhythmias (sinus bradycardia, atrioventricular conduction block, 
or atrial arrhythmias) were present in 71% of patients increasing with age to 
92% after the age of 30 (figure 2.1). Heart failure was reported at a later age 
but less frequently then dysrhythmias. Patients died at a mean age of 46 years. 
The incidence of sudden death was very high and more prevalent than death 
due to heart failure (46% versus 12%, respectively). The risk of sudden death 
was equal in lamin A/C mutation carriers with a neuromuscular phenotype or 
isolated cardiac phenotype. However, it appeared that sudden death was not 
reduced by pacemaker therapy, suggesting a ventricular arrhythmogenic cause 
of death.67, 69 
Table 2.3. Cardiac abnormalities and prognosis in Emery-Dreifuss muscular dystrophy
Disease ECG Echo Cardiac death Age at death
EDMD1 - low P wave amplitude
- atrioventicular block
- atrial fibrillation 
- atrial standstill with 
junctional escape 
rhythm
- atrial dilatation
- ventricular 
dilatation 
- left ventricular 
dysfunction
high risk of
sudden death 
in non-paced
patients 
sudden death 
usually before 
50 years (range 
25-59)61, 64 
Carrier - low P wave amplitude
- atrioventicular block
- atrial fibrillation
- atrial dilatation probably no 
major
cause of death
unknown
EDMD2* - low P wave amplitude 
- atrioventricular block 
with initially narrow QRS
- atrial arrhythmias
- dilated 
cardiomyopathy
43% sudden 
death
11% heart failure69 
mean 45 years69
* based on cases with LMNA mutations leading to emery-dreifuss or limb-girdle muscular 
dystrophy
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Figure 2.1. Electrocardiographic changes in a patient with limb girdle muscular 
dystrophy type 1B
Legend to figure 2.1. A: ECG showing sinus rhythm with low amplitude P wave and PR 
prolongation at the age of 28. QRS duration is already increased. B: at 32 years of age the ECG 
showed sinusbradycardia with grade II AV-block.
A prospective study on 19 patients with a lamin A/C mutation receiving an 
implantable cardioverter-defibrillator (ICD), showed effective treatment of 
possibly lethal tachyarrhythmias.70 It is not yet clear which clinical factors predict 
increased risk of sudden death and can guide therapy. 
A recent report suggests that competitive sport activity is possibly an important 
risk factor,71 but this awaits larger studies to more definitively establish 
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clinical parameters of risk in this group. A summary of the reported cardiac 
abnormalities in EDMD is presented in table 2.3.
Limb-girdle muscular dystrophy 
Limb-girdle muscular dystrophies (LGMD) are a clinically and genetically 
heterogeneous group of muscular dystrophies in which the pelvic and shoulder 
girdle musculature are predominantly involved.72 Currently, 7 autosomal 
dominant (LGMD1A to LGMD1G) and 13 autosomal recessive forms (LGMD2A 
to LGMD2M) are recognized.73 The disease course of autosomal dominant 
LGMD usually is relatively mild.74 Age of onset ranges from childhood to the 
fourth decade. The clinical picture of autosomal recessive LGMD is more severe 
and closely resembles that of the dystrophinopathies.74  Distinction between 
the different types of LGMD is difficult on clinical criteria alone and requires 
protein analysis in muscle biopsy and genetic studies. Estimated prevalence of 
all forms of limb-girdle muscular dystrophy ranges from 1 in 23 000 to 1 in 150 
000.2, 74
Protein defects in LGMD occur in several pathways concerned with skeletal 
and/or cardiac muscle function. These include proteins associated with the 
dystrophin-glycoprotein complex, nuclear lamina or sarcomere. Furthermore, 
disruption of proteins that mediate sarcolemmal repair or other cell-signalling 
pathways and defective enzymes can result in the limb-girdle dystrophic 
phenotype.75 Although the primary defect in many limb-girdle dystrophies 
is known, the exact functional role of the affected proteins and the precise 
pathogenic mechanism leading is largely unknown. Moreover, mutations 
within the same gene can give rise to distinct phenotypes without limb-girdle 
syndrome (i.e. allelic heterogeneity).
Cardiac involvement in LGMD1
Cardiac involvement is common in LGMD1B and has been described above. 
To date, LGMD1A (myotilinopathy) and LGMD1C (caveolinopathy) have not 
been associated with cardiac problems.76, 77 However, cardiomyopathy has been 
reported in allelic disorders with mutations in myotilin (myofibrillar myopathies) 
and caveolin-3 (autosomal dominant rippling muscle disease), which may 
overlap with LGMD1A and C, respectively. LGMD1E has been reported in only one 
family to date.78 The phenotype is similar to LGMD1B. Dilated cardiomyopathy 
with conduction defects (table 2.4) and/or adult-onset limb-girdle muscular 
dystrophy were present in affected members. Sudden death was observed 
despite pacemaker therapy. Reports on LGMD1D, 1F and 1G are very rare and so 
far no cardiac abnormalities have been reported in these diseases. 
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Table 2.4. Cardiac involvement and prognosis in limb girdle muscular dystrophy
Disease ECG Echo Cardiac death Age at death
LGMD1B* - low P wave amplitude 
- atrioventricular block with 
initially narrow QRS
- atrial arrhythmias
- dilated 
cardiomyopathy
43% sudden 
death
11% heart failure69 
mean 45 
years69
LGMD1E - atrioventicular block
- complete RBBB
- ventricular tachycardia 
- dilated 
cardiomyopathy
considerable risk
33% sudden 
death78 
mean 47 
years78 
LGMD2C-F - tall R waves in lead V1 or V2
- Q waves in lateral leads
- incomplete RBBB
- ventricular 
dilatation
- left ventricular 
dysfunction
- impact on 
prognosis unclear
- cardiomyopathy  
can be fatal89, 90
third 
decade99, 100
LGMD2I - dysmorphic notched P waves
- Q waves in lateral leads
- complete or incomplete  
RBBB or incomplete LBBB
- dilated 
cardiomyopathy
considerable risk range 16-
6794, 95 
* based on cases with LMNA mutations leading to emery-dreifuss or limb-girdle muscular 
dystrophy
Cardiac involvement in Sarcoglycanopathies (LGMD 2C, 2D, 2E, and 2F)
Sarcoglycanopathies comprise four subtypes of autosomal recessive LGMD 
that are caused by mutations in the transmembrane proteins of the sarcoglycan 
complex. This complex is integrated in the muscle membrane as a part of the 
dystrophin-glycoprotein complex.79 A wide range of mutations in any of the 
α-sarcoglycan (LGMD2D), β-sarcoglycan (LGMD2E), γ-sarcoglycan (LGMD2C) 
or δ-sarcoglycan genes (LGMD2F) destabilize the whole sarcoglycan complex,80 
resulting in an inability to protect the membrane against contraction-
induced degeneration. The estimated prevalence of sarcoglycanopathies is 
approximately 1 in 178 000.81 LGM2D is the most frequent sarcoglycanopathy, 
followed by LGMD2E and LGMD2C, while LGMD2F is most uncommon.81-83 
Disease severity is related to the percentage of residual sarcoglycan protein. 
Patients present at a mean age of 8 years with pelvic muscle weakness and early 
scapular winging.84, 85 Individuals with partial deficiency will generally exhibit 
symptoms between adolescence and early adulthood.86 
In small series, mild ECG and/or echocardiographic abnormalities occurred in 
20-30% in any type of sarcoglycanopathy (table 2.4).87, 88 The risk of significant 
cardiac involvement appears low in LGMD2D patients, while severe dilated 
cardiomyopathy and lethal ventricular arrhythmias may be an important 
feature in LGMD2E patients with severe DMD-like dystrophy.89, 90 However, a 
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clear genotype-phenotype correlation and long-term follow-up to determine 
the relative impact on prognosis has not yet been established. Therefore, it is 
argued to investigate patients with sarcoglycanopathy for cardiomyopathy as 
in dystrophinopathies.29 Respiratory involvement is also common and can be a 
cause of death.88
Cardiac involvement in LGMD2I
LGMD2I is caused by mutations in the fukutin-related protein gene (FKRP).91 
FKRP mutations were initially found in a severe form of congenital muscular 
dystrophy (MDC1C) and have been reported in some cases of muscle-
eye-brain disease en Walker-Warburg syndrome.92 Mutant FKRP directly or 
indirectly disturbs glycosylation of the transmembrane protein α-dystroglycan 
in muscle cells. Appropriate glycosylation is necessary for α-dystroglycan to 
bind components of the extracellular matrix, including laminin-2.93 In LGMD2I 
patients, the 826C>A mutation is almost invariably found in one or two alleles. 
Homozygosity for this missense mutation is associated with milder muscular 
dystrophy.94 However, phenotypic variability is remarkable between affected 
relatives and ranges from severe muscle weakness to isolated exertional 
myoglobinuria or muscle cramps.
Cardiac involvement has been reported in 29-62% of LGMD2I patients with the 
use of different definitions.94-98 Left ventricular wall motion abnormalities and 
dilated cardiomyopathy start as early as the teen years. A substantial proportion 
of patients develop symptomatic cardiac failure over time, starting at a mean age 
of 38 years (range 18-58).95 Cardiac magnetic resonance imaging displays early 
functional and morphological ventricular abnormalities, including ventricular 
wall fibrosis.98 Significant arrhythmias or sudden death have not been reported. 
Cardiac abnormalities are not always associated with early and severe muscle 
weakness.95, 98 A summary of the reported cardiac abnormalities in LGMD2I 
is presented in table 2.4. LGMD2I patients are also at risk of respiratory 
impairment and may require nocturnal ventilation.94, 95
LGMD2 without cardiac involvement
There is no clear evidence for cardiac involvement in LGMD2A (calpainopathy) 
and LGMD2B (dysferlinopathy).97 Limb-girdle type 2G, 2H, 2J, 2K 2L and 2M 
have only rarely been described and have thus far not been associated with 
cardiac abnormalities. Heterozygous family members are asymptomatic. 
Myotonic dystrophy
Myotonic dystrophy is characterized by autosomal dominant inheritance, 
progressive muscle weakness and wasting, myotonia and multisystem 
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complications. There are two distinct forms recognized: myotonic dystrophy 
type 1 and myotonic dystrophy type 2. 
Myotonic dystrophy type 1
Myotonic dystrophy type 1 (DM1) is the most common muscular dystrophy 
in adults. It has a prevalence of 2.1-14.3 per 100 000 worldwide, but higher 
prevalences have been found in certain populations due to founder effect 
and genetic isolation.101 Muscle involvement consists of myotonia and 
weakness of facial, sternocleidomastoid and distal muscles. Additionally, DM1 
patients usually have serious systemic manifestations including cataracts, 
gastro-intestinal problems, central nervous system involvement and cardiac 
abnormalities. 
An earlier age of onset and increased severity of clinical symptoms has been 
observed in subsequent generations.102 Based on age at onset and symptoms, 
four clinical categories can be distinguished: congenital type, childhood-onset 
type, adult-onset (classical) type and late-onset (mild) type.103 Life expectancy 
is greatly reduced in DM1 patients, particularly in those with early onset of the 
disease and proximal muscular involvement.104 Median survival was 59-60 
years for adult-type patients and 35 years for the congenital type.105 Progressive 
respiratory failure is the leading cause of mortality, followed by death from 
cardiac causes in 20-30%.104-106
DM1 results from an expansion of a repetitive trinucleotide segment in the 
3’untranslated region of the myotonic dystrophy protein kinase (DMPK) gene.107 
The normal DMPK allele contains 5-35 CTG repeats, whereas it is expanded 
to hundreds or even thousands of copies in DM1 patients. The degree of the 
expansion correlates broadly with severity of the phenotype and is inversely 
correlated with age at onset.103 As a rule, the repeat expands in subsequent 
generations, explaining anticipation. 
The molecular pathway is not completely unravelled. Reduction of DMPK 
protein levels through depletion of mRNA in the cytoplasm may play a role 
in the cardiac disease.108 Furthermore, expression levels of neighbouring 
genes may be decreased through a change in chromatin structure.109 However, 
this does not seem to explain the wide range of clinical manifestations. The 
dominant mechanism most likely involves toxicity of the mutant DMPK 
mRNA accumulating in nuclear foci, resulting in abnormal RNA-processing of 
additional transcripts.110 However, muscle wasting cannot be readily explained 
by any of the splicing changes identified to date. Unlike some other forms of 
muscular dystrophy, muscle wasting in DM1 is characterized by muscle atrophy 
instead of extensive necrosis, suggesting defects in muscle protein metabolism. 
Furthermore, impaired proliferative capacity of DM1 satellite cells has been 
shown in vitro, which may involve a mechanism of premature senescence.111
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Cardiac involvement in myotonic dystrophy type 1 
Cardiac involvement is one of the main systemic features of DM1 and a major 
prognostic factor. Serious cardiac abnormalities can occur as early as the second 
decade of life in patients with the congenital/childhood type.112 The reported 
cardiac abnormalities in DM1 are summarized in table 2.5. Conduction deficits 
occur in approximately 65% of adult patients.113 In most patients, conduction 
disease progresses gradually (figure 2.2), but the clinical course cannot be 
predicted in individual patients.114, 115 
Figure 2.2. Progressive cardiac conduction changes on the electrocardiograms of a patient with 
adult type myotonic dystrophy type 1
Legend to figure 2.2. A: normal sinus rhythm was seen at 25 years of age. B: At the age of 37, the 
patient had right bundle branch block and left axis deviation with a long PR interval.
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Evaluation of pacemaker recordings show frequent occurrence of asymptomatic 
paroxysmal episodes of atrial and ventricular arrhythmias.116 His-Purkinje 
conduction delay is the most frequent electrophysiological abnormality.117 
Pathological investigation show focal replacement fibrosis of conduction 
tissue and diffuse interstitial fibrosis throughout the myocardium.118 Mild to 
moderate ventricular dysfunction and subtle structural changes can be found 
on echocardiograms and magnetic resonance imaging.119, 120 However, the 
prevalence of congestive heart failure is low and estimated at 2-7%.120, 121 There 
is no consensus from literature whether or not CTG repeat size has value as a 
prognostic indicator of cardiac disease. 
Sudden death is well documented in DM1. A large prospective trial demonstrated 
that an electrocardiogram showing severe abnormalities (defined as rhythm 
other than sinus, PR interval >240 ms, QRS duration >120 ms or second- or 
third degree atrioventricular block) is an independent risk factor of sudden 
death.106 Until recently, sudden death was thought to be primarily the result 
of conduction blocks. However, reports of sudden death in patients with 
implanted pacemakers, as well as sudden death closely related to documented 
spontaneous ventricular tachycardia, suggest that ventricular tachyarrhythmias 
are possibly a more frequent cause of death than previously thought.106, 
122 Ventricular tachyarrhythmias are often inducible by electrophysiological 
studies, but their predictive value remains to be determined.117 An ECG is an 
appropriate screening test and should be made yearly from diagnosis. In some 
patients cause of syncope may be difficult to establish and tilt table testing, 
repeated Holter monitoring or an implantable loop recorder may be indicated. 
Holter monitoring is recommended in patients with ECG abnormalities to 
detect asymptomatic conduction blocks and arrhythmias.29 It is important to 
address sudden death and the occurrence of ventricular arrhythmias should be 
assessed with the highest priority. Moreover, the effectiveness of prophylactic 
ICD implantation should be investigated in patients with an increased risk of 
sudden death and relatively good neuromuscular prognosis. 
Myotonic dystrophy type 2 
Myotonic dystrophy type 2 (DM2) is a recently delineated autosomal dominant 
disorder with features resembling those in adult-onset DM1. The clinical course 
of DM2 is usually more favourable compared to DM1. To date, most reported 
DM2 families are of German-Eastern European descent, suggesting that there 
may be a single founder mutation.123 Patients present typically in adult life and 
exhibit predominantly proximal lower limb weakness or weakness of deep finger 
flexors.124, 125 An earlier age of onset is present in offspring of affected parents, 
but no congenital cases or mental retardation have been noted in DM2. A 
review of 209 DM2 patients reported that first symptoms occurred between 13 
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and 67 years (median age at onset 48 years).124 Facial muscle weakness is less 
severe, myotonia is usually less apparent and muscle atrophy is milder than in 
DM1 patients. Muscle pain is a major complaint of DM2 patients. Furthermore, 
systemic involvement, like cataract, cardiac involvement and endocrine 
dysfunction may also be present. Contrary to DM1, respiratory problems or 
failure do not occur, influencing prognosis to a large extent.124, 125
The mutation underlying DM2 is an unstable expanded CCTG-repeat.126 
Expanded allele sizes ranged from 75 to 11 000 repeats. The clinical and 
molecular similarities that exist between the different myotonic dystrophies 
suggest a common pathogenic mechanism involving repeat containing RNA 
transcripts.127
Cardiac involvement in myotonic dystrophy type 2
Cardiac problems are considered to be a less frequent complication in DM2 
than in DM1 (table 2.5). Conduction abnormalities were found in 20-36% 
of patients.124, 125, 128 Furthermore, a recent study of 38 DM2 patients, aged 57 
± 15.2 years, reported (paroxysmal) atrial fibrillation in 6, mild left ventricular 
dysfunction in 4 and congestive heart failure in 2 patients.128 Sporadic cases 
of cardiomyopathy with ventricular arrhythmias and sudden death in DM2 
patients have also been reported.129-131 Life expectancy may be reduced in single 
cases, mainly if there is severe cardiac involvement. Although the risk for such 
events appears low, experts have recommended annual ECG and more extensive 
evaluation if symptoms are reported.132
Table 2.5. Cardiac abnormalities and prognosis in myotonic dystrophy
Disease ECG Echo Cardiac death Age at death
Myotonic 
dystrophy type 1
- atrioventricular block 
- complete or incomplete  
RBBB and LBBB
- atrial and ventricular  
arrhythmias
 
- left ventricular 
dilatation and 
dysfunction
20-30%104, 105 mean 54 years104, 105 
Myotonic 
dystrophy type 2
- atrioventricular block 
- complete or incomplete  
RBBB and LBBB
- atrial and ventricular 
arrhythmias
- left ventricular 
dysfunction 
probably no 
major cause 
of death133
unknown
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Congenital muscular dystrophy
Congenital muscular dystrophy (MDC) describes a number of inherited 
disorders in which muscle weakness is present at birth or within the first 6 
months of life. MDC has either a slowly progressive or non-progressive course. 
Morbidity and mortality rates depend on the type of congenital muscular 
dystrophy. Some children die in infancy, whereas others can live into adulthood 
with only minimal disability. Nearly all forms are inherited in an autosomal-
recessive manner. Structural brain defects, with or without mental retardation, 
are additional features of syndromic MDC. Approximately 60% of all forms is 
defined as classic MDC (without mental retardation). In northern-east Italy, the 
overall incidence of MDC has been estimated at 1 in 21 500 with a prevalence 
of 1 in 150 000.134 
Syndromic congenital muscular dystrophy (e.g. Fukuyama MDC, muscle-eye-
brain-disease, Walker-Warburg-syndrome and MDC1D) and the non-syndromic 
subtype MDC1C are associated with mutations in proteins that are presumed 
to be glycosyltransferases.93 Reduced glycosylation of α-dystroglycan abolishes 
its interaction with extracellular matrix receptors, such as laminin-2. Disorders 
sharing this pathogenic mechanism are referred to as dystroglycanopathies 
which also applies to LGMD2I, LGMD2K and LGMD2M (see above).
MDC1A, commonly known as merosin-deficient MDC, accounts for about 
30-40% of MDC cases in European countries, but only 6% in Japan. Affected 
individuals have a primary deficiency of the α2 chain of laminin-2 (formerly 
named merosin) due to mutations in the LAMA2 gene.135 Laminin-2 interacts 
with dystroglycan which is in turn associated, intracellularly, with dystrophin. 
LAMA2 defects can also cause partial merosin-deficient MDC. However, some 
MDC cases with partial merosin deficiency are unlinked to LAMA2. These 
include MDC1B, linked to chromosome 1q42, and several MDC subtypes with 
unknown gene defects.135
Cardiac involvement in dystroglycanopathies
Fukuyama MDC is caused by the gene encoding the fukutin protein and is 
rarely reported outside Japan. Affected infants are floppy and exhibit motor 
developmental delay and severe mental retardation.136 In most patients, systolic 
left ventricular dysfunction develops after 10 years of age, resulting in heart 
failure. Death from congestive heart failure or respiratory problems occurs by 
the age of 20.137 Myocardial fibrosis of the left ventricular free walls has been 
observed at autopsy.
MDC1C is caused by a mutation in the gene encoding the fukutin-related protein 
(FKRP). Mutations in this gene may also cause LGMD2I, which usually has a 
milder phenotype.94 MDC1C is characterized by weakness and hypotonia from 
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birth, hypertrophy of lower limb muscles and inability to achieve ambulation. 
Progressive respiratory muscle weakness leading to ventilatory insufficiency is 
a constant feature in the second decade of life. Mildly impaired left ventricular 
function can also be found.138
Cardiac involvement in merosin-deficient MDC (MDC1A) 
Occasional reports suggest that cardiac involvement may be present in 
MDC1A. Reduced left ventricular systolic function in a few patients has been 
addressed.139 Echocardiography in 6 MDC1A patients showed reduced ejection 
fraction in 3 subjects.140 Nevertheless, no clinical significant cardiomyopathy has 
been reported so far. Recurrent aspiration and respiratory insufficiency appear 
important determinants of prognosis. Data on life expectancy are lacking, but 
death during the first decade has been observed in patients with MDC1A.141 
A summary of the reported cardiac abnormalities in the abovementioned 
congenital muscular dystrophies is presented in table 2.6. Rare MDC subtypes 
with unknown gene defects are possibly accompanied by cardiac involvement. 
Table 2.6. Cardiac abnormalities and prognosis in congenital muscular dystrophy
Disease ECG Echo Cardiac death Age at death
Fukuyama MDC - tall R waves or R/S  
ratio >1 in lead V1
- deep narrow Q  
waves in lead V6
- dilated  
cardiomyopathy
~50%142 Mean 17 years
(range 3-27)142 
MDC-1C - left ventricular  
dysfunction 
no major cause
of death
2nd decade138
MDC-1A - left ventricular  
dysfunction
no major cause
of death
Some in first
decade141
Facioscapulohumeral muscular dystrophy
Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant 
myopathy with normal life span and a prevalence of 1 in 20 000. Shoulder girdle 
weakness is usually the presenting clinical symptom. It is often asymmetrical 
with relative sparing of the deltoid muscles. Facial muscle involvement, often 
mild and asymmetrical, is frequently present in the majority of cases at the time 
of diagnosis. Involvement of abdominal, foot extensor and pelvic muscles occur 
at a later stage of the disease. Symptoms start on average between 16 and 20 
years of age, but may vary from first to sixth decade.143 
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The majority of cases are linked to the subtelomeric region of chromosome 
4. A deletion of an integral number of repeats produces a shortened DNA 
fragment.144 Severity of disease and age at onset correlate with the residual 
fragment size, which remains constant in successive generations.143
Cardiac involvement in facioscapulohumeral muscular dystrophy
Clinically significant cardiac disease is uncommon in patients with FSHD. 
Studies reported to date indicate that patients may have arrhythmias (0-
12%), particularly supraventricular paroxysmal tachycardia, and minor ECG 
abnormalities.145-148 Severe cardiomyopathy is rare and usually unrelated to the 
FSHD. Earlier reports of atrial standstill in patients with facioscapulohumeral 
type of muscular dystrophy most probably represent a case of misdiagnosed 
EDMD1.148
Myofibrillar myopathies 
Myofibrillar myopathies (MFM) refer to a group of genetically distinct disorders 
that are frequently associated with peripheral neuropathy and involvement of 
the heart muscle (table 2.7). Clinically, MFM presents in adult life with slowly 
progressive weakness of distal and proximal muscles. Diagnosis is mainly 
based on muscle histology, showing morphologic changes resulting from 
disintegration of the sarcomeric Z-disk and myofibrils, followed by accumulation 
of myofibrillar degradation products and ectopic expression of multiple 
proteins.149 Several mutations have been identified (table 2.1), however, in most 
cases the disease-associated protein or gene defect has not been elucidated.
Desminopathies manifest with various phenotypes depending on the type 
of inheritance and the location of mutations. Cardiac involvement may 
precede, coincide with or succeed skeletal myopathy. Conduction blocks and 
arrhythmias requiring a pacemaker are frequent features of desmin-related 
MFM, attributed to the fact that desmin is a major component of Purkinje 
fibres.150 Mutations in α-B crystallin (i.e. chaperone for desmin) can cause 
phenotypic features of desminopathy. Some patients with α-B crystallinopathy 
develop hypertrophic cardiomyopathy.151, 152 Mutation in BAG3 causes severe 
childhood muscular dystrophy with cardiomyopathy and severe respiratory 
insufficiency.153 Cardiomyopathy is considered rare in myotilin-related MFM and 
very rare in ZASP-related MFM and filamin-C-related MFM. 
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Table 2.7. Cardiac involvement in myofibrillar myopathies
Disease Genetics Cardiac abnormalities Morbidity/mortality
Desmin-related 
MFM150
- AD (80%), AR 
(6%), sporadic 
(14%)
- atrioventricular block
- ventricular tachycardia
- dilated or restrictive 
cardiomyopathy
- heart disease in >60%
- severity is mutation 
dependent
- onset 2nd to 4th decade 
in AD, childhood to 20’s 
in AR
α-B crystallinopathy 
151, 152
- AD - hypertrophic 
cardiomyopathy
- in cases with Arg120Gly 
missense mutation, but 
not truncating mutations
BAG3-related MFM153 - 3 dominant 
cases
- restrictive or 
hypertrophic 
cardiomyopathy
- cardiac involvement in all 
cases 
- onset in teens 
- severe respiratory 
involvement
MFM with ARVD 
(ARVD7)154
- swedish family
- AD
- similar locus to 
ZASP 
- ventricular tachycardia
- atrial flutter
- right ventricular 
dilatation
- heart disease in 25%
- onset 20-60 years
AD=autosomal dominant; AR=autosomal recessive
Other muscular dystrophies
In distal myopathies, cardiomyopathy is not a consistent feature. Mild-moderate 
cardiomyopathy was present in 1 of the 3 affected members with late-onset 
autosomal dominant distal myopathy, which has recently been identified as a 
ZASPopathy.155
A few rare X-linked myopathies are associated with cardiomyopathy. X-linked 
vacuolar cardiomyopathy and myopathy (Danon disease) is caused by 
mutations in the gene encoding lysosome-associated membrane protein-2 
(LAMP-2) at Xq24.156 Muscle biopsies are characterized by autophagic vacuoles 
with sarcolemmal features.157 Cardiac disease is the dominant clinical feature 
and most important prognostic factor. Skeletal muscle involvement is usually 
mild and is observed in 90% of male patients and 33% of female relatives. Mild 
mental retardation was found in 70% of males and 6% of females. A study 
of 20 men and 18 women with genetically confirmed Danon disease, reported 
cardiomyopathy in all patients.158 Men were severely affected before the age of 
20 years. The most frequent findings were hypertrophic cardiomyopathy with 
impaired left ventricular functions and Wolff-Parkinson-White syndrome. Most 
affected women developed predominantly dilated cardiomyopathy in adulthood. 
All deceased patients died from cardiac failure at young age. 
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The mean age at death was 19 years in male patients and 40 years in females. 
Heart transplantation may be the only effective therapeutic option in patients 
with Danon disease.158
Barth syndrome, an X-linked disorder in infancy that is characterized by 
cardiomyopathy, neutropenia, skeletal myopathy, and growth delay, is caused by 
mutations in the taffazin gene at Xq28 that result in cardiolipin deficiency and 
abnormal mitochondria.159 Female carriers appear to be healthy. In a study of 34 
males, 90% had dilated cardiomyopathy, 53% had prominent LV trabeculations 
and ventricular arrhythmias were frequent in adolescents.159
McLeod syndrome is a late-onset X-linked disorder caused by mutations of 
XK, a gene of unknown function, and characterized by movement disorders 
(chorea), cognitive impairment, areflexia, myopathy and acantocytosis. 
A few cases of manifesting female mutation carriers have been reported.160 
About 65% of individuals develop cardiac manifestations including dilated 
cardiomyopathy, atrial fibrillation, and tachyarrhythmia.160 
Four-and-a-half LIM domain gene (FHL1) mutations have been identified 
as the causative gene for reducing body myopathy (RBM), X-linked 
scapuloperoneal myopathy (SPM) and X-linked myopathy with postural 
muscle atrophy (XMPMA). It should be considered in the differential diagnosis 
of patients X-linked scapuloperoneal muscle involvement (e.g. EDMD). FHL1 is 
highly expressed in skeletal and cardiac muscle. Hypertrophic cardiomyopathy 
was observed in 4 out of 9 XMPMA patients, and dilated cardiomyopathy in 
1 out of 11 RBM patients.161, 162 Respiratory failure appeared to be the major 
prognostic factor.
An early-onset myopathy with fatal cardiomyopathy due to homozygous 
C-terminal TTN deletions has been described as the only titinopathy involving 
both heart and skeletal muscle.163
Mutations in the beta-cardiac myosin heavy chain gene (MYH7) may cause 
various phenotypes ranging from pure peripheral muscle disease to isolated 
cardiomyopathies. However, MYH7 mutations combining symptomatic 
distal myopathy and cardiac involvement have been reported.164, 165
Management of muscular dystrophies
General aspects 
Muscular dystrophies are associated with progressive physical disabilities 
and medical complications. Although curative treatment is not yet available, 
quality of life and survival of muscular dystrophy patients have improved as 
a result of advances in medical management based on multidisciplinary 
care.166 In general, current symptomatic treatment is designed to maintain and 
support muscle strength, promote mobility, prevent contractures and maintain 
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optimal physical and emotional health. In ambulant DMD patients, the use of 
corticosteroids (0.75 mg/kg/day) is now generally recommended since it has 
been demonstrated to improve muscle strength and function in 6 months to 2 
years.167 Registries have suggested possible cardiac benefit from corticosteroid 
therapy,168 whereas some experimental study suggests no effect.169
The number of DMD patients surviving into adulthood is increasing, because 
of such as enhanced use of ventilatory support and management of spinal 
deformities. Despite these treatment regimens, progression of muscular 
dystrophies cannot be prevented.
Cardiac management 
Cardiomyopathy is the most prominent cardiac feature in dystrophinopathies, 
sarcoglycanopathies, and diseases associated with mutation in the fukutin-
related protein. Most cardiomyopathies in muscular dystrophy patients are of 
the dilated type. Cardiac evaluation generally includes a history and physical 
examination, electrocardiogram and transthoracic echocardiogram at diagnosis. 
Periodic Holter monitoring may be considered for patients with demonstrated 
cardiac dysfunction. Standard heart failure treatment, including ACE inhibitors 
or beta-adrenoreceptor blockers, is strongly recommended.19 These drugs 
should be started after the first abnormal echocardiography and may even be 
considered before abnormalities are found. A pacemaker is indicated in case 
of bradycardia or atrioventricular blocks, whereas symptomatic ventricular 
arrhythmias may require ICD implantation. Cardiac transplantation may be 
considered in motivated, ambulant patients with end-stage heart failure and 
relatively good neuromuscular prognosis. Hypertrophic cardiomyopathy is 
uncommon in muscular dystrophies, but has been typically described in males 
with Danon disease, α-B crystallinopathy and XMPMA. Myocardial hypertrophy 
may be present on echocardiograms among DMD and BMD patients or carriers. 
Other muscular dystrophies, mainly represented by laminopathies, Emery-
Dreifuss muscular dystrophy and myotonic dystrophy, are particularly 
associated with arrhythmias. These patients should undergo regular risk 
stratification for sudden death, which is most often caused by complete heart 
block or ventricular arrhythmias, but may also be a result of atherosclerotic 
or thrombo-embolic events. Medication known to adversely affect cardiac 
conduction (e.g. beta-blockers, class Ic antiarrhythmic agents, amiodarone, 
and tricyclic antidepressants) should be avoided. Early detection and treatment 
of conduction defects in muscular dystrophy patients is essential, since 
implantation of a pacemaker can be lifesaving. However, in lamin A/C carriers 
and DM1 patients, there is established evidence that pacemakers do not 
decrease the rates of sudden death, suggesting that lethal tachyarrhythmias 
contribute to mortality.69, 106 Myocardial degeneration, cardiac conduction- 
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system abnormalities and increased ventricular loading as a result of respiratory 
or cardiac failure may all be involved in the development of malignant 
ventricular arrhythmias. Pacemaker recordings or implantable loop recording 
devices provide continuous monitoring of heart rate and rhythm and may help 
diagnose these arrhythmias. The safety and efficacy of antiarrhythmic drugs 
is controversial as their negative inotropic and pro-arrhythmic actions are 
enhanced in patients with cardiac dysfunction. Therefore, the implantation of 
an ICD, rather than a pacemaker, may be considered for lamin A/C carriers and 
DM1 patients. 
Recommendations for cardiac investigations and follow-up of muscular 
dystrophy patients are based on present consensus guidelines, since published 
evidence is quite limited.19, 29 An algorithm with a more detailed pragmatic 
approach based on present consensus guidelines is presented in figure 2.3. 
Furthermore, treatment of atrial fibrillation is based on preventing embolism 
and cardioverting or controlling the tachyarrhythmia. Complete cardiac 
evaluation should be undertaken before scoliosis surgery or other major surgical 
procedures and monitoring should continue in the postoperative period.
Future perspectives
Muscular dystrophies are caused by mutations in genes encoding proteins 
that are indispensable for normal muscle function. In the absence of either 
component of the dystrophin-glycoprotein complex, membrane tears may 
simply develop as a result of mechanical stress, leading to muscle degeneration 
and cardiomyopathy. Mutations in nuclear envelope proteins can also cause 
muscular dystrophy and cardiomyopathy. These proteins are implicated in 
maintaining nuclear integrity of muscle as well as regulation of muscle- and 
heart-specific gene expression. Furthermore, a novel RNA-mediated disease 
mechanism is likely the cause of clinical features in DM and may primarily 
affect cardiac function. Advances in the understanding of molecular genetics 
and the pathogenesis of muscular dystrophies have raised expectations of more 
effective therapy.
In the past several years, DMD has been an important target for new therapeutic 
approaches. These include gene replacement therapy (adeno-associated virus 
vector and naked plasmid delivery), gene repair strategies (exon skipping and 
read-through), cell-based therapy (myoblast or stem cell transplantation) and 
drug therapy to compensate the dystrophic muscle.170 Several therapeutic 
concepts have moved from the laboratory setting to clinical trials, in order to 
proof their effect and to test safety and tolerability. 
The ultimate therapeutic target in DM is reversal of RNA toxicity. Methodologies 
based on neutralization or elimination of toxic RNA (antisense oligonucleotides 
and short interfering RNA) and interruption of the pathways that lead to 
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abnormal splicing (skipping of abnormally included exons, down-regulation of 
CUGBP1 activity, and up-regulation of MBNL1 activity) have shown promise 
in preclinical models.171 Less specific treatments that prevent or counteract 
muscle degeneration, reduce inflammation or stimulate muscle metabolism 
or regeneration would be feasible for all dystrophic patients.170, 171 As our 
understanding of pathogenesis continues to improve, more specific treatment 
that targets the disease mechanism will begin to replace the supportive care 
currently available.
Conclusion 
Surveillance and timely management of cardiac complications are important 
since long-term prognosis may be directly related to cardiac status. With 
increased quality of life and prolonged survival of muscular dystrophy patients, 
heart failure and arrhythmias contribute to a larger extent to premature death. 
Recognition of cardiac involvement requires active investigation, since the 
typical signs and symptoms of cardiac dysfunction may not be present, possibly 
secondary to the patient’s muscular impairment and limited mobility. Although 
the benefits of pre-symptomatic diagnosis or treatment of cardiac involvement 
may not always have been established, patients should be made aware of the 
risk of developing cardiomyopathy and offered appropriate care for the cardiac 
aspects of their neuromuscular disorder. Periodic examination is therefore 
advised and initiated as soon as the neuromuscular diagnosis is ascertained. 
Prospective studies are mandatory to evaluate current strategies and to adjust 
guidelines for surveillance, heart failure treatment and device implantation.
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Summary
Cardiac involvement is one of the main systemic features of myotonic dystrophy 
type 1 (DM1) and a major determinant of prognosis. We aimed to determine 
the occurrence rate of sudden death in a large cohort of DM1 patients and 
attempted to identify risk factors. A long-term follow-up of 412 DM1 patients 
revealed that 178 patients died, of which 40 were sudden deaths. Importantly, 
sudden death was not prevented by pacemakers. A case-control comparison 
of available electrocardiograms showed that QRS duration was significantly 
prolonged in patients with documented sudden death. In sporadic cases, 
insertion of implantable cardioverter-defibrillators (ICD) in subjects with DM1 
resulted in appropriate therapy for ventricular arrhythmias. We recommend that 
patients with myotonic dystrophy type 1 are systematically screened to identify 
those with the combination of an increased risk of sudden death and a relatively 
good neuromuscular prognosis. An ICD might be considered in subjects who 
need a pacemaker and have a wide QRS complex, but the potential benefit of 
prophylactic ICD therapy should be evaluated in a prospective trial.
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Introduction
Myotonic dystrophy type 1 (DM1), also known as Steinert’s disease, is an 
autosomal dominant inherited disorder, caused by an expansion of an unstable 
CTG repeat in the myotonic dystrophy protein kinase gene on chromosome 
19q13.3.1 The normal allele contains 5-35 repeats, but in DM1 it is expanded 
to hundreds or even thousands of copies. Patients can be classified into four 
clinical types based on age at onset and severity of neurological symptoms: 
that is congenital type, childhood-type, adult-onset (classical) type and late-
onset (mild) type.2 Most notably, the age of onset decreases and the severity of 
neurological symptoms increases with successive generations (i.e. anticipation).
DM1 has a prevalence of 5-20 per 100 000 and is characterized by muscle 
weakness, myotonia and involvement of several organs including the heart.3 
The exact pathogenic mechanism most likely involves repeat-induced 
alterations in transcript levels of various genes, including cardiac specific ones.4 
Conduction disturbances appear to be the predominant cardiac manifestation 
and often necessitate pacemaker implantation.5-7 Despite routine screening 
of the electrocardiogram (ECG) and implantation of cardiac pacemakers, 
DM1 patients still die at a young age, often suddenly,8-10 suggesting that the 
prevention and treatment of cardiac complications can be improved.
In the present study, we have retrospectively collected data on 412 DM1 patients 
in order to determine the occurrence rate of sudden death and evaluated 
available ECGs to identify risk factors. Furthermore, we aimed to report the 
efficacy of implantable cardioverter-defibrillator (ICD) therapy in sporadic cases. 
Methods
The population for this study was selected from the genetic register of DM1 
families in the region of Maastricht, the Netherlands. Since 1950, generations 
of neurologists and geneticists examined patients and their family members 
to set up a genetic register.8 The diagnosis of myotonic dystrophy had been 
made by expert neuromuscular physicians and was confirmed by genetic tests 
when available (since the early 90’s of the previous century). This resulted in 
a register containing information on disease type, results of genetic tests and 
major complications. 
The population for this study consists of 412 patients from 81 families. Patients 
of all ages and disease types were included, except for 5 patients with a rare 
type of myotonic dystrophy combined with hereditary polyneuropathy.11 Age at 
death was verified by information from family members, medical records and 
the registry office. Data on cause of death were obtained either from medical 
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records, in the case of death in hospital, or from the general practitioner, in the 
case of death at home. Sudden death was defined as instantaneous unexpected 
death due to natural causes without symptoms of illness in the preceding 24 
hours. 
In 2005, we collected data on standard 12-lead ECGs available from the last 20 
years and obtained information from the Dutch Pacemaker Registration. ECG 
recordings were evaluated for conduction defects. Two independent researchers 
measured PR interval in lead II and QRS width in the lead showing the widest 
complex (MH, YP). QTc interval was corrected for differences in heart rate 
by a modification of Bazett’s formula (QTc = QT/√RR). When more than one 
ECG was made, the last one available was analysed. ECGs after pacemaker 
implantation were excluded from the analysis. Since 2003, we implanted an 
ICD instead of a pacemaker in 3 patients with a potential high risk profile and 
evaluated the occurrence of appropriate discharges.
Statistics
Results are presented as absolute values or means ± standard deviation. 
Clinical characteristics were compared with Mann-Whitney U tests or Pearson’s 
chi-square tests. For each patient with documented sudden death and ECG 
available, two control patients were chosen through frequency matching on 
sex, age (in 10 year age groups) and type of DM1. All analyses were performed 
using SPSS software version 15.0. A P-value of <0.05 at a two-sided level was 
considered statistically significant.
Results
Over the past 55 years, we have collected data on age and causes of death of 412 
DM1 patients including 233 men and 179 women (table 3.1). A pacemaker had 
been implanted in 31 patients. At the end of data collection, 178 patients had 
died (43%) and the mode of death could be accurately determined in 111 cases 
(62%). The mean age at death was 53.9 ± 17.8 years. Sudden death occurred 
in 40 patients, including 9 patients carrying a DDD or VVI pacemaker (figure 
3.1). Other common causes of death were pneumonia (n=35), postoperative 
complications (n=5), malignancies (n=16), and others (n=14). 
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Figure 3.1. Schematic illustration of the occurrence of sudden death in DM1 patients
Table 3.1. Age and cause of death in DM1 patients
Congenital/
Childhood type
Adult type Mild type All patients
(n=412)
No. of deceased patients 35 107 36 178
Age at death (years) 34 55 71 54
Sudden death 9 24 7 40
   with pacemaker 3 5 1 9
   without pacemaker 6 19 6 31
Other cause of death 13 46 12 71
   with pacemaker 1 8 1 10
   without pacemaker 12 38 11 61
Unknown cause of death 13 37 17 67
   with pacemaker 2 1 0 3
   without pacemaker 11 36 17 64
The mean age at sudden death was 46.1 ± 13.5 years for the congenital/
childhood type, 55.3 ± 8.1 years for the adult type and 69.6 ± 7.1 years for the 
mild phenotype (P<0.001). Risk of sudden death increased with age (OR 
1.04; 95% CI 1.01-1.06), but was independent of sex. Among patients with a 
known cause of death, the proportion of sudden deaths did not differ between 
pacemaker carriers and those without (P=0.26). Overall mortality was higher 
among pacemaker recipients (P=0.001).
 
178 Died   
 
 
40 (22.5%) Died suddenly 
 
  
67 Died of unknown cause 
 
 
71 Died of other cause 
 
31 (77.5%) Did not have 
 pacemaker 
9 (22.5%) Had pacemaker 
412 Patients with myotonic  
dystophy 
70
The median duration of cardiac follow-up was 7 years (interquartile range 2-10 
years). ECGs were available from 117 patients, of which 33 ECGs belonged to 
deceased DM1 patients. Median time between the last ECG and time of death 
was 6.5 months. ECGs were available from 7 patients that died suddenly. These 
patients were classified as congenital/childhood type (n=3) or adult onset type 
(n=4). A case-control comparison corrected for age, sex and type of DM1, 
showed significantly wider QRS complexes in patients that died suddenly 
(P=0.003; table 3.2). 
Table 3.2. ECG parameters in sudden deaths and matched controls
Patients with sudden death
n = 7
Controls
n = 14 P-value
PR-interval ± SD (ms) 225.8 ± 31.8 201.2 ± 30.2 0.13
QRS-duration ± SD (ms) 133.0 ± 29.5 99.6 ± 9.3 0.003
QTc-interval ± SD (ms) 420.6 ± 20.1 417.4 ± 18.4 0.61
QRS duration was also significantly longer in patients that died suddenly 
compared to patients whose death was not sudden (P=0.02). The sample size 
was too small to test ECG indicators in a predictive model. 
Evaluation of ICD implantations identified 3 DM1 patients who received an 
ICD since 2003. One patient is a 56 year old woman without specific cardiac 
complaints who received a DDDR pacemaker for progressive conduction 
delay (first degree AV block and a broad QRS complex). Fifteen months after 
implantation, an asymptomatic nocturnal rapid ventricular tachycardia (VT) 
was monitored by the pacemaker which prompted us to replace it by an 
ICD. Ten months later a syncopal episode occurred which turned out to be 
caused by a fast VT successfully terminated by a 23 Joule biphasic shock of 
the ICD (figure 3.2). The other 2 patients are young men, aged 28 and 33, with 
complaints of fatigue, dyspnoea on exertion and dizziness. One of them already 
had undergone right bundle branch ablation several years before, because of re-
entry tachycardias. Over the years QRS width had increased and left ventricular 
function had worsened in both patients. It was decided to insert a prophylactic 
ICD with biventricular pacing mode. Both patients had an appropriate shock 
delivered by the ICD with restoration of sinus rhythm. The memory-stored 
rhythm detection mode recorded sustained VT in 1 patient and VT progressing 
to ventricular fibrillation (VF) in the other.
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Figure 3.2. Intracardiac recordings of spontaneous sustained ventricular tachycardia as recorded 
from the implantable cardioverter-defibrillator (ICD) of a DM1 patient
Legend to figure 3.2. Reading down, the tracings show the recordings from the right atrium, right 
ventricular apex and a pseudosurface electrocardiograph derived from signals recorded between 
the shock coils and the ICD. Sinusrhythm is restored after a 23 J biphasic direct current shock.
Discussion
Sudden death, most probably of cardiac origin, occurred in one third of all 
classified deaths and was associated with higher age and more severe cardiac 
involvement. In particular, QRS duration was prolonged in patients with 
documented sudden death compared to controls and deaths from other causes. 
As conduction disturbances are the predominant manifestation of cardiac 
disease and progress in time, the principal cause of sudden death in DM1 has 
traditionally been attributed to paroxysmal heart block.12-14 Practice guidelines 
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therefore recommend pacemaker insertion in advanced or symptomatic 
conduction delay.15 However, overall mortality among pacemaker carriers was 
high in our population. This may reflect more advanced disease in patients 
with a pacemaker, but also suggests that pacemakers fail to prolong life. 
More important is the fact that the rate of sudden death was not decreased 
by pacemakers. Earlier reports have also mentioned that patients with DM1 
suddenly died despite carrying a pacemaker.10, 16-19
These observations suggest that sudden death in DM1 cannot be fully 
attributed to bradyarrhythmia and conduction block. Ventricular arrhythmias 
are increasingly recognized and thought to contribute to mortality in patients 
with DM1.18, 20-22 Cardiac involvement in DM1 represents an ideal substrate for 
ventricular tachycardia and bundle branch re-entry tachycardia is the most likely 
mechanism, since the His-Purkinje system is often severely impaired.23, 24 
Invasive electrophysiological studies (EPS) have been performed to assess the 
individual risk of life-threatening tachyarrhythmic events in DM1. Young age 
appeared to be a powerful predictor of inducible ventricular arrhythmias.25 
Unfortunately its value remains uncertain, since reported inducible ventricular 
arrhythmias are often non-specific. The value of non-invasive tests, such as 
signal-averaged electrocardiography, Holter recording and magnetic resonance 
imaging, in predicting arrhythmic risk is also still controversial.26-29 
The incidence of potentially lethal tachyarrhythmias is considered not sufficiently 
high to justify defibrillator therapy routinely when permanent pacing is 
indicated.30 We have started to employ prophylactic ICD therapy in patients with 
a potential high risk profile, comprising severe conduction disorders with a wide 
QRS complex. This proved to be appropriate therapy in the first 3 patients. Our 
observation of frequent sudden death in patients with pacemakers combined 
with examples of documented spontaneous sustained VT does not establish 
a direct relationship, but suggests that the role of ventricular arrhythmia in 
sudden death should not be underestimated. Continued research should result 
in better recognition of DM1 patients at risk of ventricular arrhythmias and 
sudden death for optimal primary prevention. This hopefully will deal with the 
unacceptable rates of sudden death in patients with DM1. 
Limitations of our study lie in the fact that data were analysed retrospectively 
and we were unable to retrieve information on medical history and specific 
causes of death in a number of patients. ECG and echocardiography were often 
not available, since routine cardiac screening in DM1 patients was implemented 
only 20 years ago. Furthermore, patients often do not complain nor have cardiac 
symptoms and many refrain from seeing a doctor. Still, the cause of death could 
be determined in 62% of patients. 
73
Chapter
3.
Conclusion
Our systematic retrospective analysis demonstrates that sudden death is frequent 
in DM1 patients and is certainly not always prevented by pacemakers. Sudden 
death was associated with more severe cardiac involvement, evidenced more 
by QRS widening than by PR prolongation. Lethal ventricular tachyarrhythmias 
may be the responsible mechanism in particular cases. Although the sample 
size may be too small to draw far-reaching conclusions, we suggest that cardiac 
screening of DM1 patients should include careful monitoring of QRS duration. 
If a pacemaker is implanted in a DM1 patient with broadened QRS width, an 
implantable cardioverter-defibrillator might be considered. Further prospective 
studies, which are currently performed, should make clear how to select patients 
who could benefit from an ICD.
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Summary
Myotonic dystrophy type 1 (DM1) is a neuromuscular disorder with potential 
involvement of the heart and increased risk of sudden death. Considering 
the importance of cardiomyopathy as a predictor of prognosis, we aimed to 
systematically evaluate and describe structural and functional cardiac alterations 
in patients with DM1. Eighty DM1 patients underwent physical examination, 
electrocardiography (ECG), echocardiography and cardiac magnetic resonance 
imaging (CMR). Blood samples were taken for determination of NT-proBNP 
plasma levels and CTG repeat length. Functional and structural abnormalities 
were detected in 35 patients (44%). Left ventricular systolic dysfunction was 
found in 20 cases, left ventricular dilatation in 7 patients, and left ventricular 
hypertrophy in 6 patients. Myocardial fibrosis was seen in 10 patients (12.5%). 
In general, patients had low left ventricular mass indexes. Right ventricular 
involvement was uncommon and only seen together with left ventricular 
abnormalities. Functional or structural cardiac involvement was associated with 
age (P=0.04), male gender (P<0.001) and abnormal ECG (P<0.001). Disease 
duration, CTG repeat length, severity of neuromuscular symptoms and NT-
proBNP level did not predict the presence of myocardial abnormalities. CMR 
can be useful to detect early structural and functional myocardial abnormalities 
in patients with DM1. Myocardial involvement is strongly associated with 
conduction abnormalities, but a normal ECG does not exclude myocardial 
alterations. These findings lend support to the hypothesis that DM1 patients 
have a complex cardiac phenotype, including both myocardial and conduction 
system alteration.
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Introduction
Myotonic dystrophy type 1 (DM1), or Steinert’s disease, is an autosomal 
dominant inherited disorder caused by an unstable expansion of a repetitive 
trinucleotide sequence (CTG) on chromosome 19. The prevalence varies from 
2.1-14.3 per 100 000.1 DM1 is characterized by slowly progressive weakness 
of skeletal muscles, myotonia and involvement of several organ systems 1.
An earlier age of onset and increased severity of clinical symptoms has been 
observed in subsequent generations and is related to degree of CTG expansion.2 
Patients with DM1 usually die from respiratory or cardiac complications.3, 4
Sudden death is considered to be the result of atrioventricular block or ventricular 
arrhythmias.5 Recent studies showed that severe electrocardiographic (ECG) 
abnormalities and atrial arrhythmias are independent risk factors, although 
with moderate sensitivity, for sudden death in DM1 patients.6 Although death 
from progressive heart failure is uncommon in patients with DM1 compared to 
other muscular dystrophies,7,8 left ventricular systolic dysfunction is associated 
with an increased risk of overall mortality and sudden death.9 Therefore, the 
picture emerges that DM1 patients have a complex cardiac phenotype including 
both the myocardium and the conduction system. 
Considering the importance of cardiomyopathy as a predictor of prognosis, 
we aimed to measure cardiac function and detect structural abnormalities in 
patients with DM1. We used CMR imaging in the current study since CMR is 
an accurate and highly reproducible technique for the assessment of cardiac 
volumes, function, mass and focal fibrosis and the interstudy reproducibility 
in normal, dilated, and hypertrophic hearts was superior to 2-dimensional 
echocardiography.10
Methods
Patient selection
The protocol was approved by the local Medical Ethics Committee and each 
participant gave written informed consent. Patients older than 18 years of age 
were invited for a prospective, on-going study on cardiac involvement and early 
stratification of arrhythmogenic risk. Participants were recruited from the genetic 
register of the Maastricht University Medical Centre and through the Dutch 
neuromuscular patients’ association (Vereniging Spierziekten Nederland, VSN). 
Subjects with previously implanted pacemakers or implantable cardioverter-
defibrillators or with severe comorbidity leading to reduced life expectancy 
such as malignant disease or respiratory failure were excluded. During a 2 year 
period, 80 consecutive patients underwent CMR imaging and were enrolled in 
this study.
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Clinical examination
A standardized interview was conducted in all participants to evaluate their 
clinical history and current symptoms. A neurological and cardiac evaluation 
was conducted by the same examiner (MH) in a predefined standardized 
fashion. The DM1 phenotype was established according to the commonly 
accepted classification based on the age at onset of symptoms: mild (late 
onset), classical (adult onset) and childhood/congenital type.2 Skeletal muscle 
strength was manually tested and graded according to the Medical Research 
Council (MRC) 6-point grading system (0-5).11 A total of 22 muscle groups 
were tested: neck flexors and extensors separately plus 10 bilateral muscles: 6 
proximal muscle groups (shoulder abductors, elbow flexors, elbow extensors, 
hip flexors, knee extensors, knee flexors) and 4 distal muscle groups (wrist 
extensors, digits flexors, ankle dorsiflexors, ankle plantar flexors). Summation 
of the scores yields an extended MRC-sum score, ranging from 0 (paralytic) to 
110 (normal strength).12, 13 Furthermore, blood samples were taken to determine 
N-Terminal pro Brain Natriuretic Peptide (NT-pro-BNP) plasma levels and the 
length of the CTG repeat.
CTG repeat length analysis. Analysis of the CTG repeat length was performed on 
peripheral blood lymphocytes. Polymerase chain reaction followed by fragment 
length analysis was used to determine small allele lengths of 5 to 100 repeats, 
and Southern blotting was used to estimate repeat lengths >100. For purposes 
of statistical analysis, the CTG expansions were divided in 4 categories (<100; 
100-250; 250-500; >500).
Electrocardiography
ECG was considered abnormal if signs of conduction disease (PR interval ≥210 
ms, QRS duration ≥120 ms, left anterior or posterior fascicular hemiblock), 
hypertrophy (Sokolow-Lyon index ≥35 mm), myocardial infarction or rhythm 
other than sinus, were present. 
Echocardiography
Echocardiography was used to exclude significant valvular disease, elevated right 
ventricular systolic pressure. Transthoracic echocardiograms were performed 
using a SONOS 5500 system with S3 transducer (Philips Medical Systems, Best, 
The Netherlands). Echocardiographic investigations were performed according 
to the recommendations of the American Society of Echocardiography.
CMR
Patients were examined in supine position with a clinical 1.5 T Gyroscan Intera 
MR scanner (Philips Medical Systems, Best, The Netherlands) equipped 
with a 5 channel cardiac surface coil. ECG-gated cine images were acquired 
81
Chapter
4.
for functional analysis during multiple breath holds (10-13 seconds) using a 
steady-state free precession sequence (slice thickness 6 mm, slice gap 4 mm, 
TR/TE 3.8/1.9 ms, flip angle 50°, FOV 350 mm, matrix 256 x 256, 22-25 phases 
per cardiac cycle) in two-chamber, three-chamber and four-chamber view and a 
short-axis stacks covering the entire LV. For the detection of myocardial edema 
multislice short axis images were acquired using a dual-inversion black-blood 
T2-weighted sequence with fat suppression (slice thickness 8 mm, slice gap 2 
mm, TR/TE 1600/100 ms, flip angle 90°, FOV 350 mm, matrix 512 x 512). After 
intravenous contrast administration (Gd-DTPA 0.2 mmol/kg) a Look-Locker 
sequence (slice thickness 10 mm, TR/TE 3.6/1.7 ms, flip angle 8°, FOV 370 mm, 
resolution 256 x 256, 39 phases, phase interval 15 ms) was applied to determine 
the inversion time (TI) to optimally “null” LV myocardium (typical TI range 
200-280 ms) for the subsequent scan. To evaluate the presence of myocardial 
late gadolinium enhancement (LGE) a breath-hold 3D inversion recovery 
gradient echo sequence covering the entire LV (acquired slice thickness 12mm, 
reconstructed slice thickness 6mm, average TR/TE 3.9/2.4ms, multishot (50 
profile/shot) segmented partial echo readout every heartbeat, flip angle 15 , 
field of view 400mm, matrix 256 x 256, acquired and reconstructed pixel size 
1.56 x 1.56mm, typically 16-18 slices) was used with images in short-axis, two-
chamber and four-chamber view, acquired 10 minutes after the administration 
of intravenous contrast. 
CMR data analysis
MR images were analyzed with commercially available software (CAAS MRV 
3.0, Pie medical imaging, Maastricht, The Netherlands). Endocardial and 
epicardial contours were manually traced in end-diastolic and end-systolic 
phases on short axis cine images to determine end-diastolic and end-systolic 
volume, ejection fraction and LV end-diastolic mass. Systolic LV dysfunction 
was defined as an ejection fraction <55% or regional wall motion abnormalities. 
LV and right ventricular (RV) dilatation were defined as enddiastolic volumes 
>2SD and RV systolic dysfunction as ejection fraction <2SD of mean reference 
values normalized for gender, body surface area and age.14 We considered LV 
hypertrophy as increase in the LV mass and LV wall hypertrophy as wall thickness 
>12 mm. The presence and localization of edema or focal fibrosis was visually 
identified by a consensus of two independent experienced observers using the 
T2-weighted and LGE images. CMR was considered to be abnormal if regional 
or global dysfunction, ventricular dilatation, hypertrophy, or areas of fibrosis or 
edema were observed.
Statistics
Descriptive statistics of clinical characteristics, electrocardiographic findings 
and cardiac magnetic resonance results are presented. Categorical variables 
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were summarized by frequency counts (percentage) and differences between 
groups were evaluated using chi-square tests. For continuous variables, results 
are presented as median (range) and comparison between categories was 
made with Mann-Whitney U tests. Multiple group comparisons were made 
with Kruskal-Wallis tests. All analyses were performed using SPSS software 
version 15.0. A P-value of <0.05 at a two-sided level was considered statistically 
significant.
Results 
Patient characteristics
Characteristics of 80 DM1 patients (all Caucasian; 45 males and 35 females) 
are shown in table 4.1. No significant differences in clinical characteristics were 
found between men and women. As expected, with increasing CTG repeat 
length, the median age at onset and skeletal muscle strength score decreased 
(P<0.001). All patients were ambulant for short distances (<100 meter), but 16 
subjects used mobility aids and 4 patients were confined to a wheelchair for 
longer distances. 
Table 4.1. Clinical and genetic characteristics according to clinical phenotype category
Mild type
n = 9
Classical type
n = 63
Congenital/
childhood type
n = 8
Total
n = 80
Male 5 (56%) 33 (52%) 7 (88%) 45 (56%)
Age in years (range) 60 (46-70) 47 (24-64) 32 (24-51) 48 (24-70)
Age at onset in years (range) 52 (50-65)* 27 (10-51) 6.5 (0-10) 27 (0-65)
Muscle strength sum score (range) 110 (107-110) 96 (73-109) 100 (78-109) 98 (73-110)
Abnormal ECG 1 (11%) 41 (65%) 7 (88%) 49 (61%)
Abnormal CMR 3 (33%) 28 (44%) 4 (50%) 35 (44%)
*age at onset of neuromuscular signs and symptoms could not be determined in 3 patients, 
since they were still asymptomatic. 
Fatigue and dyspnoea were frequently reported symptoms: 48 patients were 
either dyspnoeic or fatigued after exertion and 10 subjects complained of both. 
No patient reported a history of syncope, severe palpitations at rest, angina 
pectoris or myocardial infarction. Mild peripheral oedema was seen in 4 
patients, all of whom had normal systolic and diastolic LV function and normal 
NT-proBNP levels. 
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CMR
Functional or structural abnormalities were detected with CMR imaging in 35 
patients (44%). The results of CMR analysis are summarized in table 4.2. LV 
systolic dysfunction was found most frequently, being present in 20 patients. 
An example of LV dysfunction on CMR is shown in figure 4.1. Concomitant 
dilatation of the LV was found in 4 patients, while 3 patients had LV dilatation 
with preserved systolic function. 
Table 4.2. Cardiac magnetic resonance imaging results
All 
n=80
Male 
n=45
Female 
n=35
LV ejection fraction, % (range) 58 (38-73) 57 (45-73) 61 (38-71)
LV systolic dysfunction, n (%) 20 (25%) 16 (36%) 4 (11%)
LV enddiastolic volume, ml/m2 (range) 72 (38-117) 77 (41-117) 67 (38-104)
LV endsystolic volume, ml/m2 (range) 31 (11-63) 35 (14-63) 28 (11-56)
LV dilatation, n (%) 7 (9%) 6 (13%) 1 (3%)
LV mass, g/m2 (range) 47(30-79) 50 (36-79) 41(30-67)
LV wall hypertrophy, n (%) 6 (8%) 4 (9%) 2 (6%)
RV ejection fraction, % (range) 64 (38-77) 60 (38-77) 67 (50-76)
RV systolic dysfunction, n (%) 4 (5%) 4 (9%) 0
RV enddiastolic volume, ml/m2 (range) 66 (40-117) 71 (40-117) 61 (40-102)
RV endsystolic volume, ml/m2 (range) 23 (10-66) 28 (10-66) 20 (10-46)
RV dilatation, n (%) 1 (1%) 1 (2%) 0
RV outflow tract, mm (range) 26 (21-37) 27 (22-37) 25 (21-29)
Myocardial fibrosis, n (%) 10 (13%) 7 (16%) 3 (9%)
Figure 4.1. Ventricular dysfunction in myotonic dystrophy type 1
Legend to figure 4.1. Cine images in four-chamber long-axis view in diastole and systole of a 
patient with impaired systolic left ventricular function (ejection fraction 38%): septal and apical 
hypokinesia (arrows).
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Regional LV hypokinesia was observed in 11 patients and co-localized with 
local thinning of the wall in 3 cases. LV hypertrophy was observed in 6 patients. 
None of the patients with LV hypertrophy had arterial hypertension. LV mass 
indexes of DM1 patients were remarkably low and the mean values differed 
significantly from values obtained from healthy volunteers (t-test, P<0.001).14 
Right ventricular dysfunction or dilatation was only present in patients with LV 
dysfunction. Abnormal myocardial function and structure was more frequent in 
men than in women (P<0.001) and associated with higher age (P=0.04), but 
not with duration of disease, muscle strength sum score or CTG repeat length. 
Focal myocardial fibrosis was detected on LGE images in 10 patients, most 
often as midmyocardial hyperenhancement of the septal segments and basal 
(inferio) lateral segments of the LV wall (n=8). Subendocardial and partly 
transmural hyperenhancement of the basal lateral wall was also found (n=2). 
Examples of selected CMR images are shown in figure 4.2. No patient had 
signs of myocardial oedema on T2-weighted images. No significant relationship 
between the presence of myocardial fibrosis and DM1 phenotype or CTG repeat 
length was observed.
Figure 4.2. Myocardial fibrosis in myotonic dystrophy type 1
Legend to figure 4.2. Late gadolinium enhancement (LGE) images in short axis (A, B and C) and 
4-chamber long axis views (D) of 4 patients with myotonic dystrophy type 1. Between arrows are 
regions of increased signal intensity, indicating focal fibrosis, visible as midmyocardial enhance-
ment to epicardial enhancement with endocardial sparing.
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ECG and echocardiography
Electrocardiographic findings are summarized in table 4.3. An abnormal ECG 
was recorded in 49 patients (61%). All patients were in sinus rhythm except 
for 2 with atrial fibrillation. Conduction delay was present in 46 patients (58%) 
and 1 patient had abnormal Q-waves. There were no signs of hypertrophy on 
the ECGs. In general, patients with rhythm or conduction disturbances had 
more severe skeletal muscle weakness than those without (P=0.002). Of 
the 31 patients with normal ECGs, seven showed sinusbradycardia without 
conduction abnormalities (frequency 50-60 bpm, n=4; frequency <50 bpm, 
n=3). Echocardiography ruled out hemodynamically significant valvular disease 
or elevated right ventricular pressures in all patients. 
Table 4.3. Electrocardiography results
n=80
Frequency, bpm (range) 70 (40-95)
Sinusbradycardia, n (%) 14 (18%)
Atrial fibrillation, n (%) 2 (3%)
PR interval, ms (range) 200 (136-460)
Prolonged PR interval, n (%) 30 (38%)
QRS duration, ms (range) 100 (80-164)
Intraventricular conduction delay, n (%) 26 (33%)
Left anterior fascicular block, n (%) 6 (8%)
Left posterior fascicular block, n (%) 1 (1%)
A graphic reproduction of the cardiac evaluation is shown in figure 4.3. There 
was an association between ECG abnormalities and abnormal CMR findings 
(P<0.001). Patients with an abnormal ECG were more likely to have functional 
or structural cardiac abnormalities (OR 8.2; 95% CI 2.7-25.1). However, 
myocardial involvement was also seen in 5 out of 31 patients with a normal ECG. 
The sensitivity of the ECG to predict myocardial involvement in this selected 
population was 86%, with a specificity of 58%. Late gadolinium enhancement 
was found in 9 out of 49 patients with ECG abnormalities and only 1 of the 
31 patients with a normal ECG. NT-proBNP levels did not significantly differ 
between patients with and without cardiac conduction disease or myocardial 
abnormalities. Complaints of fatigue and dyspnoea on exertion were not 
associated with abnormalities on ECG or imaging.
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Figure 4.3. Graphic reproduction of cardiac evaluation
Legend to figure 4.3. The majority of patients with ECG abnormalities had functional or structural 
cardiac abnormalities. However, a substantial number of patients with normal ECG also showed 
myocardial alterations. NT-proBNP levels did not help to distinguish between patients with and 
without impaired myocardial functioning (presented as median (range)).
Discussion 
The principal finding of this study is that structural and functional myocardial 
abnormalities are frequent in DM1 patients. The presence of mild to moderate 
left ventricular systolic dysfunction, ventricular dilatation, myocardial 
hypertrophy or fibrosis was strongly associated with electrocardiographic 
conduction abnormalities. However, 16% of patients with a normal ECG still 
had myocardial alterations. These findings lend support to the concept that the 
myocardium is generally involved in the pathogenic process of DM1. 
Myocardial involvement may be prognostic in predicting death in DM1.9 CMR 
imaging is established in cardiomyopathies, because of its greater sensitivity 
and reproducibility than conventional diagnostic investigations (ECG and 
echocardiography) to demonstrate early abnormalities or subtle changes.15 
However, the cardiac magnetic resonance imaging phenotype of DM1 had not 
been well characterized. Initial descriptions of CMR findings in DM1 revealed 
structural abnormalities, but the number of investigated subjects was small and 
80 patients with  
myotonic dystrophy 
ECG abnormal 
n=49 (61%) 
ECG normal 
n=31 (39%) 
CMR CMR 
Completely normal 
n=19 (39%) 
abnormal 
n=30 (61%) 
Completely normal 
n=26 (84%) 
abnormal  
n=5 (16%) 
- LV systolic dysfunction  n=2 
- LV dilatation n=2 
- RV systolic dysfunction  n=0 
- RV dilatation n=0 
- LV wall hypertrophy  n=1 
- RV wall hypertrophy  n=0 
- Myocardial fibrosis  n=1 
NT-proBNP 
66 pg/ml 
(10-497) 
NT-proBNP 
74 pg/ml 
(9-214) 
NT-proBNP 
60 pg/ml 
(9-966) 
NT-proBNP 
64 pg/ml 
(12-660) 
- LV systolic dysfunction  n=18 
- LV dilatation n=5 
- RV systolic dysfunction  n=4 
- RV dilatation n=1 
- LV wall hypertrophy  n=4 
- RV wall hypertrophy  n=0 
- Myocardial fibrosis  n=9 
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functional analysis had not been carried out.16 Left ventricular hypertrabeculation 
confirmed by CMR has been reported in 2 related patients with DM1.17 Another 
study described a possible relationship between CMR abnormalities of the 
right ventricle and inducible arrhythmias at electrophysiological testing in DM1 
patients.18 Yet, no gadolinium contrast was used to visualize fibrosis and the 
induced ventricular arrhythmias were mostly non-sustained. We did not find 
any isolated remarkable abnormalities of the right ventricle or left ventricular 
hypertrabeculation in our large cohort.
Fibrosis is a frequent histopathological finding in individual DM1 cases.19-23 Focal 
myocardial fibrosis as detected by LGE-CMR was present in 13% of our patients. 
As in other non-ischemic cardiomyopathies, late gadolinium enhancement 
was usually located in the interventricular septum and often limited to the 
mid-myocardium.24, 25 An increased risk of sustained ventricular tachycardia 
and sudden death is associated with midwall fibrosis in patients with dilated 
cardiomyopathy.26 Whether midwall fibrosis determined by CMR is a predictor 
of mortality in DM1 remains to be investigated.
The low prevalence of symptomatic heart failure in DM1 is usually partly 
attributed to the reduced cardiac demand due to diminished skeletal muscle 
activity.27 This lower hemodynamic load in DM1 patients can also explain the 
low LV mass indexes found in this study.
Increasing age, male sex and ECG conduction abnormalities are all significantly 
associated with myocardial disease, whereas CTG repeat length and severity 
of muscular impairment are not. Male gender and age have been positively 
associated with arrhythmia and conduction abnormalities.28 There is no 
consensus from the literature as to whether or not CTG repeat size has value 
as a prognostic indicator of conduction disturbances or cardiac event.28-30 
While age at onset of symptoms and severity of the phenotype correlate 
with the size of the CTG repeat, the association between the length of the 
CTG repeat measured in leukocytes and other symptoms of DM1 is more 
elusive. The heterogeneity of symptoms shown by patients with similar CTG 
repeat sizes can partly be explained by the presence of somatic mosaicism 
and somatic expansion over time.31 
Structural and functional cardiac changes were found in patients with mild as well 
as severe neurological phenotypes. Duration of neuromuscular disease was not 
significantly related to cardiac disease, indicating that cardiac manifestations 
can precede, coincide with or succeed skeletal myopathy. It should however be 
stressed that recall of age at onset is sometimes poor and unreliable, as the 
diagnosis is often considerably delayed. Furthermore, duration of symptoms 
do not necessarily relate to the severity of neuromuscular symptoms as disease 
progression is highly variable. Symptoms of dyspnoea or fatigue were not 
associated with LV dysfunction and may therefore largely be ascribed to the 
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progressive physical disability of the muscular disease.
The current study is a descriptive study of a large cohort of patients with DM1 
using state of the art diagnostic technology. A limitation of the descriptive 
survey is the absence of a comparison group or prognostic data allowing no 
inferences to be drawn about cause of disease and the predictive value of 
myocardial fibrosis or other CMR findings for identifying patients with DM1 
who are at risk for cardiac death.
Conclusion
Subclinical cardiomyopathy in patients with DM1 is frequently observed with 
CMR imaging. Screening for functional and structural cardiac disease should 
be considered in all patients since myocardial involvement can be overlooked 
by ECG alone. Whether the identification of structural or functional cardiac 
changes has prognostic implications for the prediction of disease progression 
or sudden death remains to be investigated in a long-term prospective study.
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Summary
Myotonic dystrophy type 1 (DM1) is an autosomal dominant inherited 
multisystemic disorder caused by a trinucleotide expansion in a noncoding 
region of the DMPK gene. A toxic RNA gain-of-function is assumed to lead to 
degeneration in many tissues. Cardiac involvement is a frequent complication, 
but the molecular mechanisms remain poorly defined. We assessed the gene 
expression patterns in human cardiac biopsies obtained from patients with 
DM1-related cardiomyopathy. Microarray analysis showed significant changes in 
the expression levels of 989 mRNAs and 16 microRNAs compared to controls. 
Bioinformatics analysis of gene expression data identified several pathological 
changes in DM1 hearts, including loss of DMPK, deregulation of mitochondrial 
oxidative phosphorylation, RNA processing, calcium signalling and cytoskeletal 
genes. These pathways largely overlap with those found in gene expression 
profiles of skeletal muscle. We show that gene expression levels in hearts of 
DM1 patients are compatible with proposed pathogenic mechanisms and that 
the observed changes may predispose DM1 hearts to conduction disturbances 
and impaired myocardial function. This suggests that similar mechanisms 
affect both skeletal and cardiac muscle in DM1.
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Introduction
Myotonic dystrophy type 1 (DM1) is an autosomal dominantly inherited 
multisystem disorder with a prevalence of 2.1-14.3 per 100 000 worldwide.1 
The diagnosis of DM1 is usually suspected in individuals with characteristic 
muscle weakness and myotonia and can be confirmed by detection of a CTG 
trinucleotide repeat in the 3’ non-coding region of the dystrophia myotonica 
protein kinase (DMPK) gene.2
Apart from neuromuscular symptoms, patients have multiple organ 
manifestations including cardiac involvement. The severity of cardiac 
complications has become increasingly appreciated over the past several years. 
Myocardial fibrosis and degeneration of the cardiac conduction system result in 
progressive conduction abnormalities, atrial and ventricular arrhythmias, and 
ventricular dysfunction. Sudden death occurs in 20-30% of cases and is believed 
to result from fatal atrioventricular block or from ventricular tachyarrhythmia.3, 4
Thus far, no intervention has effectively prevented sudden death in this 
population. 
The major pathogenic mechanism involves a toxic gain-of-function of DMPK 
RNA transcripts containing an expanded CUG repeat (CUGexp). It has been 
shown that mutant DMPK transcripts accumulate in nuclear inclusions and 
interfere with activity, localization and/or steady-state levels of RNA-interacting 
proteins like CUG binding protein 1 (CUGBP1) and muscleblind-like 1 (MBNL1).5 
In turn, loss of function of MBNL1, and hyperphosphorylation and up-regulation 
of CUGBP1 disturb splicing of pre-mRNAs, suppress translation, and deregulate 
processing of microRNAs (miRNA).5 In addition, it is assumed that reduction 
of DMPK protein levels itself and decreased expression levels of neighbouring 
genes may be involved.6, 7 
However, it remains elusive which concepts mentioned above occur in the 
myocardium of DM1 patients with signs of cardiomyopathy. Exploring the 
changes in gene expression can identify molecular pathways associated with the 
clinical hallmarks of DM1 cardiomyopathy such as disturbed cardiac conduction 
and enhanced arrhythmogenesis. Therefore, we assessed the gene expression 
patterns in human cardiac biopsies obtained from patients with DM1-related 
cardiomyopathy. Transcript levels of both protein coding genes and miRNAs 
were determined in an unbiased manner to identify potential pathophysiological 
explanations for the observed cardiomyopathy.
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Methods
Patient selection and cardiac muscle biopsies
A cohort of 170 patients with genetically proven DM1 was examined as part 
of a prospective, on-going study on cardiac involvement in DM1. The study 
protocol was approved by the institutional ethics committee of the Maastricht 
University Medical Centre and written informed consent was obtained from 
all participants. 
ECG, echocardiogram, Holter examination and cardiac magnetic resonance 
imaging (CMR) was performed in each patient. Subjects were considered to 
have DM1-related cardiomyopathy when 1) QRS duration was >120 ms, or 2) 
ejection fraction (EF) was below 45% on echocardiography, or 3) there was 
myocardial late gadolinium enhancement seen at CMR, or 4) non-sustained 
ventricular tachycardia (VT) was found at Holter examination, defined as 3 or 
more ventricular beats with a rate of >120 beats/min and a duration of <30 
s. Patients meeting one or more of these criteria were considered eligible for 
diagnostic electrophysiological studies. Between January 2007 and June 2009, 
37 out of 50 eligible patients agreed to undergo invasive electrophysiological 
studies, and 27 of these patients gave informed consent to undergo invasive 
cardiac muscle biopsy during the procedure. Control biopsies were obtained 
from subjects who underwent diagnostic endomyocardial biopsies for idiopathic 
VT (n=4), for exclusion of arrhythmogenic right ventricular cardiomyopathy/
dysplasia (ARVC/D) (n=1) and for exclusion of cardiac sarcoidosis (n=1).
Table 5.1. Clinical data
Patients
n=27
Controls
n=6
P-value
Age in years, median (range) 50 (26-63) 36 (25-56) 0.03
Male, n (%) 16 (59) 4 (67) ns
ECG 
 PR in ms, median (range)
 QRS in ms, median (range)
210 (140-460)
120 (85-165)
152 (114-202)
96 (82-114)
0.004
0.001
Echocardiography
 LVEF in %, median (range)
 LVEDD index in mm/m2, median 
(range)
58 (35-70)
24 (17-31)
55 (48-66)
28 (22-31)
ns
ns
CMR imaging
 fibrosis, n (%) 4 (15) 0 na
ns= not significant; na= not applicable
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A total of 4-5 endomyocardial biopsies were taken from the septal wall of 
the right ventricle with a flexible bioptome by fluoroscopic guidance. Cardiac 
biopsies were immediately snap-frozen for RNA extraction, or formalin-fixed for 
histological analyses. Baseline characteristics of DM1 and control patients are 
provided in table 5.1.
Histological analysis
Paraffin-embedded tissue sections of 4 µm thickness were stained using Sirius 
red for collagen and CD3, CD4, CD8, CD20, CD45, and CD68 antibodies for 
inflammatory cells. The total tissue area of the myocardial biopsies on the 
histological slide was determined by morphometric analysis and the number of 
staining inflammatory cells were counted and expressed per mm2, as described 
previously.8 Collagen volume fraction was quantified as percentage Sirius 
red stained area per total myocardial tissue area, excluding perivascular and 
endocardial fibrosis. 
RNA isolation and microarray analysis
Total RNA was isolated using the mirVana miRNA isolation kit (Ambion, Austin, 
TX) and hybridized to either Illumina Human miRNAv2 Expression Panel arrays 
or Illumina HumanHT-12 v3 Expression BeadChips by ServiceXS (Leiden, 
The Netherlands). The mRNA arrays contain 48 000 probes derived from the 
National Center for Biotechnology Information Reference Sequence (NCBI) 
RefSeq (Build 36.2, Release 22) and the UniGene (Build 199) databases. The 
miRNA arrays contained 858 human microRNA sequences described in Sanger 
Institute miRBase release 12.05, plus additional novel content derived using 
Illumina sequencing technologies, making up a total of 1146 assays per chip.
The lumi R package was used for annotation, quality control and 
normalization of both microarrays.9 A quantile normalization was applied 
to the mRNA and miRNA arrays separately.10 Differential expression was 
analysed using the limma R package.11 mRNAs and miRNAs were considered 
differentially expressed with a corrected P-value <0.05.12 
The resulting genes were analysed for enrichment in the Kyoto Encyclopaedia of 
Genes and Genomes (KEGG) pathway terms,13 using the Database for Annotation 
Visualization and Integrated Discovery (DAVID) tool.14, 15 Differentially regulated 
genes were highlighted and their regulation direction indicated on the enriched 
KEGG pathways.
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Statistics
Descriptive statistics of clinical characteristics and histological findings 
are presented. Categorical variables were summarized by frequency counts 
(percentage) and differences between groups were evaluated using chi-squared 
tests. For continuous variables, results are presented as median (range) or 
mean (SD) and comparison between categories was made with unpaired t-tests 
or Mann-Whitney U tests. All analyses were performed using SPSS software 
version 20.0. A P-value of <0.05 at a two-sided level was considered statistically 
significant.
Results
Histological analysis 
Histological analysis of biopsies of 24 patients with DM1 and 6 controls is 
summarized in table 5.2. The median collagen volume fraction (CVF) was 3.2% 
(range 0.4-8.8%) in patients with DM1 and 4.2% (range 2.2-7.9%) in controls 
(P=0.2). The CVF correlated neither with age nor with CMR measured LVEF or 
end-diastolic volume. Patients with inducible VT during the electrophysiological 
studies did not have more interstitial fibrosis in their biopsies than patients who 
did not. No patient had increased lymphocytic inflammation. 
Table 5.2. Histological analysis
Patients
n=24
Controls
n=6 P-value
CD3+, lymphocytes/mm2, mean (SD) 2.9 (2.1) 5.2 (4.7) ns
CD4+, lymphocytes/mm2, mean (SD) 1.4 (1.7) 2.6 (3.1) ns
CD8+, lymphocytes/mm2, mean (SD) 3.0 (3.9) 3.0 (3.6) ns
CD20+, lymphocytes/mm2, mean (SD) 0.04 (0.1) 0 (0) na
CD45+, lymphocytes/mm2, mean (SD) 7.7 (5.0) 9.3 (4.9) ns
CD68+, macrophages/mm2, mean (SD) 4.6 (3.4) 5.0 (3.3) ns
Interstitial collagen volume fraction 3.2 (2.3) 4.22 (2.2) ns
ns= not significant; na= not applicable
Differential microarray analysis identifies cardiac deregulation of candidate 
genes
Microarray analysis showed significant changes in the expression levels of 989 
mRNAs in hearts of DM1 patients as compared to controls. Sixteen miRNAs 
were deregulated (table 5.3). 
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First of all, levels of DMPK mRNA itself were significantly reduced in DM1 hearts. 
Concomitantly, the expression of the homeobox gene SIX5, which is located 
immediately downstream of DMPK, was also significantly reduced. On the other 
hand, gene expression level of the RNA-binding proteins MBNL1 and CUGBP1 
were increased in DM1 hearts. In addition, expression levels of cardiac troponin 
T (TNNT2), which is aberrantly spliced in cardiac tissue of DM1 patients,16 were 
also increased. Another up-regulated gene that has been implicated in DM1 is 
PDZ and LIM domain 3 (PDLIM3). Aberrant splicing of PDLIM3 transcripts was 
shown in DM1 skeletal muscle and may affect physiologic functions of heart 
muscle.17 Interestingly, its family members PDLIM5 and PDLIM7 were down-
regulated in our cardiac DM1 biopsies. In addition, we found that calsequestrin 
1 (CASQ1) gene expression, which is up-regulated in DM skeletal muscle,18 was 
also up-regulated in the hearts of DM1 patients. 
Table 5.3. Deregulated miRNAs
Name Fold-change P-value
hsa-let-7c* -1.27 0.013
hsa-miR-1236 -1.13 0.046
hsa-miR-1257 -1.29 0.021
hsa-miR-1283 -1.18 0.011
hsa-miR-1308 -1.28 0.028
hsa-miR-147b -1.46 0.033
hsa-miR-182* -1.28 0.044
hsa-miR-186* -1.14 0.032
hsa-miR-30b* -1.27 0.011
hsa-miR-32* 1.36 0.049
hsa-miR-516a-5p -1.27 0.031
hsa-miR-541 -1.18 0.025
hsa-miR-545 -1.22 0.037
hsa-miR-545:9.1 -1.31 0.023
hsa-miR-548b-3p -1.28 0.001
hsa-miR-767-5p -1.34 0.029
Expression levels of non-muscle myosin heavy-chain gene MYH14, which are 
reduced in skeletal muscle of DM1 patients,19 were also reduced in cardiac tissue. 
Finally, LIM domain binding 3 (LDB3) transcripts, which are aberrantly spliced 
in DM1 skeletal muscle,20 were found up-regulated in hearts. Interestingly, 
mutations in this gene have been associated with myofibrillar myopathy and 
dilated cardiomyopathy.21, 22 
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Pathway analyses reveal hidden cardiac pathology in DM1 patients
Microarray data were subjected to pathway analysis using the KEGG pathway 
database.23 Top enriched KEGG pathways included those for mitochondrial 
oxidative phosphorylation (OXPHOS), fatty acid metabolism, ribosome, 
spliceosome, proteasome and cardiac muscle contraction (figures 5.1-5.6). 
Most remarkably, many subunits of the OXPHOS chain were consistently 
down-regulated in DM1 hearts (figure 5.1). In addition, in-depth functional gene 
characterization of the list of differentially expressed genes revealed a number 
of interesting patterns in hearts of DM1 patients.
Genes involved in calcium/cAMP signalling are up-regulated in DM1 hearts 
Calcium signalling, in particular the calcium/calmodulin pathway, is crucial 
both for cardiac contraction and relaxation and for the control of cardiac gene 
expression. 
We found a general up-regulation of calcium/calmodulin-related genes in DM1 
hearts, including the anchor protein AKAP1 involved in cAMP-signalling, the 
Aspartate beta-hydroxylase which regulates calcium homeostasis, the calcium/
calmodulin-binding Caldesmon 1, the Calcium/calmodulin-dependent protein 
kinase type II subunits B and D and their inhibitor CAMK2N1, the calcium-
binding protein P22 that resembles Calcineurin B and Calmodulin, the 
mitochondrial calcium-binding protein Calsequestrin 1, and finally the protein 
phosphatase PPM1K which has CAMK2G as a substrate (table 5.4). 
Table 5.4. Deregulated calcium signalling and homeostasis genes
Gene Full name of protein Fold-
change
P-value
AKAP1 A kinase (PRKA) anchor protein 1 1.38 0.040
ASPH aspartate beta-hydroxylase 1.55 0.004
CALD1 caldesmon 1 2.07 0.002
CASQ1 calsequestrin 2.25 0.008
CAMK2B calcium/calmodulin-dependent protein kinase II beta 1.78 0.002
CAMK2D calcium/calmodulin-dependent protein kinase II delta 1.44 0.044
CAMK2N1 calcium/calmodulin-dependent protein kinase II inhibitor 1 1.43 0.032
CHP calcium binding protein P22 1.26 0.030
MAP6D1 MAP6 domain containing 1 -1.31 0.003
PPM1F protein phosphatase 1F (PP2C domain containing) -1.57 0.005
PPM1K protein phosphatase 1K (PP2C domain containing) 1.52 0.031
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mRNA processing and splicing are affected in DM1 hearts
It is suggested that the CUGexp RNA associated with DM1 leads to a trans-
dominant effect on normal RNA processing. In line with this, we found 
deregulation of genes involved in mRNA processing, splicing and RNA binding 
and stability (i.e. genes involved in mRNA surveillance and nonsense-mediated 
mRNA decay) in DM1 hearts (table 5.5).
Genes involved in mRNA processing are the cleavage and polyadenylation 
specificity factor CPSF1; the heterogeneous nuclear ribonucleoproteins 
HNRNPAB, HNRNPD, HNRNPU and HNRNPUL which are involved in pre-
mRNA processing and other aspects of mRNA metabolism and transport; both 
the small nuclear ribonucleoprotein SNRPN and associated SNURF involved 
in pre-mRNA processing, possibly tissue-specific alternative splicing events; 
SSB involved in RNA metabolism; and finally the nuclear mRNA factory protein 
WBP11.
Genes involved in mRNA splicing included the aforementioned alternative 
splicing regulators MBNL1 and CUGBP1; the spliceosome RNA helicase 
BAT1; the DEAD box proteins DDX19B, -31, -46, and -51 and DHX37 and -40 
which are RNA helicases implicated in a number of cellular processes involving 
alteration of RNA secondary structure such as translation initiation, nuclear and 
mitochondrial splicing, and ribosome and spliceosome assembly; the nuclear 
protein LUC7L3 possibly involved in spliceosome formation; the RNA-binding 
protein NONO with roles in transcriptional regulation and RNA splicing; the 
splicing factor SLU7; and finally the tRNA splicing endonuclease TSEN15.
Genes encoding for RNA binding and stabilizing proteins include the RNA 
binding HADHB which decreases the stability of some RNAs; Ligatin which 
contains PUA and SUI1 domains that may function in RNA binding and 
translation initiation; the RNA-binding motif proteins RBM42, RBMS1 and 
RBMX; the RNA binding and posttranscriptional regulator SAMD4A; the mRNA-
binding protein SERBP1 involved in mRNA stability; the mRNA surveillance 
proteins UPF1, which is part of a post-splicing multiprotein complex; WDR61; 
and SMG7.
DM1 heart gene expression analysis reveals protein synthesis, folding and 
degradation abnormalities
KEGG pathway analysis identified genes encoding ribosomal proteins to 
be generally down-regulated (figure 5.3), which could signify a decrease in 
translational capacity. We found additional deregulated genes involved in 
ribosome assembly and function. These included the above-described DEAD 
and DEAH box proteins which are also involved in ribosome assembly, the 
snoRNP gene family members NOP10 and NOP56 which are required for 
ribosome biogenesis and Nucleolin which is involved in the synthesis and 
maturation of ribosomes.
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Table 5.5. Deregulated RNA processing genes
Gene Full name of protein Fold-change P-value
ADPRHL1 ADP-ribosylhydrolase like 1 1.87 0.0002
ARL16 ADP-ribosylation factor-like 16 1.65 0.013
ARL2 ADP-ribosylation factor-like 2 -2.00 0.002
ASAP3 ArfGAP with SH3 domain, ankyrin repeat and PH domain 3 -1.50 0.014
BANF1 similar to barrier-to-autointegration factor 1 1.57 0.006
CUGBP1 CUG triplet repeat, RNA binding protein 1 1.23 0.014
CMPK1 cytidine monophosphate (UMP-CMP) kinase 1, cytosolic 1.47 0.021
CPSF1 cleavage and polyadenylation specific factor 1, 160kDa -1.33 0.023
DDX19B DEAD (Asp-Glu-Ala-As) box polypeptide 19B -1.23 0.049
DDX31 DEAD (Asp-Glu-Ala-Asp) box polypeptide 31 -1.22 0.006
DDX46 DEAD (Asp-Glu-Ala-Asp) box polypeptide 46 -1.35 0.004
DDX51 DEAD (Asp-Glu-Ala-Asp) box polypeptide 51 1.50 0.049
DHX37 DEAH (Asp-Glu-Ala-His) box polypeptide 37 -1.26 0.047
DHX40 DEAH (Asp-Glu-Ala-His) box polypeptide 40 1.15 0.032
EXOSC1 exosome component 1 -1.33 0.016
GEMIN6 gem (nuclear organelle) associated protein 6 -1.25 0.036
HADHB hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme 
A thiolase/enoyl-Coenzyme A hydratase (trifunctional protein), 
beta subunit
1.32 0.014
HNRNPAB heterogeneous nuclear ribonucleoprotein A/B -1.55 0.008
HNRNPD heterogeneous nuclear ribonucleoprotein D (AU-rich element 
RNA binding protein 1, 37kDa)
1.37 0.006
HNRNPU heterogeneous nuclear ribonucleoprotein U (scaffold attach-
ment factor A)
2.06 0.008
HNRNPUL1 heterogeneous nuclear ribonucleoprotein U-like 1 1.57 0.0493
HSPA1A heat shock 70kDa protein 1A 1.63 0.003
IMP4 IMP4, U3 small nucleolar ribonucleoprotein, homolog (yeast) -1.52 0.011
INTS1 integrator complex subunit 1 -1.31 0.029
IPO11 importin 11 -1.23 0.016
IPO7 importin 7 1.38 0.013
LGTN ligatin -1.20 0.045
LUC7L3 cisplatin resistance-associated overexpressed protein 1.51 0.023
MBNL1 muscleblind-like 1 1.34 0.040
MBP myelin basic protein -1.51 0.010
MED10 mediator complex subunit 10 -1.47 0.003
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Gene Full name of protein Fold-change P-value
NHP2L1 NHP2 non-histone chromosome protein 2-like 1 (S. cerevisiae) -1.50 0.029
NONO non-POU domain containing, octamer-binding 1.40 0.011
POLR3B polymerase (RNA) III (DNA directed) polypeptide B -1.35 0.011
PRDM9 PR domain containing 9 -1.18 0.031
PUS1 pseudouridylate synthase 1 -1.31 0.019
RBM42 RNA binding motif protein 42 1.39 0.030
RBMS1 RNA binding motif, single stranded interacting protein 1 1.40 0.004
RBMX RNA binding motif protein, X-linked 1.24 0.032
SAMD4A sterile alpha motif domain containing 4A -2.04 0.0006
SERBP1 SERPINE1 mRNA binding protein 1 -1.25 0.005
SLU7 SLU7 splicing factor homolog (S. cerevisiae) 1.40 0.002
SMG7 Smg-7 homolog, nonsense mediated mRNA decay factor (C. 
elegans)
-1.12 0.049
SNRPN small nuclear ribonucleoprotein polypeptide N 1.61 0.004
SNURF SNRPN upstream reading frame protein 1.65 0.017
SSB Sjogren syndrome antigen B (autoantigen La) 1.20 0.047
SSSCA1 Sjogren syndrome/scleroderma autoantigen 1 -1.24 0.029
TADA3 transcriptional adaptor 3 (NGG1 homolog, yeast)-like 1.34 0.0496
TAF6L TAF6-like RNA polymerase II, p300/CBP-associated factor 
(PCAF)-associated factor, 65kDa
-1.23 0.035
TCEB2 transcription elongation factor B (SIII), polypeptide 2 (18kDa, 
elongin B)
-1.64 0.012
TSEN15 tRNA splicing endonuclease 15 homolog (S. cerevisiae) -1.48 0.010
UPF1 UPF1 regulator of nonsense transcripts homolog (yeast) -1.30 0.043
WBP11 WW domain binding protein 11 1.43 0.002
WDR61 WD repeat domain 61 -1.19 0.044
XAB2 XPA binding protein 2 1.44 0.027
Following protein synthesis in ribosomes, correct protein folding is essential for 
normal protein function. Deregulated genes involved in protein folding included 
Calnexin which facilitates protein folding and assembly and is involved in quality 
control of folded proteins; the heat shock protein 70 family member HSPA1A 
which stabilizes existing proteins against aggregation and mediates the folding 
of newly translated proteins; and TCP1 which contributes to a complex that 
folds various proteins including actin and tubulin.
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We identified the proteasome as another significantly deregulated pathway in 
DM1 hearts (figure 5.3). As for the ribosome, most proteasome genes were 
found to have reduced expression levels, including 6 of the 7 beta subunits of 
the 20S proteasome (PSMB2-7), and PSMB10, PSMC3 and PSMD4. Protein 
degradation is mediated by the proteasome on the one hand, and by ubiquitin 
ligases on the other hand. From the list of differentially expressed genes, we 
identified additional deregulated genes involved in proteasome function and 
ubiquitin ligation (table 5.6). These are the positive regulator of E3 ubiquitin 
ligases COPS8; the F-box protein family member FBXO6 which constitutes 
one of the four subunits of the ubiquitin protein ligase complex; the ring finger 
protein RNF7 which is an essential subunit of the F-box protein ubiquitin ligases; 
HSPA1A which is also involved in the ubiquitin-proteasome pathway; PSME3 
which is part of the immunoproteasome; Ubiquilin 2 which functionally links the 
ubiquitination machinery to the proteasome to affect protein degradation, and 
valosin-containing protein which functions in the 26S proteasome in ubiquitin-
dependent protein degradation. Two highly interesting down-regulated 
genes are the cathepsins B and L1, which are involved in intracellular protein 
catabolism, in particular of collagen and elastin, and have been implicated in 
myofibril necrosis in myopathies. Finally, we found up-regulation of Calpastatin, 
which is thought to affect the expression levels of genes encoding structural or 
regulatory proteins by proteolysis. YAF2 interacts with YY1, a zinc finger protein 
involved in negative regulation of muscle-restricted genes including sarcomeric 
actin, and facilitates proteolytic cleavage of YY1 by the calcium- activated 
protease. YAF2 down-regulation in DM1 hearts may result in excess YY1 levels, 
putatively decreasing actin levels.
Cytoskeletal genes are deregulated in DM1 hearts
The cytoskeleton provides structural support to the cell and the main types 
of fibres comprise microfilaments, microtubules, and intermediate filaments. 
Genes coding for structural constituents of cytoskeleton are crucial for 
cardiac myocyte functioning and were generally up-regulated in DM1 hearts. 
Besides the aforementioned LDB3, PDLIM3 and TNNT2 genes, these include 
the intermediate filament proteins vimentin and synemin; the microfilament 
protein actin; and the actin-binding proteins CAPZA1, cofilin 2 and profilin 2 
involved in actin growth; the actin-binding nexilin, SORBS2, supervillin and 
tropomyosin; CCT7 and -8 involved in actin folding; CDC42 involved in actin 
polymerisation; the actin depolymerizing factor destrin involved in actin 
turnover; and intersectin 1, NEBL and WDR1 which are all involved in actin 
assembly. 
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Table 5.6. Deregulated protein folding and degradation genes
Gene Full name of protein Fold-
change
P-value
CANX calnexin -1.52 0.0002
CAST calpastatin 1.52 0.012
COPS8 COP9 constitutive photomorphogenic homolog 
subunit 8 (Arabidopsis)
1.24 0.047
CTSB cathepsin B -1.43 0.035
CTSL1 cathepsin L1 -1.43 0.030
DDX19B DEAD (Asp-Glu-Ala-As) box polypeptide 19B -1.23 0.049
DDX31 DEAD (Asp-Glu-Ala-Asp) box polypeptide 31 -1.22 0.006
DDX46 DEAD (Asp-Glu-Ala-Asp) box polypeptide 46 -1.35 0.004
DDX51 DEAD (Asp-Glu-Ala-Asp) box polypeptide 51 1.50 0.049
DHX37 DEAH (Asp-Glu-Ala-His) box polypeptide 37 -1.26 0.047
DHX40 DEAH (Asp-Glu-Ala-His) box polypeptide 40 1.15 0.0321
FBXO6 F-box protein 6 -1.26 0.019
HSPA1A heat shock 70kDa protein 1A; heat shock 70kDa protein 1B 1.63 0.003
NCL nucleolin 1.51 0.002
NOP10 NOP10 ribonucleoprotein homolog (yeast) -1.41 0.049
NOP56 NOP56 ribonucleoprotein homolog (yeast) 1.54 0.008
PSMB10 proteasome (prosome, macropain) subunit, beta type, 10 -1.55 0.049
PSMB2 proteasome (prosome, macropain) subunit, beta type, 2 -1.43 0.003
PSMB3 proteasome (prosome, macropain) subunit, beta type, 3 -1.44 0.012
PSMB4 proteasome (prosome, macropain) subunit, beta type, 4 -1.28 0.009
PSMB5 proteasome (prosome, macropain) subunit, beta type, 5 -1.28 0.028
PSMB6 proteasome (prosome, macropain) subunit, beta type, 6 -1.39 0.005
PSMB7 proteasome (prosome, macropain) subunit, beta type, 7 -1.26 0.039
PSMC3 proteasome (prosome, macropain) 26S subunit, ATPase, 3 -1.36 0.037
PSMD4 proteasome (prosome, macropain) 26S subunit, non-ATPase, 4 -1.32 0.045
PSME3 proteasome (prosome, macropain) activator subunit 3 
(PA28 gamma; Ki)
1.31 0.029
RNF7 ring finger protein 7 -1.31 0.040
TCP1 hypothetical gene supported by BC000665; t-complex 1 1.33 0.010
UBQLN2 ubiquilin 2 1.47 0.002
VCP valosin-containing protein -1.50 0.013
YAF2 YY1 associated factor 2 -1.34 0.003
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Table 5.7. Deregulated cytoskeletal genes
Gene Full name of protein Fold-
change
P-value
ACTC1 actin, alpha, cardiac muscle 1 1.49 0.001
CAPZA1 capping protein (actin filament) muscle Z-line, alpha 1 1.17 0.0498
CCT7 chaperonin containing TCP1, subunit 7 (eta) 1.29 0.048
CCT8 similar to chaperonin containing TCP1, subunit 8 (theta) 1.27 0.017
CDC42 cell division cycle 42 (GTP binding protein, 25kDa) 1.23 0.016
CFL2 cofilin 2 (muscle) 1.14 0.031
DSTN destrin (actin depolymerizing factor) 1.88 0.005
ITSN1 intersectin 1 (SH3 domain protein) -1.51 0.007
LDB3 LIM domain binding 3 1.31 0.049
MAP1LC3A microtubule-associated protein 1 light chain 3 alpha 1.57 0.021
MAP1LC3C microtubule-associated protein 1 light chain 3 gamma -1.19 0.008
MAST4 microtubule associated serine/threonine kinase family member 4 -1.69 0.008
MB myoglobin -1.43 0.021
MKLN1 muskelin 1, intracellular mediator containing kelch motifs -1.28 0.010
MTMR14 myotubularin related protein 14 -1.57 0.007
MTMR3 myotubularin related protein 3 1.36 0.010
MYBPC3 myosin binding protein C, cardiac -1.34 0.035
MYF5 myogenic factor 5 -1.27 0.004
MYH14 myosin, heavy chain 14 -1.30 0.003
MYOZ2 myozenin 2 1.59 0.016
NEBL nebulette 1.91 0.00008
NEXN nexilin (F actin binding protein) 1.54 0.029
PDLIM3 PDZ and LIM domain 3 2.28 0.004
PFN2 profilin 2 1.47 0.033
SORBS2 sorbin and SH3 domain containing 2 1.90 0.0047
SPTAN1 spectrin, alpha, non-erythrocytic 1 (alpha-fodrin) 1.50 0.020
SVIL supervillin 1.15 0.02
SYNM synemin, intermediate filament protein 1.63 0.005
TNNT2 troponin T type 2 (cardiac) 1.54 0.013
TPM2 tropomyosin 2 (beta) 1.90 0.019
TUBA3D tubulin, alpha 3d; tubulin, alpha 3c -1.89 0.007
VIM vimentin 1.56 0.008
WDR1 WD repeat domain 1 1.24 0.033
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Differentially expressed microtubule(-associated) genes include the 
microtubule-constituent tubulin TUBA3D; MAST4, with a possible broad range 
of neural functions; and MAP1LC3A and MAP1LC3C, which mediate the physical 
interactions between microtubules and components of the cytoskeleton and 
are involved in microtubule assembly, an essential step in neurogenesis. Other 
deregulated structural protein genes include Muskelin 1, which mediates 
cytoskeletal responses to the extracellular matrix component thrombospondin 
I; the myotubularin related proteins MTMR3 and -14 for which mutations 
have been associated with autosomal dominant centronuclear myopathy; the 
cardiac myosin binding protein C MYBPC3; the myogenic factor MYF5 involved 
in muscle differentiation; the myosin heavy chain MYH14; myozenin 2, which 
is important for calcineurin signalling as it tethers calcineurin to alpha-actinin 
at the z-line of the sarcomere of cardiac and skeletal muscle cells; and the cell 
stabilizing alpha spectrin SPTAN1 (table 5.7).
Discussion
This is the first study that charts the myocardial mRNA and miRNA expression 
profiles of human DM1-related cardiomyopathy. Microarray analysis showed 
significant changes in the expression levels of 989 mRNAs and 16 miRNAs 
in hearts of DM1 patients as compared to controls. We show that mRNA 
expression levels in hearts of DM1 patients are compatible with proposed 
pathogenic mechanisms and that several pathological changes in DM1 hearts 
may have potential functional consequences. 
First, we found reduced DMPK transcript levels in human DM1 hearts in 
accordance with studies in other tissues.24 This suggests that the presence 
of a large number of repeats in the 3’ untranslated region of the DMPK gene 
reduces both the synthesis and/or processing of DMPK mRNA. It has indeed 
been shown that CUGexp transcripts are processed into small RNAs that 
trigger down-regulation of mutant transcripts.25 DMPK encodes several serine/
threonine protein kinase isoforms that are necessary for ion homeostasis and 
remodelling of the cytoskeleton and could be a contributing factor in the cardiac 
involvement in of DM1.26 Secondly, we found reduced cardiac transcript levels 
of SIX5, which is located immediately downstream of DMPK. These reduced 
levels may contribute to the molecular pathogenesis of cardiac disease, as 
experimental heterozygous loss of SIX5 in mice causes cataracts and cardiac 
conduction disease.27-29
Furthermore, the RNA binding proteins MBNL1 and CUGBP1 have an established 
role in DM1 pathogenesis. Their expression and stability was not altered in 
skeletal muscle biopsies from DM1 patients.30 By contrast, both MBNL1 and 
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CUGBP1 mRNA levels were mildly up-regulated in heart samples from our DM1 
patients. In addition, many mRNAs known to be aberrantly spliced in DM1 
muscle were up-regulated, including TNNT2, PDLIM, LDB3 and CASQ1. This 
may possibly reflect a compensatory mechanism to overcome protein isoforms 
that do not provide the necessary functional properties. Alternative splicing 
has a major role in cardiac adaptive responses, and aberrant splicing has been 
associated with heart disease.31
miRNAs are small non-coding RNAs that regulate gene expression post-
transcriptionally and may be involved in the regulation of the pathological 
pathways leading to cardiac dysfunction. Misregulation of miRNA-1 has been 
demonstrated in heart samples from patients with DM1 obtained at autopsy.32 
Our miRNA microarray data did not confirm this finding. In addition, the 
miRNAs that have been found to be deregulated in skeletal muscle of patients 
with DM1,33 or other types of dystrophy,34 were unaltered in the hearts of our 
patients with DM1-related cardiomyopathy. Most notably, miRNA-30b was 
down-regulated among a relatively small number of down-regulated miRNAs in 
our cardiac samples. This may be of interest since the miRNA-30 family inhibits 
CTGF and thereby may act as a natural inhibitor of fibrosis.35 Loss of miRNA-
30b may contribute to the fibrosis seen in DM1 hearts. 
Furthermore, we identified deregulated pathways in cardiac muscle of DM1 
patients through the analysis of gene expression profiles. Deregulated expression 
of genes involved in fatty acid metabolism and oxidative phosphorylation 
suggest altered energy metabolism. In addition, genes encoding proteasomes, 
ribosomes and spliceosomes were down-regulated suggesting concerted 
changes in RNA processing. Cytoskeletal genes were generally up-regulated, 
as were calcium signalling related genes. Interestingly, these pathways largely 
overlap with those found enriched in gene expression profiles of skeletal muscle 
from patients and mouse models of DM1, including calcium signalling and 
homeostasis, energy metabolism and ribosomal proteins.18, 36
It has been suggested that mitochondrial oxidative alterations can occur in DM1 
and may be a possible mechanism underlying cell damage in skeletal muscle of 
DM1 patients.37 However, direct evidence of a mitochondrial defect in DM1 has 
not yet been established and possible links between molecular abnormalities 
and mitochondrial dysfunction have still to be clarified in this disease. Here, we 
show global down-regulation of genes involved in the mitochondrial OXPHOS 
pathway in hearts of DM1 patients. In addition, we found reduced expression 
of the mitochondrial transcription factor TFAM mRNA, which is required for 
mtDNA transcription initiation and thus for the expression of several OXPHOS 
subunits.38, 39 Mitochondrial dysfunction is common to skeletal muscle and 
neurological disorders. OXPHOS deficiency is also an established cause of 
cardiomyopathies and conduction abnormalities.40 Our findings strongly 
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point towards DM1-dependent disturbance of cardiac mitochondrial function, 
putatively predisposing DM1 hearts to conduction disturbances and impaired 
myocardial function. In addition, abnormal cardiomyocyte calcium handling 
may further impact contractile dysfunction and render hearts susceptible to 
arrhythmias, although the precise mechanisms involved remain to be fully 
elucidated.
Recent evidence indicates that functional insufficiency of the ubiquitin-
proteasome system plays a pathogenic role in a subset of heart diseases.41, 42 We 
observed decreased levels of proteasomal and ubiquitin system-related genes 
in DM1 hearts, putatively compromising protein quality control in DM1 heart 
muscle cells and predisposing these patients to arrhythmias or progressive 
cardiomyopathy. Our data are not supported by findings in skeletal muscle of 
a transgenic DM1 mouse model, in which polyubiquitin/proteasome stress-
signalling pathways were activated.43
The endomyocardial biopsies used in this study have recognized limitations. 
First, sampling error may occur in case of local cardiac damage, such as focal 
fibrosis or focal inflammation. Secondly, cellular heterogeneity, i.e. muscular 
and endothelial as well as fibrotic components, can be obtained. Although 
endomyocardial biopsy is an invasive procedure with certain limitations, 
biopsies obtained from clinically stable DM1 patients allowed us to identify 
early changes in cardiac gene expression profiles in contrast to patients with 
end stage DM1. We were able to reproduce gene expression changes in DM1 
cardiac tissue that have been directly linked to established concepts on DM1 
pathophysiology, for instance the loss of DMPK and SIX5 expression. 
As has been shown, the expansion mutation has complex effects on gene 
expression in DM1 hearts. Altered global gene expression has previously been 
shown in skeletal muscle biopsies of DM1 patients,18, 20, 44 and in skeletal muscle 
of MBNL1 knock-out mice and of transgenic mice expressing non-coding 
CUG repeats.36 These gene expression abnormalities may result from effects 
on transcription, RNA processing and RNA stability.36 Transcription can be 
disrupted through several mechanisms, including transcription factor leaching 
from chromatin by expanded DMPK transcripts,45 or MBNL1 loss of function.36 
While it is tentative to speculate that all mRNA expression changes are the 
direct consequence of the DMPK repeat expansion, secondary effects of cardiac 
dysfunction on these genes cannot be ruled out.
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Conclusion
We demonstrate for the first time that cardiac involvement in DM1 is associated 
with distinct gene expression signatures reminiscent of those found in skeletal 
muscle and experimental models. Gene expression profiles identified several 
pathological changes in DM1 hearts with potential functional consequences, 
including loss of DMPK, altered RNA processing and deregulation of OXPHOS, 
calcium signalling and cytoskeletal genes. While DM1 patients exhibit 
heterogeneous cardiac manifestations, their cardiac gene expression profiles 
suggest a rather uniform DM1-associated cardiomyopathy.
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Figure 5.1. Genes mapping to KEGG pathway for fatty acid metabolism
Legend to figure 5.1. Each green box is representative of a human protein for which a gene has 
been identified in the genome. The numbers in the boxes are the Enzyme Commission (EC) 
number for the proteins. Green and red arrows indicate down- and up-regulated genes respec-
tively.
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Figure 5.2. Genes mapping to KEGG pathway for oxidative phosphorylation system (OXPHOS)
Legend to figure 5.2. Each green box is representative of a human protein for which a gene has 
been identified in the genome. The numbers in the boxes are the Enzyme Commission (EC) 
number for the proteins. Green and red arrows indicate down- and up-regulated genes respec-
tively.
113
Figure 5.3. Genes mapping to KEGG pathway for ribosome
Legend to figure 5.3. Each green box is representative of a human protein for which a gene has 
been identified in the genome. The numbers in the boxes are the Enzyme Commission (EC) 
number for the proteins. Green and red arrows indicate down- and up-regulated genes respec-
tively.
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Figure 5.4. Genes mapping to KEGG pathway for spliceosome
Legend to figure 5.4. Each green box is representative of a human protein for which a gene has 
been identified in the genome. The numbers in the boxes are the Enzyme Commission (EC) 
number for the proteins. Green and red arrows indicate down- and up-regulated genes respec-
tively.
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Figure 5.5. Genes mapping to KEGG pathway for proteasome
Legend to figure 5.5. Each green box is representative of a human protein for which a gene has 
been identified in the genome. The numbers in the boxes are the Enzyme Commission (EC) 
number for the proteins. Green and red arrows indicate down- and up-regulated genes respec-
tively.
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Figure 5.6. Genes mapping to KEGG pathway for cardiac muscle contraction
Legend to figure 5.6. Each green box is representative of a human protein for which a gene has 
been identified in the genome. The numbers in the boxes are the Enzyme Commission (EC) 
number for the proteins. Green and red arrows indicate down- and up-regulated genes respec-
tively.
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Summary
Myotonic dystrophy type 1 (DM1) is a dominantly inherited multisystemic 
disorder. New and emerging therapeutic interventions require high quality 
outcome measures to determine the effect in future clinical trials. Various 
measurement instruments are available, but no systematic evaluation has been 
conducted to determine the scientific soundness of these scales in the DM1 
population.
In this study, a comprehensive systematic literature search was conducted with 
predefined selection strategy to identify measurement instruments applied in 
clinical trials with DM1 patients. An overwhelming amount of health measures 
have been used. A total of 141 measures were evaluated in terms of applicability, 
validity, reliability and responsiveness. Very few outcome measures fulfilled the 
complete spectrum of clinimetric requirements. Recommendations are made to 
adopt modern rather than classical clinimetric approaches when constructing, 
evaluating and selecting outcome measures and to assemble a core set of 
outcome measures at various levels which can be applied in future therapeutic 
trials to improve comparability of the obtained results between trials.
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Introduction
Myotonic dystrophy type 1 (DM1) is a progressive autosomal dominant 
multisystem disorder with a prevalence of 2.1-14.3 per 100 000.1 DM1 is caused 
by an unstable CTG-repeat expansion in the myotonic dystrophy protein kinase 
(DMPK) gene on chromosome 19.2 The disease is characterized primarily 
by myotonia and muscle weakness of facial, axial and distal limb muscles. 
Other clinical features include cataracts, gastro-intestinal complaints, cardiac 
involvement, endocrine dysfunction, respiratory problems, excessive daytime 
sleepiness, and impairments in cognitive executive functions.1 An earlier age 
of onset and increased severity of clinical symptoms has been observed in 
subsequent generations and is related to degree of CTG expansion. DM1 leads 
to physical impairment, activity limitations and participation restrictions, and 
decreased health-related quality of life.3-6 
Future clinical trials evaluating the efficacy of (non-)pharmacological 
interventions aim at improving health outcome in patients with DM1. The 
selection of the most appropriate instrument for measuring a specific outcome 
is not easy with the wide range of measurement instruments available. However, 
high quality outcome measures are important since the validity of inferences 
from these trials is directly dependent on the quality of the applied instrument.7 
Selected outcome measures therefore need to be evaluated for their clinical 
applicability and scientific soundness, meeting the demands of being simple, 
communicable, valid, reliable, and responsive.
This review provides an overview of measurement instruments applied in 
clinical studies of patients with DM1 from January 1948 until March 2012 
and summarizes the clinimetric properties of the selected instruments. 
Recommendations are made to adopt modern rather than classical clinimetric 
approaches when constructing outcome measures for DM1 and to use a certain 
degree of standardization to facilitate comparison of future clinical trial results 
and improve communication in clinical practice.
Methods
Since the number of outcome measures in DM1 is probably infinite when 
covering all multisystemic clinical features, we focused on non-invasive, bedside 
clinical outcome measures. To identify outcome measures used in trials with 
DM1 patients between January 1948 and March 2012, a systematic literature 
search was performed in PubMed. Selection was based on the keywords and 
MESH terms myotonic dystrophy type 1, DM1, and human. Furthermore the 
bibliographies of all articles were checked. A sample population of at least 
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10 patients was required for inclusion in this review. Outcome measures for 
patients younger than 18 years of age were excluded. Studies included in this 
review were selected independently by two authors (FDK, IM). All selected 
outcome measures, primary and secondary, were categorized according to 
the International Classification of Functioning, Disability and Health (ICF) 
framework,8 and quality of life concept,9 and subsequently evaluated in terms of 
clinical applicability and scientific soundness.10
 
Results
General aspects
A total of 781 articles were identified and 141 outcome measures fulfilled the 
predefined criteria. All measurement instruments are systematically presented 
in table 6.1. A total of 137 (97%) outcome measures purely represented one 
level of outcome, while 4 (3%) were constructed by using a combination of 
items representing various levels of outcome (composite measures). 
Impairment measures
Muscle strength. Muscle strength measurements have had most attention 
in studies evaluating scientific clinimetric soundness in DM1. The widely 
used Muscular Impairment Rating Scale (MIRS) is a simple, valid and 
reliable clinical outcome for the measurement of muscular impairment to 
monitor major stages of progression within this population. However, the 
MIRS and other manual muscle testing scores may lack sensitivity to detect 
subtle changes in muscle strength. The quantitative muscle testing of ankle 
eversion and dorsiflexion with a hand held dynamometer seems to be a 
promising method to assess distal muscle weakness as a preliminary study 
showed good reliability and the ability to discriminate between healthy and 
DM1 patients with different levels of impairments.11 However, future research 
should be done to better characterize the intertesters reproducibility and 
responsiveness. Quantitative muscle testing has also been applied in other 
muscle groups.12 
Myotonia. Well-developed myotonia measurements are scarce. Computerized 
handgrip myometry is quite sophisticated to apply and strong evidence for 
validity and reliability is lacking.13, 14 Furthermore, relaxation time after ulnar 
nerve stimulation cannot be simply applied in clinical practice and lacks 
evidence for responsiveness.15, 16
Fatigue. With exception of a good reliability of the Krupp’s Fatigue Severity Scale 
in DM1,17 there is no evidence for proper clinimetric quality of fatigue scales 
for this patient population. 
127
Chapter
6.
Sleepiness. The Daytime Sleepiness Scale is specifically devised to assess the 
level of daytime sleepiness in patients with DM1 and has demonstrated good 
validity, reliability and simplicity.17, 18 To date, no responsiveness studies have 
been conducted. The widely applied Epworth Sleepiness Scale demonstrated 
to be inferior to the Daytime Sleepiness Scale in DM117 and less sensitive to 
changes than the more robust Maintenance of Wakefulness Test (MWT).19 
Pain. Clinimetric qualities of pain scales in DM1 patients have not been 
reported. Validity and reliability of a Numerical Rating Scale for pain have been 
demonstrated in a general chronic pain population, but the generalizability 
of these findings to other populations, like DM1 patients, is unknown.20 The 
McGill Pain Questionnaire (MPQ) as well as the Brief Pain Inventory (BPI) 
have been proved to be valid and reliable in limb loss, cerebral palsy, spinal 
cord injury, general pain populations,21-28 but have not been evaluated in DM1. 
Psychological distress. Many psychological functioning scales have been applied 
in studies with DM1 patients. Many of these measures, like the Hospital 
Anxiety and Depression Scale (HADS), Hamilton Anxiety Rating Scale, 
Montgomery and Asberg Depression Rating Scale (MADRS), Depressive 
Mood Scale (EHD), Tyrer Anxiety Scale and General Health Questionnaire-12 
(GHQ-12), have been extensively evaluated and shown to be valid, reliable, 
simple or responsive to some extent, but data obtained in the DM1 population 
are missing.29-37 
Activity and participation measures
Only the 6-minute walking test (6-MWT) and the Purdue Pegboard have been 
properly evaluated for its clinimetric properties in DM1 patients showing 
moderate to good reliability and responsiveness.38, 39 The self-report Activities 
of Daily Living (ADL) has been shown to have a good construct validity and 
more sensitivity for changes over time than the Mental adjustment to cancer 
(MAC) scale, the Psychosocial well-being questionnaire and the ADL staircase 
in muscular dystrophy patients, including patients with DM1.40, 41 
Quality of life measures
Compared to measures of functioning and disability, quality of life seems to be 
neglected in clinical trials. The SF-36 and Sickness Impact Profile (SIP) are most 
widely used quality of life measures in DM1, probably because there is a lot 
evidence of clinimetric quality in various other populations.9, 42-44 However, no 
quality of life measures have been appropriately evaluated for their clinimetric 
soundness in DM1. 
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Discussion
An overwhelming amount of outcome measures have been used in studies 
involving DM1 patients over the last 60 years as demonstrated in table 6.1. This 
large pool of measurement instruments hampers comparison of the results of 
clinical trials. More important is the fact that clinimetric evidence is poor or 
incomplete for most measurement instruments. In particular, responsiveness 
studies are lacking.45 At the impairment level of outcome, the MIRS has shown 
to be simple, communicable, valid and reliable. However, it is a single item 
scale, having limited ability to detect difference between individuals and detect 
subtle changes over time.46 The MIRS may therefore not be suitable for efficacy 
measurements in short-term therapeutic trials.47 Quantitative muscle testing 
using a hand‐held myometer may seem to offer an alternative to evaluate as it 
can detect small changes in distal muscle strength. However, minimal changes 
do not necessarily correlate with noticeable changes for the patient.
At the activity level of outcome, the 6-minute walking test and the Purdue 
Pegboard bimanual were reliable, feasible and sensitive enough to detect 
clinical changes in subjects with DM1.38, 39
The SF-36 is one of the most widely used generic health status measure. 
Normative data are available from general population surveys that can be used 
to determine whether a group or individual in question scores above or below 
the average. However, the SF-36 is not disease-specific making it less efficient 
for more subtle changes experienced by DM1 patients.
Since clinimetric properties are dependent on the study population, evaluation 
of clinimetric properties of measurement should be performed in the population 
in which the instrument is intended to be used. However, many of the outcome 
measures that have been used in studies with DM1 patients have only been 
evaluated in populations other than DM1. 
New therapies require identification of high quality outcome measures
Although no effective treatment is available in clinical practice, research 
advances for potential molecular therapeutic targets for DM1 are promising.48 
Preclinical studies mainly focus on selective elimination or neutralization of the 
toxic expanded CUG repeat transcripts,49, 50 alteration of RNA binding proteins 
levels,51, 52 or alteration of downstream splicing targets.53 In addition, (non-)
pharmacological symptom management may improve health status. However, 
before we are able to evaluate these therapies in clinical trials, appropriate 
measurement instruments should be selected. Furthermore, longitudinal 
studies are needed to study the natural progression of DM1. High quality 
measures of disease modification are mandatory in order to accurately detect 
clinically meaningful changes of therapeutic intervention.
In this perspective, researchers have started to developed new outcome 
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measures. A new disability scale was developed specifically for DM1 patients 
by Contardi et al.54 Good results for interobserver agreement (ICC=0.72-0.97),
intra-observer reliability, internal consistency (Cronbach’s α>0.73) and external 
validity are shown. The scale is easy and simple to use, requiring approximately 
15 minutes, and proved to be sensitive to clinical changes over a maximum 
period of 12 months. However, results are based just on a small cohort (n=33), 
and therefore the scale needs to be further evaluated in a larger population. 
Other impairment and activity measures were developed, but all have limitations 
for implementing in clinical practice for DM1 population since they are not 
specifically developed for DM1 patients,55, 56 or time consuming and difficult to 
apply.57 
Ordinal outcome measures have limitations
Most health-related outcomes, such as daily functioning or quality of life cannot 
be measured directly. Therefore, these variables are measured indirectly by 
how they manifest using rating scales. The majority of health-related outcome 
measures in DM1 are multi-item rating scales. Besides poor evaluation of 
clinimetric quality aspects, a major limitation of these scales is that they are all 
based on the classical test theory (CTT) and all provide ordinal measurement.58 
The value of numbers used in an ordinal scale and the numerical distance 
between each point in a scale is unknown. Furthermore, a sum of item scores 
is often calculated, but the relevance of each item to the variable of interest is 
not necessarily equal.43 Ordinal scales are currently used in an inappropriate 
way by addressing obtained scores as interval measures and exposing them to 
parametric analyses. 
Shifting from classic to modern clinimetric approach 
Considering these shortcomings, it is clear that a modern scientific approach is 
needed for health evaluation in clinical trials. The most widely used approach is 
the Rasch unidimensional measurement model.59, 60 This statistical technique 
models the probability of an individual’s response to an item. Once data fit 
Rasch model expectations, an interval-scale measure of a latent variable can 
be estimated from an observed raw score. These interval level variables can 
be used in parametric statistics. Furthermore, they enable individual patient 
assessment in addition to comparisons at the group level and enable scales 
measuring the same health construct to be equated on a common metric.
We started in 2008 with an evaluation and development program of outcome 
measures in DM1, aiming to present new outcome measures for clinical trials 
based on modern test theory. Recently, two scales specifically designed for 
patients with DM1 have been developed using the Rasch Model. These are the 
Myotonic Dystrophy type 1 Activity and Participation Scale (DM1-Activ)61 and the 
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Fatigue and Daytime Sleepiness Scale (FDSS).62 The DM1-Activ compromises 
20 items at the activity and participation level. High internal consistency 
(person separation index=0.95) and good test-retest reliability values of item 
difficulty hierarchy and patient location were demonstrated. Patient measures 
had acceptable correlations with MRC sum scores and MIRS grades (intraclass 
correlation coefficient=0.69 and 0.71, respectively), indicating good external 
construct validity. The FDSS is composed of 12 items selected from the 
Epworth Sleepiness Scale, Daytime Sleepiness Scale and Fatigue Severity Scale. 
High internal consistency (person separation index=0.80) and validity were 
demonstrated. Further research is needed to determine the responsiveness 
of these scales. However, its use is recommended in future clinical trials and 
follow-up studies since the scales are developed and validated for DM1 and 
overcomes the limitations of ordinal based measures. 
Conclusion
It is strongly recommended to develop a core set of outcome measures covering 
the most relevant ICF concepts which can be applied in future therapeutic trials 
with DM1 patients to improve comparability of the obtained results. Since 
ordinal-based outcome measures have serious weaknesses, we propose to 
move from classic to modern clinimetric approach when constructing outcome 
measures.
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Table 6.1. Overview of outcome measures in DM1 
Outcome Measure Validity Reliability Sensitivity to change 
and responsiveness*
Impairment measures
Muscle strength
1 Muscular Impairment 
Rating Scale (MIRS)38, 
63-84‡
Construct validity:
- correlation with MMT 
(Spearman’s r=−0.81 
to −0.88, P< 0.001)47
- correlation with FSI 
(Spearman’s r=0.50, 
P<0.001)47
- correlation with eight 
timed functional tasks 
(Spearman’s r=0.34 to 
0.67, P< 0.001-0.012)47
Intraobserver reliability: 
Cohen’s к=0.7447
Interobserver reliability: 
Cohen’s к=0.77-0.7947
Lacks sensitivity to 
detect subtle changes47
2 Medical Research 
Council (MRC) grade85-92
- Intra-/interobserver 
reliability: MRC grade 
4 is covered by a wide 
range of muscle strength. 
Subdivision to 4+ and 4- 
expands the scale but will 
decrease intraobserver 
and interobserver 
reliability92 
Lacks sensitivity to 
detect subtle changes 
in muscle strength92 
3 Modified-modified 
Medical Research 
Council Scale (MM-
MRCS)11
- - Unsuitable for 
detecting the small 
changes in strength 
compared to 
quantitative muscle 
testing11
4 Medical Research 
Council Sum Score 
(MSS)93-96
- Interobserver reliability: 
ICC> 0.8496
-
5 MRC-Megascore97, 98 - - -
6 Manual Muscle 
Testing (12 muscles) 
according to Daniels and 
Worthingham57
- - -
7 Manual Muscle Testing 
(11 muscles)99, 100
Construct validity:
correlation with MIRS 
(Spearman’s r=-0.81 to 
-0.88, P<0.001)47
Intraobserver reliability: 
ICC=0.9347
Interobserver reliability: 
ICC=0.8747
-
8 Modified Manual of 
Muscle Testing (30 
muscles) according to 
Ahlskong101
- - -
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9 Manual Muscle Testing 
(26 muscles) according 
to Personius13, 102
- -
10 Quantitative scale 
from the Center for 
Myopathies Investigation 
and Treatment (CIM)103
- - -
11 Five point muscular 
involvement scale104
- - -
12 Walton Score105 - - -
13 Functional Impairment 
Scale according to 
Harper106
- - -
14 Muscular involvement 
score107
- - -
15 Muscle weakness score108 - - -
16 Cybex II isokinetic 
dynamometer109-111
- - -
17 Grippit instrument 82, 112 - Test-retest reliability:
- Grip force left hand (ICC 
≥0.61),right hand (ICC 
≥0.81)39 
- Pinch grip force left 
hand (ICC ≥0.41), right 
hand (ICC≥0.61)39
Interrater reliability:
- Grip force bilateral
(ICC≥0.81)39
- Pinch grip force bilateral 
(ICC≥0.61)39
RC left hand=23.15 N, 
RC right hand=29.65 
N39§
18 Jamar dynamometer99, 
100, 113
- - -
19 Hand-grip Dynamometer 
(Kratos Equipamentos 
Industriais Ltd)114
- - -
20 Handgrip strain gauge 
(Rank Stanley Cox)15
- - -
21 Hand held dynamometer 
(Takei and Company)92
- - -
22 Dynamometer (Penny 
and Giles transducers 
Ltd.)15
- - -
Outcome Measure Validity Reliability Sensitivity to change 
and responsiveness*
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23 Chatilon push-pull 
hand-held dynamometer 
(ankle dorsiflexion & 
eversion)11, 12
Face validity: patients 
had lower mean peak 
torque values compared 
to controls (P<0.001)11 
Test-retest reliability:
- Ankle dorsiflexion
(R2=0.90-0.96)11 
- Ankle eversion
(R2=0.89-0.94)11 
Interrater reliability:
- Ankle dorsiflexion
(Pearson’s r=0.7-0.93)11 
- Ankle eversion
(Pearson’s r=0.72-0.94)11
Able to detect small 
changes between 
groups (SEM=1-1.3 
Nm)11¶
 
24 Multi Muscle Tester M3 
Diagnos System96
- - -
25 Hand held dynamometer 
(not specified)115
- - -
26 Strain gauge 
dynamometer (not 
specified)111
- - -
27 Nicholas electronic 
handheld 
dynamometer100 
- - -
28 Fixed dynamometer 
(Biomech Designs Ltd)13, 
102
- - -
29 Baseline Pinch Gauge 
(Fabrication Enterprises 
Inc.)99, 100
- - -
30 Dynamometer model 
IDDK (bite force)114
- - -
31 Test of involuntary 
isometric muscle force15
- - -
Myotonia
32 Clinical relaxation time 
after making fist116-118
- - -
33 Percussion myotonia 
thenar eminence (time in 
seconds)117
- - -
34 Relaxation time with 
surface electrodes after 
MVC119
- - -
35 Mean score of 3 clinical 
relaxation times and 3 
EMG relaxation times120
- - -
36 Hand opening time (10 
times)121
- - -
Outcome Measure Validity Reliability Sensitivity to change 
and responsiveness*
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37 Computerized handgrip 
myometry14, 102, 122
Construct validity: 
correlation between 
handgrip myotonia 
and grip PF (r=-0.42, 
P=0.03), MMT (r=-0.37, 
P<0.05), and QST (r=-
0.42, P=0.03)13
Test-retest reliability:
- Peakforce (r=0.96, 
P<0.0001) 
- Relaxation time (r=0.76-
0.77, P<0.001)13
Lacks sensitivity to 
detect mild degrees of 
myotonia13
38 Relaxation time after 
ulnar nerve stimulation15, 
16
Face validity: RT longer 
in patients than controls 
(P=0.0006-0.07)16#
Test-retest reliability: 
pearson’s r=0.972, 
P<0.000516
-
Fatigue
39 Krupp’s Fatigue Severity 
Scale (FSS)6, 17, 73, 78, 80 
- Test-retest reliability: 
ICC=0.88 and 
Goodman-Kruskal’s γ 
coefficient=0.55-0.8817
Internal consistency: 
(Cronbach’s α=0.86)17
-
40 Checklist individual 
strength subscale fatigue 
(CIS-fatigue)88, 89, 91, 123-126
- - -
41 4 item abbreviated 
fatigue questionnaire 
(AFQ)91
- - -
42 13 item fatigue 
questionnaire127 
- - -
43 VAS-fatigue128 - - -
44 Physiological fatigue 
and activation failure 
measurement (central/
peripheral)91
- - -
Sleepiness
45 Daytime Sleepiness Scale 
(DSS)18, 78, 128, 129 
Construct validity: 
normalized factor 
loadings 0.6-0.818
Test-retest reliability: 
ICC=0.82 and 
Goodman-Kruskal’s γ 
coefficient=0.60–0.8617
Internal consistency: 
Cronbach’s α=0.7218
-
46 Epworth Sleepiness Scale 
(ESS)19, 78, 83, 90, 91, 128-136
- Test-retest reliability: 
ICC=0.68 and 
Goodman-Kruskal’s γ 
coefficient=0.54-0.9017†
Internal consistency: 
Cronbach’s α=0.2417
ESS score showed 
non-significant 
reduction
after modafinil 
treatment19
Outcome Measure Validity Reliability Sensitivity to change 
and responsiveness*
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47 Pittsburgh Sleep Quality 
Index 
(PSQI)78, 129 
- - -
48 Stanford Sleepiness 
Scale (SSS)131
- - -
49 Maintenance of 
Wakefulness Test 
(MWT)19, 135
- - MWT significantly 
prolonged after 
modafinil treatment19
50 VAS-effect scale135 - - -
51 Daily Sleep Diary 
(DSD)90, 137
- - -
52 Self-Observation List89 - - -
53 Maudsley Hospital sleep 
questionnaire127 
- - -
54 Sleep Questionnaire 
and Assessment of 
Wakefulness (SQAW)128, 
136
- - -
55 Ullanlinna-Narcolepsy 
Scale78
- - -
Pain
56 Numeric Rating 
Scale138-141 
- - -
57 VAS-pain89 - - -
58 McGill Pain 
Questionnaire (MPQ)126
- - -
59 Brief Pain Inventory 
(BPI)+ modified 
version138-141 
- - -
Psychological distress
60 Symptom Checklist-90 
(SCL-90)+ revised version 
(SCL-90-R)88, 89, 128
- - -
61 Beck Depression 
Inventory (BDI)78, 82, 83, 88, 
90, 140, 142, 143
- - -
62 Beck Depression 
Inventory for Primary 
Care (BDI-PC)89
- - -
63 Hamilton Depression 
Rating Scale (HDRS)5, 
135, 137, 144
- - -
64 Profile of Mood States 
(POMS)131, 145
- - -
Outcome Measure Validity Reliability Sensitivity to change 
and responsiveness*
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65 Montgomery and Asberg 
Depression Rating Scale 
(MADRS)144
- - -
66 Self-administered 
depression rating scale143
- - -
67 Depressive Mood Scale144 - - -
68 Physical Anhedonia Scale 
(PAS)144 
- - -
69 Social Anhedonia Scale 
(SAS)144
- - -
70 Hospital Anxiety and 
Depression Scale 
(HADS)90, 115, 142, 146
- - -
71 Irritability-Depression-
Anxiety scale (IDA-
scale)147
- - -
72 Symptom Rating Test 
(SRT)148
- - -
73 Hamilton Rating Scale 
for Anxiety5, 149
- - -
74 Covi Brief Anxiety Scale144 - - -
75 Tyrer Anxiety Scale144 - - -
76 State-Trait Anxiety 
Inventory Form Y 
(STAI-Y)5, 149
- - -
77 Abrams and Taylor scale 
for emotional blunting 
(AT)144
- - -
78 General Health 
Questionnaire-12 (GHQ-
12)88, 146 
- - -
79 Psychological Distress 
Index of Santé-Québec 
(IDPESQ-14)150 
- Internal consistency: 
Cronbach’s α=0.94150
-
80 Rosenberg Self-Esteem 
Scale150
- Internal consistency: 
Cronbach’s α=0.86150
-
81 International Personality 
Disorder Examination151
- - -
82 Schedule for Affective 
Disorders and 
Schizophrenia (SADS)148
- - -
83 Apathy Evaluation Scale 
(AES)127, 137
- - -
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84 Temperament and 
Character Inventory 
(TCI)152, 153 
- - -
85 Beck Hopelessness Scale 
(BHS)146
- - -
Activity and Participation measures
Activity limitations
86 A four point muscular 
disability rating scale154, 155
- - -
87 Disability score 
according to 
Beijersbergen156
- - -
88 Clinical disability scale157 - - -
89 Self-report ADL scale3, 
40, 41, 158
- - -
90 Activity of Daily Living 
Staircase3, 40, 41
- - -
91 Activities of daily living 
(ADL) score101
- - -
92 50-item questionnaire of 
instrumental activities of 
daily living (IADL)90
- - -
93 Katz ADL Index3, 73 - - -
94 Frenchay Activities Index 
(FAI)73
- - -
95 Functional Disease 
Severity Scale by Scott96
- - -
96 Neuromuscular
Symptom and Disability 
Functional Score (NSS)96
- - -
97 VAS (activities of daily 
living)159, 160
- - -
98 Function in daily life 
activities111
- - -
99 Timed functional testing 
(TFT)99, 102
- Test-retest reliability: 
ICC=0.67-0.9647**
-
Activity limitations-mobility
100 Endurance and 
fatigability test15
- - -
101 Gait and running test15
102 Brooke’s grading scale 
for mobility40, 82
- - -
Outcome Measure Validity Reliability Sensitivity to change 
and responsiveness*
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103 Level of functional deficit 
according to Zellwenger 
and Hanson’s 
classification148
- - -
104 Rivermead Mobility 
Index73, 90, 115
- - -
105 Walking time over 20 m 
with one turn90
- - -
106 Walking time over 30 m111 - - -
107 6-minute walking test73, 
102, 132 
- Test-retest reliability: 
ICC
2.1
=0.9938 
- Acceptable sensitivity 
to detect changes 
between groups 
(SEM=12 meter)38
- RC=33 meter 38§
108 Performance Oriented 
Mobility Assessment 
(POMA)115
- - -
109 Barthel index161 - - -
110 Timed-stands test 
(TST)73, 132
- - -
111 Timed up-and-go test 
(TUG)132
- - -
112 Battery of functional 
tests15
- - -
113 Gait and activity indices 
measured by using the 
Step WatchTM step 
activity monitor (SAM) 
(Cymatech, Seattle, 
Washington, USA)115
- - -
114 Actometer (Actilog 
V3.0)89
- - -
Activity limitations – motor skills
115 Purdue Pegboard 
bimanual78, 102
- Test-retest reliability: left 
hand (ICC=0.63), right 
hand (ICC=0.67)39
Interrater reliability 
left hand: (ICC=0.47), 
right hand (ICC=0.73)39
RC left hand=1.75, RC 
right hand=2.1439§
116 Nine-Hole Peg Test 
(NHPT)73
- - -
117 Motor Function 
Measurement Scale  
(MFM scale)81
- - -
118 The Appel ALS rating 
scale100, 110
- - -
Outcome Measure Validity Reliability Sensitivity to change 
and responsiveness*
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Participation restrictions
119 Assessment of Life 
Habits (LIFE-H)6, 162
- Test retest reliability: total 
and subscores (ICC=0.80-
0.91)163
Interrater reliability:
total and subscores 
(ICC=0.86-0.92)163
-
120 Novel structured 
interview to measure an 
increase in spontaneous 
activity134
- - -
121 Sonderen Social Support 
Inventory (SSL)89
- - -
Quality of Life measures
General
122 SF-36 Mental Health 
scale5, 6, 19, 100, 123, 125, 126, 128, 132, 
135, 139, 141, 164
- - -
123 Sickness Impact Profile 
(SIP)40, 89, 102, 158, 165-167
- - -
124 Western Ontario and 
McMaster University 
Ostheoarthritis Index 
(WOMAC)109
- - -
125 Problem Elicitation 
Technique (PET)109
- - -
126 The Quality of Life 
Profile41
- - -
127 RAND-36 
questionnaire131, 134, 140
- - -
128 Modified activities-
specific balance 
confidence scale (ABC-
UK)115
- - -
Psychosocial wellbeing
129 Measure of the quality of 
the Environment (MQE)6
- - -
130 Multidimensional Scale 
of Perceived Social 
Support (MSPSS)139
- - -
131 (Catastrophizing 
subscale of the) Coping 
Strategies Questionnaire 
(CSQ) 139, 141
- - -
Outcome Measure Validity Reliability Sensitivity to change 
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132 Mental Adjustment to 
Cancer (MAC) scale3, 167
- - -
133 Psychosocial Well-Being 
Questionnaire3
- - -
134 Chronic Pain Coping 
Inventory (CPCI)139, 141
- - -
135 Survey of Pain Attitudes 
(SOPA)139, 141
- - -
136 Pain Catastrophizing 
Scale141
- - -
137 Kaasa test40, 167 - - -
Composite level measures
138 A 3-point-scale for 
exploration of patients’ 
global assessment of 
treatment96
- - -
139 ICF-Checklist (modified 
version)74
- - -
140 Treatment effect 
questionnaire15 
- - -
141 Functional status 
questionnaire111
- - -
* Sensitive to change indicates the ability to measure any change in health status, while responsiveness indicates 
the ability to detect meaningful change
† Goodman-Kruskal’s γ was significant for ESS items 1, 2, 4, 5, and 7, but not for ESS item 8 (in a car, while stopped 
for a few minutes in traffic). In addition, Goodman-Kruskal’s γ coefficient could not be computed for ESS items 3 
and 6
‡ Muscular Impairment Rating Scale (MIRS) was called Muscular Disability Rating Scale (MDRS) in literature 
published before 2001
§ Repeatability coefficient is the difference required to detect a true difference between two measurements for the 
same subject
¶ The smallest mean group difference observed between DM1 patients was 2.3 Nm, a difference about twice than 
the Standard Error of Measurement (SEM)
# Different phases of relaxation were distinguished at 90, 50, 25, 10 and 5% of the peak force (PF). RT was 
determined after twitch and tetanic contraction of the first dorsal interosseous muscle. Separate P-values for each 
phase of relaxation were determined
** ICCs were calculated for each item separately: 0.96 for turning blocks and for climbing and descending four 
standard steps, 0.91 for assembling peg units, 0.81 for propelling a wheelchair 20 feet, 0.79 for walking 20 feet, 0.77 
for cutting Theraplast, 0.71 for standing from lying supine, and 0.67 for standing from chair
Legend to table 6.1. Abbreviations: - = not available, VAS= Visual Analogue Scale; MWT= 
Maintenance of Wakefulness Test; MMT= Manual Muscle Testing; FSI= Functional Status Index; 
RT= Relaxation Time; N=Newton; SEM= Standard Error of Measurement; RC= repeatability 
coefficient; MVC: Maximal Voluntary Contraction; ICF= International Classification of Functioning, 
Disability and Health ICC= Intra class correlation coefficient 
Outcome Measure Validity Reliability Sensitivity to change 
and responsiveness*
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Introduction
Medical doctors are generally well-informed about the basic clinimetric 
requirements of outcome measures that should be fulfilled prior to use in clinical 
practice. A proper outcome measure should be simple (non-time consuming), 
communicable (easily interpretable), valid (measures what it purports to 
measure), reliable (stable or consistent scores over time or across raters), and 
responsive (captures relevant changes over time).1, 2 However, current outcome 
measures produce ordinal scores that are not suitable for conventional 
statistical testing, since an ordinal score is not a quantitative measurement, like 
temperature in degrees Celsius or weight in kilograms, but just a statement that 
one thing is more than another. Modern clinimetric techniques set additional 
quality standards for outcome measures and attempt to create measurement 
at the interval level. This chapter is intended to inform the neuromuscular 
doctor about the various steps in the evaluation and construction of outcome 
measures using the Rasch method.3 The construction of the Fatigue and 
Daytime Sleepiness Scale for patients with Myotonic Dystrophy type 1 (FDSS, 
chapter 10) will be used by way of illustration.
Limitations of multi-item ordinal scales
Some variables (e.g., height and weight) can be measured directly. Other 
variables (e.g., disability, fatigue or quality of life) are measured indirectly by 
how they manifest. Therefore, we need a method to transform the manifestations 
of these “latent” variables into numbers that can be taken as measurements.4 
Rating scales are a means of measuring a latent variable. The construction of 
these scales has been based on the classical test theory (CTT).5 Outcome 
measures based on CTT are composed of multiple items with ordered 
(Likert-type) response options and create measurement at an ordinal level. 
Consequently, the value of numbers used in an ordinal scale and the numerical 
distance between each point in a scale is unknown. Therefore, a change in scale 
scores at one level in the scale (say from 1 to 2) is not necessarily equivalent 
to a change between two other points in the scale (say from 3 to 4) (figure 7.1). 
Moreover, sum of the item scores are often calculated, but the relevance of 
each item to the variable of interest is not necessarily equal.6 Ordinal scales 
are currently used in an inappropriate way by addressing obtained scores as 
interval measures and exposing them to parametric analyses. Therefore, CTT-
based scales may hamper the comparison between patients and various 
studies.
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Figure 7.1. The Fatigue Severity Scale   
Disagree Agree
My motivation is lower when I am fatigued 1 2 3 4 5 6 7
Exercise brings on my fatigue 1 2 3 4 5 6 7
I am easily fatigued 1 2 3 4 5 6 7
Fatigue interferes with my physical functioning 1 2 3 4 5 6 7
Fatigue causes frequent problems for me 1 2 3 4 5 6 7
My fatigue prevents sustained physical functioning 1 2 3 4 5 6 7
Fatigue interferes with carrying out certain duties  
and responsibilities
1 2 3 4 5 6 7
Fatigue is among my three most disabling symptoms 1 2 3 4 5 6 7
Fatigue interferes with my work, family, or social life 1 2 3 4 5 6 7
Legend to figure 7.1. The fatigue severity scale is an outcome measure based on classical test 
theory. The true difference between response categories is not known. A one point difference in 
score is not necessarily equivalent along the range of scores. 
Rasch measurement model
Considering the shortcomings of the CTT based measures, it is clear that a 
modern scientific approach is needed for the evaluation and construction of 
outcome measures to improve the findings in observational and interventional 
trials. Using interval instead of ordinal measures would give a more accurate 
reflection of disease impact, differences between individuals and groups, and 
treatment effects. The Rasch method is a technique to estimate measures 
at the interval level from obtained ordinal data.3, 6 Rasch analysis of the 
FDSS was performed using the Rasch unidimensional measurement model 
(RUMM2020).7 The Rasch model is a tool to investigate outcome measures 
based on the logical assumption that persons with high levels of whatever 
construct that is being measured (for example, fatigue or sleepiness) should 
have an increased probability, relative to persons with low levels, of getting a 
higher score on any item (for example, fall asleep during reading). Similarly, one 
item being more difficult than another means that for any person the probability 
of affirming the second item is the greater one.3 The Rasch model separates 
persons according their level of the measured construct and items according 
their difficulty and places both patient and item estimates on the same log-
odds units (logit) scale, thereby creating measurement at the interval level 
(figure 7.2). This can only be obtained when the data fulfil all the Rasch model’s 
?
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                Increasing item diffi culty
Item 1 Item 2 Item 3 Item 4 sum score
Person A 0 0 0 0 0
Person B 1 0 0 0 1
Person C 1 1 0 0 2
Person D 1 1 1 0 3
Person E 1 1 1 1 4
Increasing patient location
Easiest 
items 
Most difficult 
items 
Most sleepy 
1 0 2 3 5 4 -4 -5 -3 -2 -1 -6 6 
Least sleepy 
Chance of dozing 
during watching tv 
Chance of dozing 
during reading 
Chance of dozing 
during driving 
Figure 7.2. Linear ruler
Legend to fi gure 7.2. The Rasch model compares the item response patterns of individuals 
to the entire sample of patients being examined in order to estimate person location (level of 
sleepiness) and item diffi culty (chance of dozing during various activities), and places both item 
and person estimates on the same logit scale.
expectations. Items and persons not fulfi lling the model criteria should be 
evaluated and removed one by one if needed. 
Ordering item and person estimates on the same ruler.
The statistical calculations for ordering the location of the persons and 
the diffi culty of the items are based on the so-called Guttmann scaling.8 As 
illustrated in fi gure 7.3, items are arranged in an order so that a person who 
agrees with a particular item also agrees with items of lower rank-order. Persons 
are also ordered according to their person location: patient E has a higher sum 
score than others, indicating a higher level of the measured trait than the others 
patients.
Figure 7.3. Guttman scaling
Legend to fi gure 7.3. Items can be ranked from most easy (coded 01111) to most diffi cult (coded 
00001). Persons with a higher sum score have a higher level of the measured trait.
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Figures 7.4A-C illustrate the statistical steps taken by the Rasch model to order 
the item and patient estimates on a same metric. Suppose we are examining 
100 patients experiencing excessive daytime sleepiness and we want to look at 
the “chance of dozing” during everyday activities using a rating scale consisting 
of 4 items (activity A, B, C, and D) with 4 ordinal response options ranging from 
0 (would never doze), to 1 (slight change of dozing), to 2 (moderate chance of 
dozing), and to 3 (high chance of dozing) (figure 7.4A).
Figure 7.4A. Rating scale measuring the chance of dozing during activities
Never
0
Slight 
chance
1
Moderate 
chance
2
High 
chance
3
Activity A
Activity B
Activity C
Activity D
The obtained scores after completion of the scale by 100 persons are 
summarized in figure 7.4B. Item A turns out to be the “easiest item” based on 
the highest percentage (95%) of patients examined choosing response option 3 
(high chance of dozing) for this item. Conversely, 98 of the 100 patients scored 
0 (would never doze) on item B, making this the most difficult item. Since 50% 
of the patients had scored 0 (would never doze) on item D and only 10% on 
Item C, it is obvious that Item D is ranked as an more difficult item than item 
C. Figure 7.4C shows the ordering of the items by the Rasch model on the same 
ruler. 
Figure 7.4B. Ordering of items according to difficulty
Never
0
Slight 
chance
1
Moderate 
chance
2
High 
chance
3
Activity A 1 44 95
Activity B 98 2
Activity C 10 40 36 14
Activity D 50 35 10 5
 Most difficult item Easiest item
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Figure 7.4C. Ordering of items on a logit scale
Figure 7.4D-E illustrate the ordering of the persons on the same ruler. As an 
example, we will compare the results of 3 patients completing the 4-item rating 
scale measuring chance of dozing during activities. Figure 7.4D shows the 
same rating scale, but now the items are listed in order of diffi culty. The scores 
of patients I, II and III are shown. Patient I scored response option 3 (high 
chance of dozing) for all items. Based on the scoring results it can be concluded 
that patient I has the highest level of the measured construct, i.e. high level of 
sleepiness. Patient III had the lowest scores compared to the others. Figure 
7.4E shows the ordering of patients by the Rasch model on the same ruler. 
The corresponding location of items and persons (expressed as logit) are also 
calculated by the model depending on the interaction between the items and 
patients.
The Rasch model estimates the person location and item diffi culty, thereby 
creating measurement at the interval level, provided that the ordinal obtained raw 
data fulfi l the Rasch model’s expectations, like good item and person statistical 
fi t, threshold ordering, no item bias or local dependency and unidimensionality.
Figure 7.4D. Ordering of patients according to level of sleepiness
Never
0
Slight 
chance
1
Moderate 
chance
2
High 
chance
3
Activity A X X X
Activity B X X X
Activity C X X X
Activity D X X X
 
       Increasing item diffi culty Patient I Patient II Patient III
Activity D 
10 
50 
EASY DIFFICULT 
1 0 2 3 5 4 -4 -5 -3 -2 -1 -6 6 
1 logit 1 logit 
A D C B 
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Figure 7.4E. Ordering of patients on a logit scale
 
Fit statistics
A variety of fit statistics determine whether the observed data do not significantly 
deviate from the expected response pattern calculated by the mathematical 
(Rasch) model. Three overall fit statics are generally considered. Two are item-
person interaction statistics, which are a summary of all the individual item and 
person fit residuals (i.e. item or person deviations from model expectations). 
The fit residuals are then standardized to approximate a z-score representing 
a standardised normal distribution. For model fit, a mean of 0 and a standard 
deviation (SD) of 1 would be expected, although SD<1.4 is usually accepted. A 
third overall fit statistic is an item-trait interaction statistic reported as a chi-
square, and reflects whether the hierarchical ordering of the items is consistent 
for different groups of responders across the trait (called class intervals). This is 
calculated by summing all the chi-square values for each of the individual items 
and calculating the significance value using the summated degrees of freedom. 
A non-significant chi-square indicates the required property of invariance.9
Fit statistics at the individual item and person level are also available as residual 
values, acceptable within the range ±2.5, and chi-square statistics, reflecting the 
deviation from the model by class intervals for each item. Chi-square statistics 
should indicate non-significant deviation the from model, after multiple testing 
Bonferroni corrections. Individual item fit is also examined graphically by 
plotting the observed item responses for class intervals against the expected 
model item characteristic curve (figure 7.5).10 Items with good fit will show each 
plot on the expected model curve. 
In addition to these overall fit statistics a Person Separation Index (equivalent 
to Cronbach’s alpha) is available. A value of 0.7 is the minimum required for 
group comparisons.10
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Figure 7.5. Item Characteristic Curve (ICC) for an item 
Legend to figure 7.5. Item Characteristic Curve showing the relationship between item score and 
person location estimate. The grey curved line represents where expected scores of an item lie if 
the item is functioning properly. The black dots represent the observed scores of persons within 
six class intervals.
Threshold ordering
For polytomous scale (i.e. items having more than two score categories), 
response category structure should be examined for correct ordering. This can 
be verified by inspection of category probability curves. The category probability 
curve is a graph showing the relation between the probability of a given category 
as a function of person location. Thresholds are the boundaries between 
response categories and correspond with the location on the trait continuum at 
which it is equally likely that a person will be classified into adjacent categories 
(figure 7.6). Ordered thresholds represent an increase in level of the measured 
trait for each category. For example, a higher numbered category in the Daytime 
Sleepiness Scale (DSS) is thought to imply more excessive daytime sleepiness. 
Where thresholds are ordered, a person location between category boundaries 
will give that category the greatest probability of being observed.11
Disordered thresholds are a common source of item misfit and occur when 
respondents use the response options inconsistently. Persons can experience 
difficulties discriminating between response options when there are too many 
response options or when the labeling of response options is potentially 
confusing or open to misinterpretation. Disordered thresholds can usually be 
solved by collapsing categories. The number of patients in each class interval 
should always be checked before collapsing categories (figure 7.7).
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Figure 7.6. Category probability curves with ordered thresholds
Legend to figure 7.6. Category probability curves for an item with 4 response categories. 
Thresholds are ordered (T1<T2<T3) and each category has a certain distance across the trait 
where it is the most probable response. 
Figure 7.7. Category probability curves with disordered thresholds
Legend to figure 7.7. Category probability curves for an item with 7 response categories. Left 
panel: thresholds were disordered and crowded together. Note that categories 1, 2 and 3 would 
never be the most probable response. Furthermore, categories 4 and 5 correspond to only a 
very narrow interval on the variable. Right panel: response options for all items were rescored in 
order to obtain ordered thresholds. The original 7 response options (coded 1-2-3-4-5-6-7) were 
collapsed into 3 categories (coded 0-0-1-1-1-2-2).
Differential item functioning
Differential item functioning (DIF or item bias) occurs when different groups 
within the sample (e.g., men and women) with equal levels of the measured 
trait respond in a different manner to an individual item.12 For example, Dutch 
and Canadian patients with equal levels of excessive daytime sleepiness may 
respond systematically different to an item in the Epworth Sleepiness Scale 
(figure 7.8). By contrast, the expected score on an item from the Fatigue Severity 
Scale was the same across countries for persons with the same level of fatigue 
(figure 7.8). 
Threshold T1
 
Threshold T2
 
Threshold T3
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Figure 7.8. Differential item functioning
Legend to figure 7.8. Item Characteristic Curve displays the expected value for the item in relation 
to the person location. Left panel: respondents in Canada (red line) have a higher probability 
of affirming this item than Dutch respondents (blue line), indicating uniform differential item 
functioning. Right panel: no differential item functioning was observed across countries for this 
item.
Two types of DIF may be identified. Uniform DIF occurs where a particular 
subgroup shows a consistent systematic difference in their responses to an 
item, across the whole range of the attribute being measured. When there is 
non-uniformity in the differences between the group, this is referred to as non-
uniform DIF. Uniform DIF can be resolved by separately calibrating the item 
for each group. With non-uniform DIF removal of the item is often the only 
solution. 
Local independence
Local independence of items is an assumption in Rasch model.7 This assumption 
is violated when items in a test are related to each other. The classic example of 
this is where several walking items are included in the same scale (figure 7.9).13 
Figure 7.9. Local dependence
Does your health now limit you in 
these activities? If so, how much?
Yes, 
limited a lot
Yes, 
limited a little
No, 
not limited at all
Walking more than a amile? 1 2 3
Walking several hunderd yards? 1 2 3
Walking one hunderd yards? 1 2 3
Legend to figure 7.9. An example of the SF-36 health status questionnaire was chosen to illustrate 
local dependence. If a patient scores 3 (no, not limited at all) on item “walking more than a 
mile”, this automatically will determine the response on the other two questions “walking several 
hundred yards” and “walking one hundred yards”. Since the results of these items are linked 
in some way, the obtained scores will inflate reliability and the final scale score in a particular 
direction.
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Such sets of items inflate classic reliability and affect parameter estimation in 
Rasch analysis.14 Local dependency can be identified through inspection of the 
residual correlation matrix. Item sets with correlations <0.28 are considered 
acceptable. In cases of local dependency, the researcher may consider to remove 
items or to create subsets of correlating items to improve model fit.
Unidimensionality
The Rasch model requires that all items in the questionnaire work together to 
measure a single underlying construct. For example, when we are interested 
in fatigue, no questions about quality of life should be addressed. A principal 
component analysis (PCA) of the residuals is conducted to detect any signs of 
multidimensionality. The absence of any meaningful pattern in the residuals will 
be deemed to support the assumption of unidimensionality of the scale.15 This is 
formally tested by allowing the item loadings on the first factor of the PCA of the 
residuals to determine two subtests of items (defined by positive and negative 
loadings on the first residual component). A series of independent t-tests is 
then undertaken to see if the person estimates derived from these subsets 
significantly differ. The percentage of tests outside the range ±1.96 should not 
exceed 5% or the associated binomial proportions confidence interval should 
overlap the 5% expected value for the scale to be unidimensional.14, 15 
Conclusion
The Rasch model can be seen as the ideal response pattern, where persons with 
high level of the measured trait should have a higher probability of receiving 
a higher score on any item compared to persons with lower levels. Also any 
person should always have a greater probability of receiving a higher score on 
an easier item than on a more difficult one. In the model, person location and 
item difficulty are estimated separately. All data should fulfil the Rasch model’s 
expectations like good item and person statistical fit, threshold ordering, 
absence of item bias, local independence and unidimensionality. Only then an 
interval-scaled measure of a latent variable can be estimated from an observed 
raw score, giving meaning to the scores and allowing comparison of (change 
in) scores. Since logits are difficult to interpret intuitively, it is more useful to 
convert the patient logit measures into a scale score with positive and integer 
values, like a centile metric score.
160
References
1. Streiner DL, Norman GR. Health measurement scales. A practical guide to their development and use. 
New York: Oxford University Press; 1995
2. Feinstein A. Clinimetrics. New Haven, Connecticut: Yale University Press; 1987
3. Rasch G. Probabilistic models for some intelligence and attainment tests. Chicago: University of Chicago 
Press; 1980
4. Hobart JC, Cano SJ, Zajicek JP, Thompson AJ. Rating scales as outcome measures for clinical trials in 
neurology: Problems, solutions, and recommendations. Lancet Neurol. 2007;6:1094-1105
5. DeVellis RF. Classical test theory. Med Care. 2006;44:S50-59
6. Stucki G, Daltroy L, Katz JN, Johannesson M, Liang MH. Interpretation of change scores in ordinal 
clinical scales and health status measures: The whole may not equal the sum of the parts. J Clin Epidemiol. 
1996;49:711-717
7. Andrich D, Lyne A, Sheridan B, Luo G. Rumm 2020. 2003
8. Altman DG. Practical statistics for medical research. London: Chapman and Hall; 1991
9. Pallant JF, Tennant A. An introduction to the rasch measurement model: An example using the hospital 
anxiety and depression scale (hads). Br J Clin Psychol. 2007;46:1-18
10. Fisher WP. Reliability statistics. Rasch Measure Trans. 1992;6:238
11. Andrich D, Luo G. Conditional pairwise estimation in the rasch model for ordered response categories 
using principal components. J Appl Meas. 2003;4:205-221
12. Dorans NJ, Holland PW. Dif detection and description: Mantel-haenszel and standardisation. In: Holland 
PWW, H., ed. Differential item functioning. Hillsdale: Lawrence Erlbaum Associates; 1993:36-66
13. Ware Jr JE, Kosinski M, Keller DS. Sf-36 physical and mental health summary scales: A user’s manual. 
Boston: The Health Assessment Lab, New England Medical Center; 1994
14. Tennant A, Conaghan PG. The rasch measurement model in rheumatology: What is it and why use it? 
When should it be applied, and what should one look for in a rasch paper? Arthritis Rheum. 2007;57:1358-
1362
15. Smith EV, Jr. Detecting and evaluating the impact of multidimensionality using item fit statistics and 
principal component analysis of residuals. J Appl Meas. 2002;3:205-231
161
Chapter
7.

Chapter 8
Rasch-built Myotonic 
Dystrophy type 1 
Activity and Participation 
Scale (DM1-Activ)
Mieke C.E. Hermansa, Catharina G. Fabera, Marc H. De Baetsb,c, Christine E.M. de 
Die-Smuldersd, Ingemar S.J. Merkiesa,e
aDepartment of Neurology, Maastricht University Medical Centre, Maastricht
bSchool for Mental Health and Neuroscience, University of Maastricht, Maastricht
cNeuroimmunology Group, Biomedical Research Institute, Hasselt University, Hasselt
dDepartment of Clinical Genetics, Maastricht University Medical Centre, Maastricht
eDepartment of Neurology, Spaarne Hospital, Hoofddorp
Neuromuscul Disord. 2010 May;20(5):310-8
163
164
Summary
We describe the development of an outcome measure of activity and participation 
for patients with myotonic dystrophy type 1 using the Rasch measurement 
model. A 49-item questionnaire was completed by 163 DM1 patients. Data 
were subsequently analyzed with Rasch software to design the item set to fit 
model expectations. Through systematic investigation of response category 
ordering, model fit, item bias, and local response dependency, we succeeded in 
constructing a 20-item unidimensional scale of activity and participation (DM1-
Activ). High internal consistency (PSI=0.95) and good test-retest reliability 
values of item difficulty hierarchy and patient location were demonstrated. 
Patient measures had acceptable correlations with MRC sum scores and MIRS 
grades (ICC=0.69 and 0.71 respectively), indicating good external construct 
validity. DM1-Activ is a practical, reliable and valid outcome measure that fulfils 
all clinimetric requirements. Further evaluation of this scale is needed to provide 
a nomogram for clinical use.
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Introduction
Myotonic dystrophy type 1 (DM1) is the most common muscular dystrophy in 
adults with a prevalence of 2.1-14.3 in 100 000.1 The most noticeable symptoms 
are myotonia and progressive weakness of facial, axial and distal muscles. In 
addition, systemic manifestations such as cataracts, endocrine dysfunction 
and cardiac involvement may occur. Based on age at onset and severity of 
symptoms, four clinical types can be distinguished: congenital type, childhood-
onset type, adult-onset (classical) type and late-onset (mild) type.2 The clinical 
course is usually slowly progressive, but DM1 may be extremely disabling when 
more generalized limb weakness and respiratory muscle involvement develop. 
Systemic manifestations may also have a considerable effect on the patient’s 
health status.
As a result, DM1 leads to physical impairment, activity limitations and 
participation restrictions with reduced quality of life expectations.3-6 At present, 
no curative treatment is available. However, development of innovative 
strategies for targeted therapy has begun since studies on pathogenesis have 
elucidated a novel disease mechanism, in which mutant RNA has deleterious 
effects on gene expression.7, 8 Preclinical studies have already demonstrated that 
myotonia can be reduced by antisense oligonucleotides correcting abnormal 
regulation of alternative splicing of muscle-specific chloride channel.9 In order 
to evaluate future therapeutic interventions in randomized controlled trials, 
high quality outcome measures are needed to demonstrate relevant changes at 
various levels of outcome.10, 11
Functioning and disability of DM1 patients have been assessed in studies using 
a variety of (composite) outcome measures.3, 4, 12-18 Only a few scales have been 
formally evaluated in terms of scientific soundness.19 The muscular impairment 
rating scale (MIRS), an ordinal 5-point grading system based particularly on 
clinical muscle strength evaluation, has been most widely used in DM1.12, 20 It 
can easily monitor major stages of disease, but does not refer to the functional 
impact of muscle weakness. Still, the MIRS is shown to be valid, reliable and to 
correlate with functional scores.20 The motor function measure demonstrated 
good validity and reproducibility in patients with neuromuscular disorders.17 
However, this scale takes 36 min to complete and only 29 DM1 patients were 
included in its validation study. The Life Habits measure demonstrated good 
reliability scores, but its use is limited since the presented domains have up to 
10 response options, assuming that patients are able to discriminate between 
the degrees of difficulty when performing a life habit.18
The construction of these ordinal scales has been based on the classical test 
theory (CTT). DeVellis has summarized various aspects of CTT including its 
advantages and disadvantages.21 Outcome measures based on CTT may 
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constitute items that are arbitrarily collected and patients are requested to 
complete all items, even though some may be irrelevant or inappropriate for 
their level of ability. Furthermore, a sum of item scores is often calculated and 
the obtained data are often addressed as forming an interval range. Moreover, 
these scales may be prone to differential sensitivity, where for example a 3-point 
change at the centre of the sum score range may represent a different true score 
than a 3-point change at one of the extremes.21, 22 Therefore, CTT-based scales 
may hamper the comparison between patients with different functional levels.
Considering these shortcomings, it is clear that a modern scientifi c approach is 
needed for health evaluation in clinical trials. The most widely used approach is 
that of Rasch unidimensional measurement model.23, 24 The Rasch model shows 
what should be expected in responses to items if interval scale measurement is 
to be achieved. This statistical technique compares the item response patterns 
of individuals to the entire sample to estimate person ability and item diffi culty 
and places both item and person estimates on the same logit scale (fi gure 8.1). 
Once data fi t Rasch model expectations, logits of person estimates can be used 
as an interval level variable in parametric statistics.24, 2 
Figure 8.1. Linear ruler
Legend to fi gure 8.1. The Rasch model places both item and person parameter estimates on the 
same interval scale. The units of this scale are log-odds-units or logits.
Recently, a Rasch-built measure of activity limitations for patients with 
neuromuscular disorders (ACTIVLIM) has been presented.26 Despite having 
good scientifi c soundness, this scale should be considered as a generic activity 
measure for neuromuscular disorders, not particularly targeting a specifi c 
neuromuscular disease. Only 17% of the patient sample had DM1. In the current 
study, we aimed to develop a patient-based disease-specifi c outcome measure 
at the activity and participation level of outcome in DM1 patients (DM1-Activ) 
Easiest 
items 
Most difficult 
items 
High activity level 
1 0 2 3 5 4 -4 -5 -3 -2 -1 -6 6 
Low activity level 
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using the Rasch model and evaluate its validity and reliability in these patients. 
We hypothesized that a disease-specific activity and participation scale for DM1 
patients would lead to differences in items selection and difficulty of selected 
items.
Methods
Participants
Patients older than 18 years with genetically proven DM1 were invited for 
a prospective, on-going study on cardiac involvement. Participants were 
recruited from the genetic register of the Maastricht University Medical Centre 
and through the Dutch neuromuscular patients’ association. According to 
the protocol, subjects with previously implanted pacemakers or cardioverter-
defibrillators and patients with severe comorbidity who had life expectancies 
of less than 3 years were not eligible for participation in the study. The protocol 
was approved by the local Medical Ethics Committee. Informed consent was 
obtained prior to entrance in the study. A total of 163 patients with DM1 were 
included.
Questionnaire development
For the construction of the DM1-Activ scale, accepted development procedures 
were applied.19, 27 These procedures consist of four stages: 
Stage I: the International classification of functioning, disability and health 
(ICF) frame was used to provide a definition of functioning and disability 
associated with health.11 Disability should be described in terms of activity 
limitations and participation restrictions. The ICF item list for activities and 
participation was examined to design the patient-based scale. 
Stage II: a systematic PubMed search was performed, reviewing scales for 
measuring of functional outcome used in studies with DM1 patients. Papers 
published over the last decades in English were identified using the following 
keywords: clinical studies, trial, myotonic dystrophy type 1, scales, disability, 
validity, and reliability. Items representing activity limitations or participation 
restrictions were, if not yet, identified and added to the questionnaire. 
Stage III: additional items were collected during routine examination of DM1 
patients at our institute. Efforts were made to describe these potential items 
in a short, simplistic and unambiguous way. Selected items were subjected to 
expert judgment and adaptations were made according to their suggestions, 
hereby obtaining face and content validity for the pre-phase scale.19 
Stage IV: the constructed pre-phase DM1-Activ scale contained 49 items with 
5 response options: unable to perform (0), able to perform, but with great 
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difficulty (1), able to perform, but with some difficulty (2), able to perform, but 
with little difficulty (3), easy to performed without difficulty (4). An item was 
scored (6) if it was not applicable to the patient.
Procedures
The pre-phase DM1-Activ questionnaire was completed by 163 DM1 patients. 
A random sample of 138 patients was re-examined one year later for test-retest 
reliability studies.28 Sample description is provided in table 8.1. Standardized 
neurological examination was conducted by one examiner (MH). The degree 
of muscle weakness was manually tested and graded according to the Medical 
Research Council (MRC) 6-point grading system.29 A total of 22 muscle groups 
were tested: neck flexors and extensors separately plus 10 bilateral muscles: 6 
proximal muscle groups (shoulder abductors, elbow flexors, elbow extensors, 
hip flexors, knee extensors, knee flexors) and 4 distal muscle groups (wrist 
extensors, digits flexors, foot dorsiflexors and plantar flexors). Summation 
of the scores yielded an MRC sum score ranging from 0 (paralytic) to 110 
(normal strength).30 The muscular impairment rating scale (MIRS) grade was 
also assessed.20 Its score ranges from 1 (no clinical muscular impairment) to a 
maximum of 5 (severe proximal weakness).12
Table 8.1. Patient sample description
First sample Second sample
(for test-retest reliability)
Number of patients 163 138
Age (years)
mean (SD), range 44.2 (11.7), 18-69 46.0 (11.5), 19-70
Gender (%)
Female 
Male
79 (48.5)
84 (51.5)
70 (50.7)
68 (49.3)
Diagnosis type (%)
mild type 
adult type 
childhood/congenital type 
13 (8.0)
134 (82.2)
16 (9.8)
10 (7.3)
116 (84.0)
12 (8.7)
Duration of symptoms (years) 
mean (SD), range 17.6 (10.3), 0-48 19.4 (10.1), 0-49
Rasch analysis
Obtained pre-phase DM1-Activ data were subjected to the Rasch unidimensional 
measurement model software (RUMM2020), which allows for a unified 
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approach to several measurement issues.25, 31 A sample size of at least 150 
patients is needed to estimate item difficulty, with 99% confidence that item 
calibrations are stable within ±0.5 logit, given appropriate targeting.32 Items not 
fulfilling the following requirements were removed from the pre-phase DM1-
Activ scale or adjusted to fit the model. 
Fit statistics. Three overall fit statistics are considered to test whether the observed 
data meet the model expectations, which are based on a probabilistic form 
of Guttmann scaling.33 Two are item-person interaction statistics transformed 
to approximate a z-score, representing a standardized normal distribution. 
Therefore, if the items and persons fit the model perfectly we would expect 
to see a mean of approximately zero and a standard deviation (SD) of 1. A 
third fit statistic score is an item-trait interaction statistic reported as a chi-
square, reflecting the degree of invariance across the trait to be measured (i.e. 
activity and participation level). A non-significant chi-square indicates that the 
hierarchical ordering of the items remains the same at different levels of the 
underlying trait, thus fulfilling the required property of invariance.
Fit residuals. Individual person and item fit statistics are presented, both 
as residuals (a summation of individual patient and item deviations from 
expected model scores) and as a chi-square statistic. In the former case, 
residuals between ±2.5 are considered adequate fit to the model. In the latter 
case a chi-square statistic is available for each item. Summation of the overall 
chi-square for items gives the item-trait interaction statistic. Item misfit to the 
model can also be examined graphically when observed model fit for groups 
of responders representing different ability levels across the trait (called class 
intervals) are plotted against the expected model item characteristic curve. 
Items with good fit will show each plot on the expected model curve. Over-
discrimination of an item is suggested by highly negative fit residuals and 
means that the observed responses form a steeper line than the expected item 
characteristic curve. It indicates that the item does not add to the information 
gained from the other items. Highly positive fit residual suggest low levels of 
discrimination and poor fit to the model. 
Internal reliability. An estimate of the internal consistency reliability of the scale 
is available as a person separation index (PSI). The estimates on the logit scale 
for each person are used to calculate reliability. A PSI of ≥0.7 is consistent 
with the scale being able to differentiate at least 2 groups of patients and 
considered the minimum requirement for measurement.34
Threshold examination. Proper ordering of response categories should 
be verified. The term threshold refers to the point between two adjacent 
response categories where either response is equally probable (figure 8.2). 
One of the most common sources of item misfit concerns respondents’ 
inconsistent use of response options, resulting in disordered thresholds. 
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Figure 8.2. Category probability curves with ordered thresholds
Legend to figure 8.2. Ideal category probability curves for an item with five response categories. 
The y-axis represents the probability of obtaining a response category and the x-axis represents 
the patient’s level of ability. The term threshold refers to the point between two adjacent response 
options and corresponds to the level of ability at which a person is equally likely to obtain one of two 
successive scores. Where thresholds are ordered, a person location between category boundaries 
ensures that the probability of a response in that category is larger than of any other single category. 
Disordered thresholds occur when respondents have difficulties discriminating 
consistently between response options. This can occur when there are 
too many response options, or when the labelling of options is potentially 
confusing or open to misinterpretation (e.g. great - some - little). Collapsing 
of categories where disordered thresholds occur, may improve overall fit to 
the model.
Item bias. A scale should always work in the same way irrespective of which 
group within the sample is being examined.35 For example, if the probability 
of responding to an item is systematically different between men and women 
with equal levels of disability, then this item would be considered to display 
differential item functioning (DIF=item bias). DIF was checked with regard to 
five personal factors, categorized as follows: age (<30 years, 30-50 years, ≥50 
years), gender, diagnosis type (mild type, adult type, childhood/congenital 
type), duration of complaints (<5 years, 5-10 years, 10-20 years, ≥20 years) and 
degree of education (elementary school, high school, university). DIF can be 
detected by analysis-of-variance and was conducted for each item comparing 
scores across each level of personal factor and across different class intervals. 
Local dependency. Local response dependency arises when items are linked 
such that the response on one item may be dependent upon the response 
to another. This affects the estimation of test information and item 
discrimination parameters, hereby inflating reliability of the final scale score.36 
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Residual correlations between the individual items were examined to detect 
local dependency (defined as a correlation ≥0.3). 
Test for unidimensionality. When issues of fit, DIF and threshold disordering 
have been resolved, it is necessary to perform a principal component analysis 
of the residuals. The absence of any meaningful pattern in the residuals 
will support the assumption of local independence and consequently the 
unidimensionality of the scale.37 This is formally tested by allowing the 
factor loadings (correlation between items and the first residual factor) to 
determine subsets of items. A series of t-tests is then undertaken to see if 
the person estimate (the logit of ‘person ability’ or, in this case ‘degree of 
activity and participation performance’) derived from these two subsets of 
items significantly differs. The percentage of tests outside the range ±1.96 
should not exceed 5% OR the binominal confidence interval should overlap 
the 5% expected value for the scale to be unidimensional.37
External construct validity and reliability
The external construct validity of the final DM1-Activ scale was assessed 
by correlations with the MIRS and MRC sum score (intraclass correlation 
coefficient reported after applying regression analyses with restricted cubic 
spline functions on transformed DM1-Activ scores).38 Moreover, test-retest 
reliability studies were performed to investigate whether hierarchy of item 
difficulty and patient ability location were consistent over time.28 Reliability was 
quantified by calculation of the intraclass correlation coefficient using a one-way 
random effects analysis-of-variance model for group comparison.
Statistics
Rasch analysis was performed with a partial credit model using RUMM2020.31 
Further analyses were undertaken using Stata Statistical Software, release 10.0 
for Windows XP. Bonferroni corrections were applied to adjust the P-values 
for multiple testing.39
Results 
Rasch analysis of the pre-phase DM1-Activ scale
The pre-phase 49-items DM1-Activ scale did not meet Rasch model expectations 
(table 8.2, analysis 1). The item fit residual SD value deviated from the expected 
value of 1. Patients showed reasonable model fit (mean residual -0.035, SD 
1.123). The item-trait chi-square probability was significant, indicating lack of 
invariance of item difficulty across the scale. Category probability curves showed 
disordered thresholds for 33 items, particularly in the mid response category area 
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(figure 8.3). This indicated an inability of the patients to differentiate between 
the options: able to perform, but with great difficulty (1); able to perform, but 
with some difficulty (2); and able to perform, but with little difficulty (3). The 
ordered thresholds of the remaining 16 items were extremely close to each 
other in the mid response area. Furthermore, the test for unidimensionality on 
the initial item set indicated that a degree of multidimensionality was apparent.
Figure 8.3. Disordered thresholds
Legend to figure 8.3. Category probability curves for item “are you able to do sports” is presented 
as an example of disordered thresholds. Left panel: thresholds are disordered, e.g. response 
categories one and three have never the greatest probability of being observed. Right panel: 
threshold ordering is restored after rescoring response categories. 
Table 8.2. Rasch analysis findings during the construction of the activity and participation scale 
for myotonic dystrophy type 1 patients
Analysis Item fit  
residuals
Person fit  
residuals
Item-trait
Chi2-probability
PSI unidimensionality
t-tests (CI)
nr Mean SD Mean SD DF P-value
1 0.068 1.571 -0.035 1.123 98 <0.000001 0.98 0.21 (0.175-0.244)
2 -0.163 1.318 -0.304 1.050 98 <0.000001 0.98 0.22 (0.189-0.258)
6 -0.161 1.263 -0.311 1.028 90 0.025 0.98 0.21 (0.182-0.252)
16 -0.115 1.229 -0.273 0.915 68 0.028 0.97 0.15 (0.118-0.187)
21 (final) -0.117 1.225 -0.284 0.916 40 0.089 0.95 0.08 (0.046-0.116)
Fitting data to the Rasch model
A stepwise description of the various Rasch analyses will be given. Items not 
fulfilling Rasch model criteria were analysed and removed one by one if needed. 
Changes and fit statistics of individual remaining items and overall model fit 
were monitored at each step.
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Step 1: to maintain interpretability, response options for all items were re-
scored by collapsing the 5-point scale into 3 response categories as fol-
lows: (0)=(0) unable to perform; (1-3)=(1) able to perform, but with diffi-
culty; (4)=(2) easy to perform, without difficulty. As a result, all disordered 
thresholds were restored resulting in a slight improvement of the SD of 
the items and patients (table 8.2, analysis 2). 
Step 2: uniform DIF was detected with regard to degree of education for the 
items “able to drive a car” and “able to visit friends/family”. Item “able to dry 
yourself” showed non-uniform DIF by age. These 3 items were also removed 
leading to further improvement of model (table 8.2, analysis 6). 
Step 3: after accomplishing these steps, individual fit statistics of 14 items still 
showed misfit to the model. Six items demonstrated under-discrimination 
and 8 items showed over-discrimination. These items were removed one by 
one, starting with the item with strongest misfit (item “ability to eat”). 
Step 4: a systematic evaluation of the correlation matrix (starting at correlations 
≥0.7, then ≥0.6, through to ≥0.3) was performed. Item characteristic curves 
of these items were subsequently inspected to select the items that best fit the 
expected model curve. The highest correlation was seen between item “able 
to walk up ½ flight of stairs” and “able to walk up 1 flight of stairs” (r=0.756). 
Eventually, a total of 12 items were removed on the basis of local response 
dependency. 
Clinimetric properties of the final DM1-Activ
After completing all these steps, a 20-item activity and participation scale was 
created and demonstrated good fit without any DIF or local dependency (table 
8.2, final analysis). All items of the final scale had fit residuals within range 
±2.5 with probability scores higher than Bonferroni cut-off P-value, indicating 
no significant deviation from the model (table 8.3). The person separation index 
was 0.95, demonstrating substantial internal consistency reliability. Principal 
component analysis of the residuals identified two subsets of items consisting 
of the 6 most positive and the 6 most negative loading items. t-Tests between 
person estimates from these two subsets of items demonstrated a proportion 
of 0.08 (95% CI 0.046-0.116) of the t-values falling outside the ±1.96 range, 
supporting acceptable unidimensionality of the scale.
The threshold distribution map of the final Rasch-built DM1-Activ scale shows 
the expected response to a given item as a function of the underlying activity 
and participation measure (figure 8.4). Item difficulty ranges from -2.98 to 
+3.17 logits and patient location from -4.684 to +6.364 logits. Only 0.63% of 
patients could not perform the tasks at all (floor effect) and 8.6% performed 
all activities without any problems (ceiling effect). Figure 8.5 provides the 
threshold distribution plot showing acceptable targeting between patient and 
item locations.
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Figure 8.4. Threshold map of the 20-item DM1-Activ
Legend to figure 8.4. The expected response for every person on each item is given as a function 
of the underlying activity and participation measure (0=unable to perform, 1=able to perform, but 
with difficulty, 2=easy to perform, without difficulty). Items are ordered by increasing difficulty.
External construct validity and reliability
The DM1-Activ demonstrated acceptable correlations with the MRC sum score 
and the MIRS (intraclass correlation coefficient 0.69 for MRC sum score, 0.71 
for MIRS; P<0.0001), indicating good external construct validity (figure 8.6). 
MRC sum score and MIRS findings explained 52.2% of the DM1-Activ findings. 
Test-retest reliability studies of item difficulty and patient location estimates are 
graphically represented in figure 8.7 demonstrating DIF over time for the items’ 
and patients’ location. Almost all 20-items were located within the 95% CI lines, 
indicating ideal invariance. Intraclass correlation coefficient was 0.97 for the 
item estimates and 0.93 for patient locations.
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Table 8.3. Final fit statistics for the 20-item activity and participation scale for myotonic 
dystrophy type 1 patients
Item Locationa SE Residualb P-valuec
Are you able to…
wash your face? -2.98 0.249 -1.117 0.102158
brush your teeth? -2.455 0.233 -0.497 0.633135
take a shower? -1.951 0.209 -0.71 0.056922
sit up straight? -1.621 0.204 1.315 0.915187
open toothpaste? -1.443 0.202 2.157 0.139324
prepare a meal? -0.969 0.197 0.479 0.668827
button your shirt/blouse? -0.788 0.2 0.571 0.368305
walking avoiding obstacles? -0.432 0.184 -2.24 0.042261
perform a hobby? 0.032 0.193 -0.023 0.728921
get in/out of a car? 0.038 0.178 -0.628 0.958695
walk on uneven ground? 0.088 0.181 -1.062 0.578111
bend over to pick up object? 0.241 0.185 -0.978 0.372796
walk one flight of stairs? 0.268 0.169 -1.808 0.060336
grab an object above head? 0.383 0.18 1.243 0.738543
perform study/work? 0.848 0.22 0.668 0.342525
stand up from lying down? 1.197 0.185 2.23 0.007782
do the cleaning? 1.81 0.191 -1.246 0.738787
do sports? 2.24 0.181 0.298 0.46463
do the gardening? 2.324 0.195 -0.469 0.167667
run? 3.17 0.17 -0.513 0.788601
aexpressed in linear log-odds units (logits) with mean item location set by convention at 0. bresiduals 
summarize the deviation of observed from expected responses and lie within the recommended range 
of -2.5 and +2.5. cBonferroni corrected probability scores were not significant, indicating no deviation 
from the model expectations.
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Figure 8.5. Targeting graph of the DM1-Activ
Legend to figure 8.5. Patient locations and item thresholds are displayed in the upper and the 
lower part of the graph, respectively. A well-targeted scale should include a set of items that span 
the full range of person estimates.
Figure 8.6. Relationship between DM1-activ measures and muscle strength scores
Legend to figure 8.6. DM1-Activ measures correlate significantly with MIRS grades (left panel) 
and the MRC sum score (right panel). A progressive decrease in activity and participation level 
was seen on the DM1-Activ Scale with increased muscular impairment. ICC=intraclass correlation 
coefficient. 
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Figure 8.7. Test-retest reliability
Legend to figure 8.7. Patient measures (left panel) and item difficulty hierarchy (right panel) in 
the first and second assessment are located within the 95% confidence intervals of the ideal 
invariance (solid lines). ICC=intraclass correlation coefficient.
Discussion 
We constructed an activity and participation measure for DM1 patients using 
the Rasch model (appendix A). The 20 items selected for the final DM1-Activ 
scale show no evidence of item bias or local dependency and demonstrate 
unidimensionality. Internal reliability of the DM1-Activ was high, indicating good 
differentiation between patients with different levels of disability. The observed 
invariance in item difficulty hierarchy after a delay of one year indicates that the 
questionnaire is reproducible over time. Furthermore, the estimated level of 
activity and participation remained relatively stable over a one-year period. In 
order to study the natural course of functional changes in DM1, measurements 
should be conducted over a much longer period of time.
As hypothesized in the introduction, most DM1-Activ items turned out to be 
different than those of the ACTIVLIM.26 Five items were virtually the same (i.e. 
washing one’s face, take a shower, walking outdoors, walking upstairs, and 
running), but demonstrated different difficulty levels. Moreover, some items of 
the DM1-Activ assess aspects of social participation. Based on these findings, 
a disease-specific Rasch-built scale would target the impact of DM1 more 
appropriately. 
Acceptable correlation was also demonstrated between the DM1-Activ scale 
and traditional impairment measures (MRC sum score and MIRS), supporting 
its construct validity. It should be noted that the MRC sum score is an ordinal 
rating scale with unequal intervals, although it can be argued that summed 
items approximate interval measurement levels enough to warrant parametric 
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statistics. The DM1-Activ is able to indirectly capture physical impairment 
that leads to problems in daily and social functioning. Similar associations 
between impairment, disability and handicap have been reported in patients 
with chronic immune-mediated neuropathies.40 However, only 50% of the DM1-
Activ data was explained by the MRC sum score and MIRS data, suggesting that 
other variables contribute to activity limitations and participation restrictions 
in DM1. Factors like fatigue, pain, sleep disorders, behavioural problems, 
and gastrointestinal complaints, have been demonstrated to contribute to 
the deficits in daily and social activities.5, 41-43 Focusing on these aspects is 
considered essential to capture the whole impact of a debilitating illness such 
as DM1, thereby improving the knowledge for guidance of patients, relatives 
and caregivers.
An international workshop on management of DM1 patients in 2004 focused 
on discussing published outcome measures in this disorder.44 A list of available 
impairment and disability scales was presented. Unfortunately, construction of 
all presented measures were based on the classical test theory (CTT).21 It should 
be realized that all ordinal scales are nonlinear and some caution should be 
taken when changes in sum scores are considered, since the whole score may 
not equal the sum of the parts.22 
There are some methodological limitations in the present study that should 
be addressed. First, the use of an MRC sum score should be considered 
a shortcoming, although this outcome measure has been shown to fulfil all 
scientific requirements including responsiveness.30, 45, 46 We aimed to illustrate 
the translation of general muscle weakness, measured with the MRC sum 
score, into limitations in daily activities and social participation, assessed by 
the DM1-Activ, hereby underlining the importance of the different aspects of 
an individual’s functioning as defined by the ICF model.11 Second, the analyses 
of DIF should be interpreted with some caution, since the sample sizes 
of the comparative groups were relatively restricted. Third, the DM1-Activ 
demonstrated a ceiling effect in 1 out of 12 patients which could lead to problems 
in future intervention studies. Fourth, the responsiveness of this scale needs 
to be investigated in a longitudinal study, taking into account the concept of 
minimum clinical important difference (MCID) to improve interpretability.47-49 
MCID has been defined as “the smallest difference in score in the domain of 
interest which patients perceive as beneficial and which would mandate, …, 
a change in the patient’s management”.49 MCID may provide an additional 
benchmark for future randomized controlled trials in all chronic illnesses, and 
may help clinicians and researchers better understand the clinical relevance of 
changes in scores. Practical guidelines for assessment of the MCID have been 
provided.49
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Conclusion
The constructed DM1-Activ scale is a practical, reliable and valid outcome 
measure and may help clinicians and caregivers to focus more on ameliorating 
the enormous disabling impact of this disorder on patients’ functionality. 
Further scientific evaluation of the DM1-Activ to enhance its calibration is 
currently being conducted, in order to provide a reliable raw score-to-logit score 
conversion table (nomogram) for use in future DM1 clinical observational and 
interventional studies.
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Summary 
We have recently published the first Rasch-built activity and participation scale 
specifically designed for patients with myotonic dystrophy type 1 (DM1-Activ). 
However, strengthening of the scale was needed in a larger cohort of patients to 
enable its clinical application. We report the results of the reconstructed DM1-
Activ for clinical use (DM1-Activc) through Rasch analyses on an expanded 
questionnaire containing 146 activity and participation inquiries that was 
completed by 340 patients with DM1. Through stepwise investigation including 
data quality control, model fit, response category ordering, local dependency 
and item bias, we succeeded in reconstructing the DM1-Activc consisting of 
25 items that showed good Rasch model fit, including validity, reliability, and 
unidimensionality. Also, a nomogram is provided to calculate interval-level 
logit scores from the obtained raw scores. The DM1-Activ scale has been 
reconstructed (DM1-Activc) and its use is recommended in future studies in 
patients with DM1.
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Introduction
At current stage, treatment of patients with myotonic dystrophy type 1 (DM1) 
is almost exclusively limited to symptomatic interventions without therapeutic 
options to reverse of slow down the progression of the illness. However, since 
genetically based new therapeutic treatments are emerging, solid outcome 
measures are needed to capture possible relevant clinical changes in patients 
with DM1 being exposed to these new therapies.1, 2
Recently, we have described the first Rasch-built activity and participation 
measure specifically designed for patients with myotonic dystrophy type 1 (DM1-
Activ).3, 4 The DM1-Activ fulfilled all model requirements and is thus far the only 
metric that has been extensively evaluated in this condition. However, further 
evaluation of the scale is needed in a much larger pool of patients to obtain a 
more stable model and provide a reliable raw score-to-logit score conversion 
table for use in future DM1 clinical studies.3
We have reconstructed the DM1Activ scale for clinical use (DM1-Activc) using 
a larger sample of patients with DM1 and a much broader pool of items 
representing activity and participation activities.5
Methods
Participants 
Patients older than 18 years with genetically proven DM1 were recruited through 
the Dutch neuromuscular patients’ association. The protocol was approved by 
the Medical Ethics Committee of our university. Written informed consent was 
obtained from all participants. A total of 340 patients with DM1 were included, 
fulfilling optimal sample size requirements for scale construction.6
Questionnaire development 
The questionnaire was constructed as previously described.3 In addition to the 
49 previously selected items from the pre-phase DM1-Activ scale, we collected 
extra activities and participation items from the WHO-ICF items list.1, 5 The 
preliminary DM1-Activc scale contained 146 activity and participation activities. 
Response options were: unable to perform (0), able to perform, but with 
difficulty (1), and able to perform, without any difficulty (2) and are based on 
the previously determined discriminative ability of DM1 patients.3 An item was 
scored (3) if it was ”not applicable” to the patient. 
The preliminary DM1-Activc was completed by 340 patients. A random sample of 
223 patients completed the questionnaire ~4 weeks later (test-retest reliability). 
The original 20-item DM1-Activ scale was also completed separately (external 
construct validity). 
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Rasch analysis
Obtained preliminary DM1-Activc data were subjected to Rasch analysis 
to determine whether model expectations were met. Several aspects were 
addressed including fit statistics, ordered thresholds, local independency, 
differential item functioning (item bias: DIF) and unidimensionality. Item 
bias was checked on personal factors: age (<30 years, 30-50 years, >50 years), 
gender, diagnosis phenotype (mild type, adult type, childhood/congenital type), 
and degree of education (elementary school, high school, university). Items or 
patients not fulfilling these requirements were removed or adjusted to obtain 
good model fit, hereby creating an interval scale.3, 7, 8
Validity and reliability
Internal consistency reliability of the DM1-Activc scale was determined by 
calculating the Person Separation Index (PSI). The external construct validity 
of the DM1-Activc scale was tested by correlations with the original 20-item 
DM1-Activ scale, using logits scores from both scales. Moreover, test-retest 
reliability studies were performed to investigate consistency of item difficulty 
hierarchy and patient ability locations. Reliability was quantified by calculation 
of the intraclass correlation coefficient using ANOVA for group comparison.9, 10 
Statistics
All analyses were conducted using the Rasch model (partial credit model), as 
implemented in the RUMM2030 software.11 Further analyses were undertaken 
using Stata Statistical Software version 11.0 with Bonferroni corrections if 
needed.12
Results 
General aspects and data quality control
The basic characteristics of the 340 patients are presented in the table 9.1. As 
part of data quality control, items with >10% missing values (n=29) and items 
with inadequate face validity (n=12) according to experts’ opinion (CF, IM) were 
removed. In the model construction, items scored as (3) “not applicable” were 
interpreted as missing data. Also, 28 patients were removed prior to Rasch 
analyses (16 without age record, 6 with unknown phenotype classification, 3 
with unknown gender, 2 with >10% uncompleted items, and 1 with unknown 
educational level). A total of 105 items and 312 patient records were finally 
subjected to Rasch analyses, continuously checking the distribution of persons 
within the class intervals.
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Table 9.1. Patient sample description
n=340
Age (years)
   mean (SD), range 47.5 (12.5), 18-82
Gender (%)
   female
   male
49.7%
50.3%
Diagnosis type (%)
   mild
   adult
   child/congenital
12.1%
77.3%
10.6%
Educational level (%)
   elementary school
   high school
   university
15.9%
69.4%
14.7%
Rasch analysis of the pre-phase DM1-Activc scale
The preliminary 105-items DM1-Activc showed overall misfit. The mean 
residual for items was -0.085 (SD 1.213) and for persons -0.278 (SD 1.361), 
indicating reasonable model fit. However, the item-trait chi-square probability 
was significant (P<0.00001; degrees of freedom (DF) 420), indicating lack of 
invariance. No disordered thresholds were seen. A proportion of 0.14 (95% 
CI 0.11-0.17) of the t-tests performed fell outside the ±1.96 range, indicating 
multidimensionality.
Fitting data to the Rasch model
The individual item fit statistics of 32 items demonstrated misfit to the model 
(having significant chi-square probability and/or fit residuals exceeding ±2.5) 
and were removed one by one (73 items remaining).
Local dependency was seen between many items (r≥0.3). Starting with the 
highest correlations (r≥0.7, then ≥0.6, through to ≥0.3), the item of each 
correlating set of items showing the least face validity according to experts’ 
opinion (CF, IM) or over- or under-discrimination on its category probability 
curve, was removed (45 items removed stepwise; 28 items remaining).
One item showed item bias (uniform DIF) on age and diagnosis phenotype 
and two items had non-uniform DIF on diagnosis phenotype. All 3 items 
were removed. Hence, at this stage 25 items were kept. Item “able to run” 
demonstrated uniform DIF on age. This item was one of the most difficult 
activities to perform. Since we aimed to obtain a wide range of measurement, 
we decided to keep this item in the model. However, before splitting this 
item and creating 2 subgroups (age <30 years versus ≥30 years), a test for 
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unidimensionality was performed, since RUMM2030 software does not provide 
the opportunity to do this after splitting an item. 
Clinimetric properties of the final DM-Activc
The 25-item DM1-Activc met all Rasch model expectations. The mean fit residual 
for items was -0.197 (SD 0.869) and for persons -0.273 (SD 0.774). The overall 
item-trait interaction chi-square probability was non-significant (P=0.24; DF 
100), indicating the required property of invariance. The independent t-tests 
between person estimates from 7 most positive versus 7 most negative loaded 
items demonstrated a proportion of 0.067 (95% CI 0.043-0.091) falling outside 
the ±1.96 range, suggesting acceptable unidimensionality. Subsequently, the 
item “able to run” was split into 2 separate age-dependent items.
In the final DM1-Activc scale (table 9.2), item “able to eat soup” (-3.305 logits) 
was the easiest item while “able to run” for patients ≥30 years (3.904 logits) 
was the most difficult item. Two patients (0.6%) demonstrated no activity 
limitations or participation restrictions (floor effect), while 23 patients (7.4%) 
had a maximum score (ceiling effect). Table 9.3 provides a nomogram allowing 
the translation of raw summed scores of the final DM1-Activc (range 0 to 50) 
into logits, and subsequently into a more easily interpretable centile metric 
score ranging from 0 (most severe activity and social participation restrictions) 
to 100 (no activity and social participation limitations).
Figure 9.1. Test-retest reliability
Legend figure 9.1. Patient measures (left panel) and item difficulty hierarchy (right panel) in 
the first and second assessment are located within the 95% confidence intervals of the ideal 
invariance (solid lines). The fraction of variance is expressed by R2.
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External construct validity and reliability
The 25-item DM1-Activc scale demonstrated high external construct validity 
(R2=0.91 correlation with the 20-items DM1-Activ; P<0.0001).3 Internal reliability 
was robust (PSI=0.95). The test-retest reliability for patient location and item 
difficulty was good (R2=0.93 and R2=0.99, respectively; P<0.0001; figure 9.1). 
All item and almost all patient locations were within the 95% CI lines, reflecting 
ideal invariance.
Table 9.2. Final fit statistics for the 25-item DM1-Activc scale
Item Locationa SE Residualb P-valuec
Are you able to...
eat soup? -3.305 0.198 -0.185 0.610198
visit family or friends? -2.967 0.176 -0.113 0.653494
care for your hair and body? -2.608 0.18 -0.136 0.793144
dress your lower body? -2.314 0.162 -0.314 0.532921
wash your upper body? -2.278 0.164 0.076 0.933869
take a shower? -2.222 0.162 -0.91 0.422836
wash your lower body? -2.15 0.16 -0.549 0.80354
get out of bed? -1.777 0.151 1.836 0.003088
move a chair? -1.217 0.143 -0.609 0.811204
do the dusting/cleaning? -1.071 0.145 -0.743 0.514443
do the shopping? -0.825 0.137 0.818 0.452093
tie the laces of your shoes? -0.569 0.134 1.727 0.218672
catch an object (e.g. a ball)? -0.527 0.134 0.268 0.282685
use dustpan and brush? -0.145 0.132 -0.821 0.605114
empty dustbin? -0.013 0.127 -1.434 0.294051
make up your bed? 0.491 0.128 -0.238 0.740776
vacuum clean? 0.807 0.124 -1.127 0.195076
serve coffee/tea on a tray? 1.408 0.121 -0.918 0.587366
dance? 1.844 0.125 0.149 0.08681
stand up from squatting position? 2.162 0.129 0.534 0.580312
stand on one leg? 2.287 0.126 1.141 0.100675
run (for those <30 years)? 2.343 0.486 -2 0.823465
walk uphill? 2.399 0.133 -1.085 0.628618
walk 3 flights of stairs? 2.832 0.134 -1.114 0.140408
carry and put down heavy object (10 kg)? 3.509 0.139 -0.674 0.244503
run (for those ≥ 30 years)? 3.904 0.148 -0.599 0.709763
aexpressed in linear log-odds units (logits) with mean item location set by convention at 
0. bresiduals summarize the deviation of observed from expected responses and lie within 
the recommended range of -2.5 and +2.5. cBonferroni corrected probability scores were not 
significant, indicating no deviation from the model expectations.
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Table 9.3. Nomogram
Age <30 years Age ≥30 years
Raw 
sumscore 
Person 
location 
(logit)
Centile 
metric 
score
Raw 
sumscore
Person 
location 
(logit)
Centile 
metric 
score
0 -6,551 0 0 -6,55 0
1 -5,67 7 1 -5,669 6
2 -5,037 11 2 -5,036 11
3 -4,582 15 3 -4,58 15
4 KEY1 KEY1 4 KEY2 KEY2
5 -3,901 20 5 -3,899 20
6 -3,623 22 6 -3,62 22
7 -3,37 24 7 -3,367 23
8 -3,136 25 8 -3,133 25
9 -2,918 27 9 -2,913 27
10 -2,711 29 10 -2,706 28
11 -2,514 30 11 -2,508 30
12 -2,325 31 12 -2,318 31
13 -2,143 33 13 -2,135 33
14 -1,967 34 14 -1,958 34
15 -1,796 35 15 -1,786 35
16 -1,629 37 16 -1,617 36
17 -1,465 38 17 -1,452 38
18 -1,305 39 18 -1,29 39
19 -1,147 40 19 -1,13 40
20 -0,992 41 20 -0,972 41
21 -0,838 43 21 -0,816 42
22 -0,685 44 22 -0,661 43
23 -0,533 45 23 -0,506 45
24 -0,383 46 24 -0,352 46
25 -0,233 47 25 -0,198 47
26 -0,083 48 26 -0,045 48
27 0,067 49 27 0,109 49
28 0,216 50 28 0,264 50
29 0,367 52 29 0,419 51
30 0,519 53 30 0,576 53
31 0,672 54 31 0,735 54
32 0,828 55 32 0,897 55
33 0,988 56 33 1,063 56
34 1,151 57 34 1,233 57
35 1,32 59 35 1,409 59
36 1,495 60 36 1,593 60
37 1,679 61 37 1,785 61
191
Chapter
9.
38 1,873 63 38 1,988 63
39 2,079 64 39 2,204 65
40 2,301 66 40 2,437 66
Discussion 
In the current study, the reconstructed DM1-Activc outcome measure for activity 
limitations and participation restrictions is presented (appendix B). This 25-
item scale has been specifically designed for patients with DM1 and fulfilled all 
Rasch model expectations, with robust validity and reliability aspects. We have 
reconstructed the DM1-activ scale in a larger sample of patients in order to 
provide a better and more stable model with a nomogram for use in future DM1 
clinical studies (table 9.3). 
The internal reliability (PSI) of the DM1-Activc scale was high, demonstrating 
discriminative ability of the scale to differentiate between patients with various 
levels of disability.9 Its responsiveness is currently being examined as part of an 
ongoing natural course study. As previously stated, the concept of minimum 
clinically important difference (MCID) may also help clinicians and researchers 
to determine whether significant statistical differences between scores imply 
a clinically relevant change.3 Practical guidelines for assessment of the MCID 
Age <30 years Age ≥30 years
Raw 
sumscore 
Person 
location 
(logit)
Centile 
metric 
score
Raw 
sumscore
Person 
location 
(logit)
Centile 
metric 
score
41 2,543 68 41 2,689 68
42 2,808 70 42 2,965 70
43 3,101 72 43 3,269 72
44 3,428 74 44 3,605 75
45 3,791 77 45 3,976 78
46 4,197 80 46 4,388 81
47 4,657 83 47 4,849 84
48 KEY3 KEY3 48 KEY4 KEY4
49 5,923 93 49 6,096 93
50 6,871 100 50 7,016 100
Translation of raw sum scores into logits or centile metric score is only possible if there 
are no missing data. KEYs are available by contacting the corresponding author.
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have been provided and will be implemented in the natural course study.13
Compared to the previously published 20-item DM1-Activ scale,3 the current 
reconstructed DM1-Activc contains five more items. The item difficulties of the 
DM1-Activc cover a wider range than the DM1-Activ (7.209 logits versus 6.15 
logits), thus providing a better targeting of patients. This was also reflected in a 
lower percentage of ceiling effect in DM1 patients (7.4% versus 8.6%).3
Conclusion
The reconstructed activity and participation scale specifically designed for 
patients with DM1 (DM1-Activc) fulfills all modern clinimetric requirements. 
Its use is proposed in future clinical observational and interventional studies 
studies in DM1 patients. 
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Summary
Fatigue and excessive daytime sleepiness are frequent complaints in 
myotonic dystrophy type 1 (DM1) that often overlap. We aimed to construct 
a combined fatigue and daytime sleepiness rating scale for DM1 using the 
Rasch measurement model. Questionnaires, including the Epworth Sleepiness 
Scale, Fatigue Severity Scale, and Daytime Sleepiness Scale were completed by 
354 patients. Data were subjected to Rasch analyses and tested for required 
measurement issues such as appropriate response categories, absence of item 
bias, local independence, and unidimensionality. The initial 22 items did not meet 
Rasch model expectations. After rescoring and removing misfitting items, the 
final 12-item scale showed good model fit and unidimensionality. High internal 
consistency (person separation index=0.80) and validity were demonstrated. 
The Rasch-built Fatigue and Daytime Sleepiness Scale, developed specifically 
for DM1 patients, provides interval measures on a single continuum. Its use is 
suggested in future clinical trials and therapeutic follow-up.
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Introduction
Myotonic dystrophy type 1 (DM1) is an autosomal dominant inherited 
multisystem disorder. It affects skeletal and smooth muscles, the heart, the 
eyes, the endocrine system and central nervous system. The diagnosis of DM1 is 
confirmed by molecular genetic testing of an expansion of a CTG trinucleotide 
repeat in the DMPK gene.1 Based on age at onset and severity of symptoms, 
four clinical types can be distinguished: congenital type, childhood-onset type, 
adult-onset (classic) type and late-onset (mild) type.2
Excessive daytime sleepiness (EDS) is an important and common clinical 
feature of DM1 which occurs in about one third of patients.3, 4 Unlike narcolepsy, 
daytime sleepiness in DM1 patients is not episodic, and sleep tendency occurs 
when attention is not being held, rather than during activity. EDS can be a 
symptom of sleep-disordered breathing, chronic hypercapnia, or depression, 
but these conditions alone cannot entirely explain EDS in DM1.5-7 Complaints 
of excessive fatigue appear even more frequently than those of EDS in patients 
with DM1.8  DM1-related fatigue is characterized by a subjective lack of physical 
and/or mental energy. Although fatigue is an important symptom in any 
progressive physically disabling disease, it is more common in DM1 than in 
other neuromuscular disorders and may even be prominent when muscular 
impairment is relatively mild.9 The presence of fatigue can have a major impact 
in daily life, general well-being, and social participation.9 
EDS and fatigue have overlapping features, and both patients and physicians 
may have difficulty distinguishing between these 2 entities. Patients cannot 
always specify whether their complaint relates to sleepiness, fatigue, or both.10 
Several patient-based measures are available to evaluate daytime sleepiness 
or fatigue levels, but generally as separate entities. However, fatigue and EDS 
levels are associated in DM1 patients,8, 9 suggesting that available outcome 
measures do not necessarily represent separate constructs. 
Current outcome measures are all ordinal scales based on classical test theory 
(CTT).11 A major limitation of CTT is that scores create measurement at an 
ordinal level with unequal intervals that hamper accurate measurement 
of differences in scores and changes over time among individuals. Rasch 
analysis attempts to transform ordinal scores into interval measures that are 
scale independent and suitably accurate for individual patient assessment.12, 
13 This methodology has previously been used to develop an outcome measure 
of activity limitations and participation restrictions for DM1 patients (DM1-
Activ).14 In view of the multisystem nature of this disease, health outcome 
measures at several levels of outcome are necessary for patient assessment. 
We aimed to construct a combined fatigue and daytime sleepiness rating scale 
(FDSS) for DM1 using the Rasch method, provided that fatigue and daytime 
sleepiness items address the same underlying health construct. 
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Methods
Participants and procedures
The study population comprised 354 adult DM1 patients (167 recruited at 
Maastricht University Medical Center in the Netherlands and 187 patients at 
Neuromuscular Clinic of the Centre de Santé et de Services Sociaux de Jonquière 
in Canada).8 The study was approved by both local Medical Ethics Committees, 
and informed consent was obtained from all participants. A description of the 
patient sample is provided in table 10.1. 
Table 10.1. Patient sample description
Dutch population
n=167
Canadian population
n=187
Age (years)
mean (SD), range 44.1 (11.6), 18-69 46.0 (11.0), 20-80
Gender (n, %)
female
male
81 (48.5)
86 (51.5)
115 (61.5)
72 (38.5)
Diagnosis type (n, %)
mild type
adult type
childhood/congenital type
14 (8.4)
137 (82.0)
16 (9.6)
36 (19.3)
151 (80.7)
-
The concept scale was composed of all 22 items from the Epworth Sleepiness 
Scale (ESS), Daytime Sleepiness Scale (DSS) and Fatigue Severity Scale (FSS). 
The ESS is a widely used questionnaire intended to measure daytime sleep 
propensity.15, 16 Patients rate their chances of dozing on 8 everyday situations on 
a 4-point scale. Good reliability aspects have been demonstrated for the ESS in 
subjects with sleep-disordered breathing, primary sleep disorders and healthy 
subjects.17-19 However, in DM1, weak internal consistency was reported, possibly 
because some items were irrelevant or inappropriate for these patients.20 The 
5-item DSS was built to assess daytime sleepiness in DM1 and showed good 
validity and reliability.4, 20 The FSS is the questionnaire used most commonly to 
assess the impact of fatigue on daily activities. It contains 9 items, and each 
item is scored on a 7-point Likert scale. This scale has demonstrated high 
internal consistency and adequate validity.21 An evaluation in DM1 patients 
showed good reliability of the FSS.20
All patients completed a questionnaire including socio-demographic and 
clinical information, and it containing ESS, FSS, and DSS items placed 
randomly. Patients were examined by a neurologist, and muscular impairment 
was categorized according to the muscular impairment rating scale (MIRS).22
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Rasch analysis 
The Rasch unidimensional measurement model was used to construct the 
fatigue and sleepiness scale. Chapter 7 clearly explains the various steps of the 
Rasch method. In brief, the Rasch model can be seen as the ideal response 
pattern, where persons with a high level of the measured trait should have a 
higher probability of receiving a higher score on any item compared to persons 
with lower levels. Also, any person should always have a greater probability of 
receiving a higher score on an easier item than on a more difficult one.12 In order 
to obtain an interval scale, the final scale should fulfill the model’s expectations, 
like good item and person statistical fit, threshold ordering, lack of item bias or 
local dependency, and with demonstrated unidimensionality.23-26 We assessed 
potential differential item functioning (DIF or item bias) for 6 person factors: 
gender, age groups (<30 years, 30-50 years, >50 years), diagnosis type (mild, 
adult, childhood/congenital), use of psychostimulants (yes, no), degree of 
education (elementary school, high school, university) and possible cultural 
differences (Dutch versus Canadian). Items and persons that did not fulfill 
Rasch model criteria were evaluated and removed one by one, if needed. 
Validity and reliability
The external construct validity of the scale was assessed by correlation with the 
MIRS. An estimate of the internal consistency reliability of the scale is available, 
based on the person separation index (PSI). PSI (equivalent to the Cronbach’s 
alpha) should be greater than 0.7 for group comparison.23
Statistics
All analyses were conducted using the Rasch model (partial credit model), as 
implemented in the RUMM2030 software.25 Further analyses were undertaken 
using Stata Statistical Software version 11.0. One-way analysis of variance with 
corrections according to Bonferroni multiple testing was used to compare FDSS 
scores between subgroups.27
Results
Rasch analysis
The draft 22-item scale did not meet the Rasch model expectations. The item-
trait chi-square probability was significant (P<0.00001), indicating lack of 
invariance of item difficulty across the scale. The mean residual for items was 
0.24 (SD 2.44). The mean residual for persons was -0.26 (SD 1.14), indicating 
no serious misfit among respondents. The person separation index was 0.91.
Thresholds were examined to see if disordering affected fit. Category probability 
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curves showed disordered thresholds for 4 ESS items, 1 DSS item and for all 
FSS items. In order to restore threshold ordering, response options for all items 
were rescored with the aim of creating a uniform set of response categories 
and strengthening the category frequencies.28 For the ESS and DSS items, the 
original 4 response options (coded 0-1-2-3) were collapsed into 3 categories 
(coded 0-1-1-2). The original FSS items with 7-point response categories (coded 
1-2-3-4-5-6-7) demonstrated a uniform disordered pattern and were subsequently 
collapsed into 3 categories (coded 0-0-1-1-1-2-2) (figure 10.1).
Figure 10.1. Disordered thresholds
Legend to figure 10.1. Category probability curve for item FSS2 (“exercise brings on my fatigue”) 
with 7 response categories (coloured curves correspond to score options 0 to 6) showing the 
relation between the probability of a given category as a function of person location. Left panel: 
thresholds were disordered and crowded together. Right panel: after rescoring into 3 response 
categories (coloured curves correspond to score options 0 to 2), showing ordered response 
categories and ordered thresholds. Note that each response category has a point along the 
fatigue and sleepiness continuum where it is the most likely response.
Next, we systematically checked for item misfit, local dependency and DIF. 
A total of 10 items were removed one by one based on the following: item 
ESS2 (“fall asleep while watching TV”) was removed due to local dependency; 
items ESS5 (“fall asleep while lying down to rest in the afternoon when able”), 
EES7 (“fall asleep while sitting quietly after a lunch without alcohol”), DSSd 
(“difficulty being inactive for prolonged periods”), FSS4 (“fatigue interferes 
with my physical functioning”), FSS6 (“my fatigue prevents sustained physical 
functioning”), and FSS3 (“I am easily fatigued”) were removed for showing 
significant misfit; item FSS7 (“fatigue interferes with carrying out certain duties 
and responsibilities”) was removed due to item misfit and local dependency; 
items DSSb (“at times, sudden need to sleep during the day”) and FSS9 
(“fatigue interferes with my work, family or social life), showed differences in 
response between Dutch and Canadian patients with equal levels of excessive 
daytime sleepiness or fatigue (DIF related to cultural differences) and were also 
removed.
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Clinimetric properties of the final FDSS scale
After these steps, we succeeded in obtaining a 12-item scale that fulfilled all 
model expectations. Adequate item and patient fit statistics were obtained (mean 
fit residual -0.36 (SD 1.07) and mean fit residual -0.38 (SD 0.96), respectively). 
The overall item-trait interaction chi-square probability was non-significant (P= 
0.61), thereby showing invariance. Finally, 2 item subsets were defined by the 
4 most positive (ESS1, ESS3, ESS4, ESS6) and negative loading items (FSS1, 
FSS2, FSS5, FSS8) using a principal component analysis of residuals (see figure 
10.2 for item identification). An independent t-test between person estimates 
from these 2 subsets of items demonstrated a proportion of 0.05 (95%CI: 0.03-
0.08) of the tests falling outside the ±1.96 range, supporting unidimensionality 
of the scale.
Figure 10.2. Threshold map of the 12-item FDSS
Legend to figure 10.2. Threshold map indicating patient’s expected response for each item as 
a function of their level of fatigue and sleepiness (0 = seldom or never, 1 = sometimes, 2 = 
almost always). Items are ordered by increasing difficulty. Item “my motivation is lower when I 
am fatigued” was the easiest item and item “do you fall asleep while sitting and talking” the most 
difficult item.  
The threshold distribution map of the FDSS shows the expected response to 
a given item as a function of the underlying fatigue and sleepiness measure 
(figure 10.2). Item difficulty ranged from -2.624 to +2.924 logits, and patient 
location ranged from -5.122 to +3.137 logits. Only 0.3% of patients were not 
fatigued or sleepy at all (floor effect), and 0.6% graded themselves as having 
the maximum score (ceiling effect). To compare targeting of the outcome 
measures, i.e. the difficulty range of outcome measures in relation to the levels 
of fatigue and sleepiness of the sample, various FDSS items were used for 
202
anchoring each of the scales to the FDSS ruler separately. Figure 10.3 shows 
that the item locations of the ordinal DSS, ESS and FSS are poorly targeted to 
the sample population and cover a small range of measurement. By contrast, 
the targeting graph of the FDSS shows that the items are well spread across the 
continuum and sufficiently cover the patient sample (mean patient location of 
-0.38 logits).
Figure 10.3. Person and item distribution on a logit scale
Legend to figure 10.3. The numbers -5 to 3 represent corresponding logits on a linear ruler 
(y-axis). The crosses under persons represent the number of patients having a person location at 
that point on the ruler. Item locations are presented on the right side. Positive values on the logit 
scale represent the more fatigued or sleepy patients and the more difficult items. Negative values 
on the logit scale represent the less fatigued or sleepy persons and the least difficult items. For a 
well-targeted scale (not too easy, not too hard), items should represent a wide range in difficulty. 
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Validity and reliability
The interval FDSS scores differed significantly between MIRS grades, a measure 
of the disease involvement (F= 5.77, P= 0.0002). A significant trend (P= 0.003) 
was seen toward higher fatigue and sleepiness levels in patients with more 
severe muscular impairment. However, at subgroup level, only the FDSS scores 
of patients with MIRS score 1 differed significantly from those with MIRS scores 
of 3, 4, and 5 (figure 10.4). There was no association between FDSS measures 
and CTG repeat length (F= 2.39, P= 0.07). The person separation index was 
0.80, demonstrating acceptable internal consistency reliability.
Figure 10.4. Relationship between FDSS outcomes and MIRS grades 
Legend to figure 10.4. FDSS values are presented in a box plot. A progressive increase in 
fatigue and sleepiness level was seen on the FDSS scale with increased muscular impairment 
demonstrated by higher MIRS grade. FDSS scores did not differentiate significantly between all 
subgroups.
-6
-4
-2
0
2
4
F
D
SS
 lo
ca
ti
on
 (
lo
g
it
s)
1 2 3 4 5
MIR S
p=NS p=0.004 p=0.001 p<0.001
204
Discussion
We constructed a Rasch-built combined fatigue and daytime sleepiness scale 
(FDSS) specifically designed for patients with DM1 (appendix C). The FDSS 
is composed of items from the ESS, DSS, and FSS. The 12 items selected for 
the final scale fulfilled all Rasch model expectations, and the hierarchy of items 
was invariant across DM1 patients of different ages, gender, disease types, 
education levels, use of psychostimulants, and between patients from different 
countries (the Netherlands and Canada). Items retained for the FDSS are 
shown to measure a single construct combining aspects of sleep propensity as 
well as behavioural consequences of fatigue, which argues strongly in favour of 
a combined clinical outcome measure of these attributes. Fatigue items were 
the easiest items, while sleepiness items were the most difficult items. A 
significant association was found between FDSS measures and MIRS grade. 
This is in line with previous reports which showed that patients with fatigue 
and/or EDS had greater muscular impairment than patients without these 
symptoms.4, 8
Previous reports in inflammatory neuropathies and multiple sclerosis 
demonstrated the inability of patients to differentiate between the original FSS 
response categories.29, 30 Similar disordered threshold patterns were seen in 
patients with DM1 and can only be visualized using a modern technique like the 
Rasch method. In addition, Rasch analysis allows one to investigate targeting. 
As shown in this study, conclusions based on FSS, ESS and DSS data may be 
questioned, since the sets of items might not be at the appropriate level of 
difficulty for the patients being examined (figure 10.3).
Interval measures can be deduced from FDSS raw scores and can be used for 
parametric statistical analyses. It is also possible to describe patients with a 
given sum score in functional terms using the logit measure or the modeled 
probability of a category score for each item (e.g., the percent difference in 
the probability of “fall asleep when sitting and reading”), thereby improving 
the interpretation of test scores and trial effects.31 
The high person separation index is supportive of a good discriminatory 
capacity of the scale among patients with various degrees of fatigue and 
sleepiness, suggesting that the scale can measure change in fatigue induced 
by, for example, medical intervention. The FDSS scale would be a more suitable 
patient-based outcome measure for randomized trials of psychostimulants, as 
it is specifically devised and validated for DM1 and overcomes the limitations of 
ordinal based measures. 
The ability of the FDSS to detect meaningful changes over time (responsiveness) 
needs further evaluation. Also, the use of this new scale should be complemented 
whenever possible by monitoring of multiple physiological parameters during 
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sleep (polysomnography), determination of physiologic sleepiness during the 
daytime (multiple sleep latency test), and assessment of potential immunologic 
and neuroendocrine disturbances, impaired psychophysiologic responses, and 
dysfunction in central and peripheral motor pathways.32-34
Conclusion
This study addresses various measurement issues required to construct a 
clinically meaningful combined Fatigue and Daytime Sleepiness Scale (FDSS) 
specifically for patients with DM1 using Rasch analysis. The FDSS interval 
measure meets all Rasch model expectations and bypasses the difficulty 
of differentiating between fatigue and sleep problems by providing interval 
measures on a single continuum for both entities. Its use is therefore suggested 
in future clinical trials and follow-up studies in DM1 in order to determine its 
responsiveness.
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This thesis describes a series of studies on myotonic dystrophy type 1 (DM1). In 
this chapter, an overview of this thesis is presented where the main findings and 
conclusions of each of the chapters are summarized and discussed. 
Chapter 1 is a general introduction illustrating the multisystemic characteristics 
of DM1. The underlying molecular mechanisms of DM1 are likely to be 
exceedingly complex as the mutation can affect gene expression in multiple ways. 
Misregulation of alternative splicing plays a central role in the development of 
DM1 symptoms, but major disease symptoms like muscle wasting and cardiac 
arrhythmias cannot be readily explained by any of the splicing changes identified 
to date. DM1 is a clinically heterogeneous disorder in which age at onset and 
severity of symptoms may vary widely. As a consequence, affected individuals 
need different approaches depending on the severity of their particular problems 
and their age. Despite the fact that a curative treatment is not available and 
affected individuals may not see the need for regular treatment or follow-up, 
structured multi-disciplinary management is of value as several measures can 
help diminish complaints, improve daily life, and prolong survival.1
 
Cardiac disease
As prognosis of DM1 patients may be directly related to cardiac status, 
surveillance and timely management of cardiac complications are important. 
However, despite the high incidence of cardiac abnormalities in DM1, there 
is no consensus on the management of heart disease and the risk of sudden 
death may not be fully appreciated. The main objectives of the first part of this 
thesis were to determine the occurrence and predictors of sudden death, to 
establish the presence and nature of cardiomyopathy in DM1 and to describe 
changes in gene expression that may lead to cardiac dysfunction, in order to 
improve standard follow-up and treatment regimens.
Chapter 2 gives a comprehensive overview of the extensive literature on hereditary 
muscular dystrophies associated with cardiac disease. The incidence and nature 
of cardiac involvement vary between different types of muscular dystrophies. 
Some types mainly lead to dilated cardiomyopathy, resulting in systolic 
dysfunction and heart failure, while others particularly affect the conduction 
system, leading to arrhythmias and sudden death. Molecular pathology, clinical 
aspects, cardiac findings and the mechanism and risk of cardiac death of 
different types of muscular dystrophies are summarized to provide insight into 
the present management of these diseases. However, recommendations for 
the investigation and treatment of cardiac involvement in muscular dystrophies 
are largely based on consensus statements, since published evidence of benefit 
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from any treatment is quite limited. Prospective well-coordinated multi-centre 
collaborative studies are mandatory to evaluate current strategies and to adjust 
guidelines for surveillance, heart failure treatment and device implantation. 
Until recently, sudden death in DM1, defined as instantaneous unexpected death 
due to natural causes without symptoms of illness in the preceding 24 hours,2 
was thought to be primarily the result of conduction blocks. Current guidelines 
for device-based therapy of cardiac rhythm abnormalities recommend that: 
permanent pacemaker implantation may be considered for neuromuscular 
diseases such as myotonic dystrophy with any degree of AV block, with or without 
symptoms, because there may be unpredictable progression of AV conduction 
disease (level of evidence: B) or with bifascicular block or any fascicular block, 
with or without symptoms (level of evidence: C).3 
Chapter 3 shows that sudden death occurred in one third of all classified 
deaths in a retrospective study of 412 DM1 patients. Moreover, sudden death 
was certainly not always prevented by pacemakers. This high rate of sudden 
deaths demands for a new treatment strategy. ICDs have been increasingly 
used in patients with muscular dystrophies that predispose to sudden death.4 
The efficacy of an ICD in DM1 is suggested from nonrandomized observations 
of ventricular tachyarrhythmias and appropriate ICD therapy. The challenge 
remains to identify patients with a relatively good neuromuscular prognosis 
who would benefit from an ICD. Our case-control comparison of available 
electrocardiograms showed that QRS duration was significantly prolonged in 
patients with documented sudden death compared to controls and deaths from 
other causes. Others have identified a severe abnormality on ECG and a clinical 
diagnosis of atrial tachyarrhythmia as independent risk factors, although with 
moderate sensitivity, for sudden death in this population.5 DM1 patients with 
this risk profile would be the ideal cohort for a long-term follow-up study to 
assess the survival benefit from ICD therapy versus pacemaker therapy, or 
alternatively, an insertable loop recorder. Other possible prognostic factors 
should be evaluated for their association with cardiac events. Because of the 
possibility of low event rates, the follow-up period should be adequate (e.g. 5-10 
years).
Chapter 4 describes the structural and functional myocardial abnormalities 
depicted by CMR imaging in patients with DM1. Although death from 
progressive heart failure is uncommon in patients with DM1 compared to 
other muscular dystrophies, myocardial involvement may also be prognostic 
in predicting overall mortality and sudden death in DM1.6 CMR imaging 
has a greater sensitivity and reproducibility than conventional diagnostic 
investigations (ECG and echocardiography) to demonstrate early myocardial 
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abnormalities or subtle changes, but the CMR findings in DM1 had not been well 
characterized. We found that the presence of mild to moderate left ventricular 
systolic dysfunction, ventricular dilatation, myocardial hypertrophy or fibrosis 
on CMR imaging was strongly associated with electrocardiographic conduction 
abnormalities. However, a normal ECG did not exclude myocardial alterations. 
These findings lend support to the concept that DM1 patients have a complex 
cardiac phenotype, including both the myocardium and the conduction system. 
The predictive value of myocardial fibrosis or other CMR findings for identifying 
DM1 patients who are at risk for cardiac disease progression or sudden death 
remains to be investigated in a long-term prospective study. 
CTG repeat length was not associated with myocardial involvement. There is no 
consensus from the literature as to whether or not CTG-repeat size has value 
as a prognostic indicator of cardiac disease.7, 8 Indeed, CTG repeat analysis 
from peripheral blood leukocytes may be of limited value in individual patients 
because of the overlap between expansion sizes seen in different phenotypic 
groups (congenital type, childhood-onset type, adult-onset type, and late-
onset type).9 In addition, the size of the mutation observed in leukocytes does 
not necessarily reflect the CTG expansion size in the cardiac myocytes due to 
variability between tissues (somatic mosaicism),10 which may explain why the 
CTG repeat length in peripheral blood leukocytes does not necessarily correlate 
with the severity and nature of symptoms.
Chapter 5 reports the changes in gene expression in cardiac biopsies obtained 
from patients with DM1-related cardiomyopathy. Altered global gene expression 
has previously been shown in skeletal muscle biopsies of DM1 patients,11-13 and 
in skeletal muscle of MBNL1 knock-out mice and of transgenic mice expressing 
non-coding CUG repeats.14 Microarray analysis showed significant changes in 
the expression levels of 989 mRNAs and 16 miRNAs in hearts of DM1 patients 
as compared to control subjects. We were able to reproduce gene expression 
changes in DM1 cardiac tissue that have been directly linked to established 
concepts on DM1 pathophysiology, such as the loss of DMPK and SIX5 
expression. Bioinformatics analysis of mRNA expression data identified several 
pathological changes, including disturbance of cardiac mitochondrial function, 
RNA processing, calcium signalling and expression changes in genes involved 
in cytoskeleton regulation. The observed changes may predispose DM1 hearts 
to conduction disturbances, arrhythmias and myocardial abnormalities. It 
would be interesting to identify gene expression profiles characteristic of 
disease subgroups to find prognostic or predictive molecular signatures as 
previously demonstrated in the context of cancer.15
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Outcome measures
Over time, DM1 leads to muscle and organ impairments causing progressive 
disability. Most of the treatment thus far is directed towards symptom 
management. In addition, advances in understanding of the complex 
pathogenesis have led to potential molecular therapeutic targets in preclinical 
studies.16 Before being able to evaluate therapeutic interventions in clinical 
trials, consensus is needed on which core set of appropriate outcome 
measures should be used. In the second part of the thesis, we aimed to show 
the importance of modern clinimetric methods and construct new outcome 
measures for future DM1 studies. 
Chapter 6 provides an overview of outcome measures applied in clinical 
studies involving patients with DM1 over the last 60 years. A multitude of 
outcome measures have been used, which hampers comparison of different 
trials results. In addition, clinimetric properties, including validity, reliability 
and responsiveness, were incompletely or poorly evaluated for most of the 
measurement instruments. Another limitation of currently applied outcome 
measures was the fact that multi-item rating scales were all based on the classical 
test theory providing all ordinal measurement.17 Ordinal scales are currently 
used in an inappropriate way by addressing obtained scores as interval measures 
and exposing them to parametric analyses. Recommendations are made to 
adopt modern rather than classical clinimetric approaches when constructing 
outcome measures for DM1 and to use a certain degree of standardization to 
facilitate comparison of future clinical trial results and improve communication 
in clinical practice.
Chapter 7 is an introduction to the Rasch measurement model and informs the 
reader about the various steps in the evaluation and construction of outcome 
measures using Rasch analysis. This modern clinimetric technique sets 
additional quality standards for outcome measures and attempts to estimate 
an interval-scaled measure from an observed raw score, giving meaning to the 
scores and allowing comparison of (changes in) scores.18 
Chapter 8 describes the development of a new outcome measure of activity 
limitations and participation restrictions for patients with DM1 (DM1-Activ) 
using the Rasch measurement model. Although an interval measure at the 
activity level for patients with neuromuscular disorders (ACTIVLIM) is available,19 
a disease-specific scale is preferred over a generic scale for the evaluation of 
health outcomes. Patients with DM1 may experience different difficulties in 
daily and social functioning than patients with other neuromuscular disorders 
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(e.g. limb-girdle dystrophy), leading to differences in items selection and 
differences in weights (significance) of selected items. However, strengthening 
of the DM1-Activ scale was needed in a larger cohort of patients to enable its 
clinical application.
Chapter 9 presents the reconstruction of the DM1-Activ scale for clinical use 
(DM1-Activc) through Rasch analyses on an expanded questionnaire in a 
larger population of patients with DM1. The new outcome measure to capture 
activity limitations and participation restrictions for patients with DM1 fulfils all 
requirements of the Rasch model and demonstrated stronger discriminatory 
capacity and reliability scores. A nomogram is provided to calculate interval 
estimates from the obtained raw scores which can be used in future clinical 
observational and interventional studies.
Chapter 10 describes the construction of a combined fatigue and daytime 
sleepiness scale for patients with DM1 (FDSS) using the Rasch Model. The 
FDSS interval measure bypasses the difficulty of differentiating between fatigue 
and sleep problems by providing interval measures on a single continuum 
for both entities. Currently used patient-based rating scales measure daytime 
sleepiness or fatigue levels as separate entities. However, excessive daytime 
sleepiness and fatigue have overlapping features and patients cannot always 
specify whether their complaint relates to sleepiness, fatigue, or both. Rasch 
analysis of the FDSS showed that the included fatigue and daytime sleepiness 
items address the same underlying health construct, which argues strongly in 
favour of a combined clinical outcome measure of these attributes. Compared 
to currently often used ordinal fatigue and sleepiness scales, the FDSS was 
better targeted to the sample population.
The capacity of these new Rasch-built outcome measures to detect changes 
over time (i.e. responsiveness) needs to be investigated in longitudinal studies. 
In order to be responsive, the outcome measure must detect change when 
it has occurred and it must remain stable when no change has occurred. 
However, it is also important to assess how relevant the changes are for 
patients. Therefore, responsiveness studies should also include determination 
of the minimal clinically important difference (MCID), which is defined as the 
smallest difference in score in the domain of interest which patients perceive 
as beneficial and which would mandate, in the absence of troublesome side 
effects and excessive costs, a change in the patient’s management.20 Therefore 
differences in scores smaller than the MCID are considered not important, 
independent of their statistical significance. 
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Future perspectives
Although much has been learned about DM1 over the last 20 years, many 
important problems are still unsolved. The complexity and variability of disease 
manifestations in DM1 pose a challenge in anticipating all potential problems 
and implementing an integrated management approach of impairment, 
disability and quality of life. An optimal health management program should 
provide support to both the patient and family through an interdisciplinary 
team, which includes genetic and medical resources as well as community 
resources.1 
DM1 is still relatively unknown among medical and paramedical resources. 
Many clinical manifestations of the disease, such as gastrointestinal and 
neuropsychiatric issues, are under-recognized and require further scientific and 
clinical research. Patients may consider gastrointestinal symptoms, particularly 
abdominal pain, diarrhoea and faecal incontinence, to be the most disabling 
consequence of the disease rather than their neuromuscular symptoms.21 
Limited information is available about the pathophysiology of gastro-intestinal 
dysfunction and the effect of treatments. In addition, central nervous system 
(CNS) involvement is another underestimated symptom of DM1 and poses great 
problems not only for patients but also for their relatives.22 Increased apathy and 
personality characteristics may cause patients to lose interest in daily activities 
or relationships. Awareness of these neuropsychiatric problems is important in 
understanding related health and social consequences. In addition, intellectual 
disability, learning disabilities and/or behavioural problems are the principal 
concerns of children and adolescents with childhood-onset DM1. The wide 
range of CNS involvement in DM1 and the nature of its underlying neurological 
basis are only beginning to be understood.23
Future studies are needed to redefine guidelines concerning screening, follow-
up and treatment of cardiac involvement in DM1 patients and to improve 
the identification of patients at risk of sudden death.24 The diagnostic and 
therapeutic strategy used in our centre is presented in appendix D. Prospective 
observational clinical studies in DM1 patients who receive a pacemaker or ICD 
on the basis of a class I or IIa indication according to ACC/AHA guidelines3 or a 
nonconventional indication, could help explore the prognostic value of several 
factors in predicting life-threatening arrhythmias.25 Furthermore, studies with 
long-term recordings of implanted insertable loop recorders may also improve 
our insights in the electrophysiological abnormalities in these patients.26 
Additional studies of cardiac involvement should also address the efficacy and 
cost-effectiveness of ICD therapy in DM1 patients for primary prevention of 
sudden death. Finally, DM1 patients are also at high risk of respiratory failure 
and antiarrhythmia devices of any type in those with severe muscle involvement 
may not improve outcomes.27
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A better understanding of the underlying molecular mechanisms of cardiac 
disease in DM1 is also essential for the development of rational approaches for 
the prevention and treatment of cardiac events. RNA sequencing may provide 
a more complete characterization of RNA transcripts, including improved 
detection of alternative splicing events and identification of previously unknown 
coding and non-coding RNA species.2 In terms of treatment, several promising 
experimental strategies are obtained in cell-based and animal models that 
address the cause of DM1 rather than reduction of symptoms. Future challenges 
are to find efficient ways to systemically deliver active compounds in vivo that, 
for example, eliminate or neutralize the expanded DMPK transcript.29 Before 
new treatments and therapies can be applied in clinical trial settings, the natural 
course of disease progression and treatment outcomes should be further 
explored. A core set of clinically meaningful and scientifically sound rating scales 
are required to evaluate the therapeutic efficacy of an intervention. Modern 
test theory models, such as the Rasch measurement model, are increasingly 
adopted in health outcomes research to strength clinimetric properties of 
newly developed or revised outcome measures. The increasing importance 
of high quality rating scales has also been recognized in other neuromuscular 
disorder, including Duchenne muscular dystrophy and immune-mediated 
peripheral neuropathies.30, 31 Considering the multisystemic nature of DM1, 
health outcome measures of various aspects of DM1 disease manifestations, 
e.g. pain, muscle strength or psychological distress, are necessary for adequate 
patient assessment. In addition to self-reported measures, health status 
assessed by familial caregivers may reveal other relevant problems. 
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Dit proefschrift beschrijft een aantal studies over myotone dystrofie type 
1 (DM1). In dit hoofdstuk wordt een overzicht gegeven van de belangrijkste 
bevindingen en conclusies van elk van de hoofdstukken.
Hoofdstuk 1 is een algemene introductie waarin de complexe multisysteem 
pathologie van DM1 wordt geïllustreerd. DM1, ook wel de ziekte van Steinert 
genoemd, is de meest voorkomende erfelijke spierziekte bij volwassenen. 
Kenmerkende verschijnselen zijn een vertraagde ontspanning van skeletspieren 
(myotonie) en langzaam toenemende spierzwakte (dystrofie). Naast de myotonie 
en spierzwakte worden ook verschillende inwendige organen aangetast zoals het 
zenuwstelsel, het hart, de longen, de ogen en het maagdarmstelsel. DM1 wordt 
veroorzaakt door een verlenging van het aantal CTG trinucleotiden in het DMPK-
gen. Het moleculaire mechanisme van DM1 is zeer complex doordat de mutatie 
genexpressies op verschillende manieren ontregeld. Een gestoorde regulatie 
van alternatieve splicing speelt een centrale rol bij het ontstaan van symptomen, 
maar belangrijke symptomen, zoals spierzwakte en hartritmestoornissen, 
kunnen tot nu toe niet worden gerelateerd aan een specifiek splicing defect. 
Het klinisch spectrum van DM1 is zeer heterogeen waarbij de beginleeftijd 
en ernst van symptomen sterk variëren. Men onderscheidt vier fenotypen: 
congenitale type, kindertype, klassieke of volwassen type en het lichte (Engels: 
‘mild’) type. Ondanks het feit dat er geen curatieve behandeling voorhanden 
is en patiënten niet altijd overtuigd zijn van de noodzaak om regelmatig op 
controle te komen, is een gestructureerde multidisciplinaire aanpak van belang 
om klachten te verminderen, het dagelijks functioneren te verbeteren en de 
overleving te doen toenemen. 
Hartziekte
Aangezien de prognose van DM1 patiënten direct gerelateerd kan zijn aan de 
toestand van hun hart, zijn regelmatige controle en tijdige behandeling van 
cardiale complicaties belangrijk. Een actieve opsporing is noodzakelijk omdat 
cardiale betrokkenheid bij DM1 niet altijd gepaard gaat met symptomen en er 
geen duidelijk verband met de ernst van de neuromusculaire symptomen is. 
Ondanks de hoge incidentie van cardiale afwijkingen, is er geen consensus 
over de diagnostische en therapeutische aanpak van cardiale betrokkenheid 
en wordt het risico op plotse dood onvoldoende onderkend. De belangrijkste 
doelstellingen van het eerste deel van dit proefschrift waren het bepalen van 
het voorkomen en de voorspellers van plotse dood, het vaststellen van de aard 
van hartspierziekte (cardiomyopathie) bij DM1 patiënten en het beschrijven 
van veranderingen in genexpressie die kunnen leiden tot cardiale complicaties, 
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om zodoende een beter inzicht in de etiologie van deze ziekte te krijgen en de 
diagnostiek en behandeling van cardiale betrokkenheid te verbeteren.
Hoofdstuk 2 geeft een uitgebreid overzicht van de omvangrijke literatuur 
over erfelijke spierdystrofieën die geassocieerd zijn met hartziekte. De 
incidentie en aard van cardiale problemen verschilt tussen verschillende 
typen spierdystrofieën. Sommige gaan gepaard met een dilaterende 
cardiomyopathie leidend tot systolische disfunctie en hartfalen, terwijl 
andere typen vooral gepaard gaan met geleidingsstoornissen, leidend tot 
ritmestoornissen en plotse dood. De moleculaire pathologie, klinische 
aspecten, cardiale onderzoeksbevindingen en het mechanisme en risico op 
hartdood van de verschillende typen spierdystrofieën wordt samengevat, om 
meer inzicht te krijgen in de huidige diagnostiek en behandeling van cardiale 
betrokkenheid. Desondanks zijn aanbevelingen voor de aanpak van hartziekte 
bij spierdystrofieën grotendeels gebaseerd op consensus omdat bewijs uit 
gepubliceerd wetenschappelijk onderzoek voor de effectiviteit van behandeling 
vrij beperkt is. Prospectieve en goed gecoördineerde multicenter studies 
zijn noodzakelijk om huidige behandelstrategieën te evalueren en richtlijnen 
en protocollen voor controle, hartfalen therapie en device implantatie aan te 
passen. 
Tot voor kort werd aangenomen dat plotse dood bij DM1, gedefinieerd als een 
totaal onverwacht natuurlijk overlijden die zich voordoet binnen 24 uur na 
het begin van de symptomen, het gevolg is van geleidingsblokkades. Huidige 
richtlijnen stellen dan ook dat een pacemakerimplantatie overwogen dient 
te worden bij patiënten met een neuromusculaire ziekte zoals myotone 
dystrofie bij iedere graad van AV-blok in verband met de onvoorspelbare 
progressie geleidingsstoornissen (bewijsniveau B) of met een bifasciculair 
blok of ieder fasciculair blok met of zonder symptomen (bewijsniveau C). 
Hoofdstuk 3 laat zien dat in een retrospectieve studie van 412 DM1 patiënten 
plotse dood optreedt in een derde van alle geclassificeerde sterfgevallen. 
Bovendien werd plotse dood zeker niet altijd voorkomen door pacemakers. 
Deze hoge aantallen plotse doden vragen  om een  nieuwe behandelstrategie. 
ICD’s worden in toenemende mate gebruikt bij patiënten met spierdystrofieën 
die geassocieerd zijn met plotse dood. De doeltreffendheid van een ICD bij DM1 
wordt gesuggereerd uit niet-gerandomiseerde observaties waarin patiënten met 
ventriculaire aritmieën terechte ICD therapie hebben gekregen. De uitdaging 
blijft om patiënten te identificeren met een relatief goede neuromusculaire 
prognose die baat hebben bij een ICD. Uit onze case-controle analyse van 
beschikbare elektrocardiogrammen (ECGs) bleek dat de QRS-duur aanzienlijk 
verlengd was bij patiënten met gedocumenteerde plotse dood in vergelijking 
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met controles en sterfgevallen als gevolg van andere oorzaken. DM1 patiënten 
met dit risicoprofiel zouden moeten worden betrokken in lange termijn follow-
up studies om het overlevingsvoordeel van ICD-therapie versus pacemaker 
therapie, of als alternatief, een implanteerbare loop recorder te beoordelen.
Hoofdstuk 4 beschrijft de structurele en functionele afwijkingen van het 
myocard vastgesteld met cardiale MRI bij patiënten met DM1. Hoewel 
overlijden door progressief hartfalen zeldzaam is bij DM1 in vergelijking met 
andere spierdystrofieën, kan myocardiale betrokkenheid ook prognostische 
waarde hebben bij het voorspellen van de totale mortaliteit en plotse dood in 
DM1. Cardiale MRI heeft een grotere gevoeligheid en reproduceerbaarheid dan 
conventionele diagnostische onderzoeken (ECG en echocardiografie) voor het 
aantonen van vroege myocardiale afwijkingen of subtiele veranderingen, maar 
MRI bevindingen bij DM1 zijn nog niet goed gekarakteriseerd. We vonden dat 
de aanwezigheid van milde LV systolische disfunctie, ventriculaire dilatatie, 
myocardiale hypertrofie of fibrose op cardiale MRI sterk geassocieerd was met 
elektrocardiografische geleidingsstoornissen. Echter, een normaal ECG sluit 
myocardiale betrokkenheid niet uit. Deze bevindingen steunen de opvatting dat 
DM1 patiënten een complex cardiale fenotype hebben met zowel betrokkenheid 
van het myocard als het geleidingssysteem. De voorspellende waarde van 
myocardiale fibrose of andere cardiale MRI bevindingen voor het opsporen van 
DM1 patiënten met risico op cardiale ziekteprogressie of plotse dood dient nog 
te worden onderzocht in een langdurige prospectieve studie. 
Hoofdstuk 5 bestudeert de veranderingen in genexpressie in hartbiopten van 
patiënten met DM1-gerelateerde cardiomyopathie. Microarray analyse toonde 
significante veranderingen in de expressie niveaus van 989 mRNAs en 16 
miRNAs in harten van DM1 patiënten in vergelijking met controle personen. 
We hebben in hartweefsel een aantal veranderingen in genexpressie gevonden, 
die in overeenstemming zijn met huidige pathofysiologische concepten, zoals 
het verlies van DMPK en SIX5 expressie. Bioinformatische analyse van mRNA 
expressie data identificeerde verscheidene pathologische veranderingen, zoals 
verstoring van cardiale mitochondriale functie, RNA processing, calcium 
signalering en veranderingen in expressie van genen betrokken zijn in de 
organisatie van het cytoskelet. Deze veranderingen kunnen in het hart van DM1 
patiënten leiden tot geleidingsstoornissen, aritmie en myocardiale afwijkingen.
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Uitkomstmaten
Na verloop van tijd leidt DM1 tot ziekteverschijnselen van spieren en van tal 
van andere organen met aanzienlijke beperkingen in het dagelijks leven. De 
bestaande behandelingen zijn voornamelijk gericht op symptoombestrijding. 
Daarnaast heeft een beter begrip van de complexe pathogenese geleid tot de 
ontwikkeling van potentiële moleculaire targets voor therapeutische interventies 
in preklinische studies. Gezien deze recente ontwikkelingen in therapeutische 
mogelijkheden is het noodzakelijk dat er goede uitkomstmaten beschikbaar 
zijn om het effect van interventies op de functionele toestand van de patiënt 
in klinische trials te kunnen evalueren. De belangrijkste doelstellingen van 
het tweede deel van dit proefschrift waren het illustreren van het belang van 
nieuwe klinimetrisch methoden en het ontwikkelen van nieuwe klinische 
meetinstrumenten voor toekomstige DM1 studies. 
Hoofdstuk 6 geeft een overzicht van uitkomstmaten die in de afgelopen 
60 jaar zijn toegepast in klinische studies met DM1 patiënten. Een zeer 
groot aantal verschillende meetinstrumenten is toegepast waardoor een 
vergelijking van studieresultaten niet goed mogelijk is. Bovendien zijn de 
klinimetrische eigenschappen van de meeste meetinstrumenten, zoals 
validiteit, betrouwbaarheid en responsiviteit, onvolledig of slecht geëvalueerd. 
Een andere beperking is het feit dat vragenlijsten op de klassieke test theorie 
gebaseerd zijn en enkel gegevens met een ordinaal meetniveau opleveren. 
Ordinale uitkomsten worden vaak onjuist gebruikt als interval meetniveau in 
parametrische analyses. Het gebruik van moderne klinimetrische technieken 
wordt daarom aanbevolen bij het evalueren en ontwikkelen van uitkomstmaten. 
Daarnaast wordt gepleit voor een gestandaardiseerde set van uitkomstmaten in 
toekomstige onderzoeken om vergelijking testresultaten en de communicatie 
in de klinische praktijk te vergemakkelijken. 
Hoofdstuk 7 is een introductie over het zogenaamde Rasch model en 
bespreekt in begrijpelijke taal de verschillende stappen van het beoordelen 
en ontwikkelen van een meetinstrument volgens de Rasch methode. Deze 
moderne klinimetrische techniek stelt aanvullende kwaliteitsvoorwaarden aan 
uitkomstmaten en kan, als de data voldoen aan de verwachtingen van het 
statistisch model, de moeilijkheidsgraad van items en het functionele niveau 
van patiënten hiërarchisch ordenen op een interval schaal, zodat metingen 
onderling vergelijkbaar zijn.
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Hoofdstuk 8 beschrijft de ontwikkeling en toetsing van een “activiteiten en 
participatie” schaal voor DM1 patiënten (DM1-Activ), gebaseerd op het Rasch 
model. Deze studie illustreert het belang van nieuwe klinimetrische methoden 
bij de ontwikkeling van meetinstrumenten voor trials met neurologische 
patiënten. Met de DM1-Activ vragenlijst kunnen functionele beperkingen in 
dagelijkse leven van DM1 patiënten worden beoordeeld. De DM1-Activ is een 
doelmatig, valide en betrouwbaar meetinstrument, dat voldoet aan moderne 
klinimetrische vereisten. Om klinische toepassing van de uitkomstmaat 
mogelijk te maken, moet de DM1-Activ schaal echter in een groter cohort van 
patiënten onderzocht te worden. 
Hoofdstuk 9 beschrijft de reconstructie van de DM1-Activ schaal voor 
klinisch gebruik (DM1-Activc) met een uitgebreidere vragenlijst en een grotere 
patiëntenpopulatie. De nieuwe uitkomstmaat voldoet eveneens aan de eisen 
van het Rasch model en heeft een sterker discriminerend vermogen en hogere 
betrouwbaarheid dan de DM1-Activ. Met het nomogram kan de ruwe score 
worden omgezet naar een interval niveau score die kan worden gebruikt in 
toekomstige klinische observatie en interventie studies.
Hoofdstuk 10 beschrijft de ontwikkeling en toetsing van een gecombineerde 
“vermoeidheid en slaperigheid” schaal voor DM1 patiënten (FDSS), gebaseerd 
op het Rasch model. De FDSS omzeilt het probleem om vermoeidheid 
van slaperigheid te onderscheiden door een uitkomstmaat met een 
gemeenschappelijk onderliggend construct te veronderstellen. Bestaande 
vragenlijsten meten de ernst van slaperigheid en vermoeidheid als aparte 
entiteiten. Echter, overmatige slaperigheid overdag en vermoeidheid hebben 
veel overlappende kenmerken en patiënten kunnen niet altijd duidelijk maken 
of hun klachten berusten op slaperigheid, vermoeidheid of beide. Rasch 
analyse toonde aan dat vragen over slaperigheid en vermoeidheid inderdaad 
samen één construct meten. Dit pleit sterk voor een gecombineerde klinische 
uitkomstmaat voor deze symptomen. In vergelijking tot de veel gebruikte 
ordinale vragenlijsten om vermoeidheid en slaperigheid te meten, heeft de 
FDSS voor DM1 patiënten een groter bereik van makkelijke tot moeilijke vragen. 
Daardoor sluit de FDSS beter aan bij patiënten met verschillende niveaus 
van slaperigheid en/of vermoeidheid. Gebruik van deze uitkomstmaat wordt 
aanbevolen in toekomstige klinische trials bij DM1 patiënten.
Hoofdstuk 11 geeft een samenvatting van de verschillende studieresultaten die 
in dit proefschrift zijn beschreven. De resultaten worden ter discussie gesteld 
en er worden aanbevelingen gedaan voor toekomstig onderzoek.
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Appendices
Appendix A. The Rasch-built activity and participation scale for patients with 
myotonic dystrophy type 1 for clinical use (DM1-Activ).
Item Unable to
perform
(0)
Able to
perform, but
with difficulty
(1)
Able to
perform, without
difficulty
(2)
Are you able to...
1 wash your face? o o o
2 brush your teeth? o o o
3 take a shower? o o o
4 sit up straight? o o o
5 open toothpaste? o o o
6 prepare a meal? o o o
7 button your shirt/blouse? o o o
8 walking avoiding obstacles? o o o
9 perform a hobby? o o o
10 get in/out of a car? o o o
11 walk on uneven ground? o o o
12 bend over to pick up object? o o o
13 walk one flight of stairs? o o o
14 grab an object above head? o o o
15 perform study/work? o o o
16 stand up from lying down? o o o
17 do the cleaning? o o o
18 do sports? o o o
19 do the gardening? o o o
20 run? o o o
237
Appendix B. The reconstructed Rasch-built activity and participation scale for 
patients with myotonic dystrophy type 1 for clinical use (DM1-Activc).
Item Unable to
perform
(0)
Able to
perform, 
but with 
difficulty
(1)
Able to
perform, 
without
difficulty
(2)
Are you able to...
1 eat soup? o o o
2 visit family or friends? o o o
3 care for your hair and body? o o o
4 dress your lower body? o o o
5 wash your upper body? o o o
6 take a shower? o o o
7 wash your lower body? o o o
8 get out of bed? o o o
9 move a chair? o o o
10 do the dusting/cleaning? o o o
11 do the shopping? o o o
12 tie the laces of your shoes? o o o
13 catch an object (e.g. a ball)? o o o
14 use dustpan and brush? o o o
15 empty dustbin? o o o
16 make up your bed? o o o
17 vacuum clean? o o o
18 serve coffee/tea on a tray? o o o
19 dance? o o o
20 stand up from squatting position? o o o
21 stand on one leg? o o o
22a run (afor those aged <30 years)? o o o
23 walk uphill? o o o
24 walk 3 flights of stairs? o o o
25 carry and put down heavy object (10 kg)? o o o
22b run (bfor those aged ≥30 years)? o o o
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Appendix C. The Rasch-built fatigue and daytime sleepiness scale for patients 
patients with myotonic dystrophy type 1 (FDSS).
Item Seldom  
or never
(0)
Sometimes
(1)
Almost 
always
(2)
1 My motivation is lower when I am fatigued o o o
2 Exercise brings on my fatigue o o o
3 Fatigue is among my three most disabling 
symptoms
o o o
4 Fatigue causes frequent problems for me o o o
5 Do you take one or more naps during the day? o o o
6 Do you fall asleep while watching TV? o o o
7 Are you generally in great shape during the day? o o o
8 Do you doze off or fall asleep as a passenger in a 
car for an hour without a break?
o o o
9 Do you doze off or fall asleep when sitting and 
reading?
o o o
10 Do you doze off or fall asleep while sitting 
inactive in a public place?
o o o
11 Do you doze off or fall asleep in a car, while 
stopped for a few minutes in traffic?
o o o
12 Do you doze off or fall asleep while sitting and 
talking to someone?
o o o
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